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 Polymer carriers composed of poly(methacrylic acid – grafted – ethylene glycol) 
(P(MAA-g-EG)) hydrogels modified with poly(butyl acrylate) (PBA) to form IPNs or 
photopolymerized in the presence of poly(methyl methacrylate) (PMMA) nanoparticles 
were investigated for their use in the oral delivery of therapeutic agents for cancer 
treatment. The P(MAA-g-EG) hydrogel provided pH-responsive and hydrophilic 
properties while PBA or PMMA polymers provided hydrophobic properties. An inulin-
doxorubicin conjugate was also synthesized to provide local, direct targeting for the 
treatment of colon cancer.  
 The pH-responsive behavior of these polymer systems was investigated using 
equilibrium and dynamic swelling experiments. In gastric conditions (low pH) all 
materials were in a collapsed state and in intestinal conditions (neutral pH) these material 
were swollen. The equilibrium swelling ratios decreased with increasing hydrophobic 
content for both IPNs and compositions of P(MAA-g-EG) containing nanoparticles.  
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 The loading efficiencies of doxorubicin, a chemotherapeutic drug, were as high as 
56% for IPNs and the IPN structure and hydrophobicity influenced the loading efficiency 
values. The loading efficiency of doxorubicin using P(MAA-g-EG) containing 
nanoparticles was as high as 64% and increased with increasing weight percent of 
PMMA nanoparticles in the P(MAA-g-EG) hydrogel. In gastric conditions (low pH), 
IPNs released a majority of the encapsulated doxorubicin (up to 70%) as compared to the 
P(MAA-g-EG) containing nanoparticles (up to 27%). P(MAA-g-EG) containing 
nanoparticles was used to load and release the inulin-doxorubicin conjugate. Loading 
efficiency was 54% and release profiles behaved similarly as doxorubicin.  
 Both polymer systems were biocompatible with Caco-2, HT29-MTX, and SW620 
cell models over concentration ranging from 1 mg/mL to 5 mg/mL and exposure times 
lasting from 2 hr to 24 hr. The 75/25 IPN exhibited the highest degree of mucoadhesion 
and the P(MAA-g-EG)-5.0NP the lowest. Using the same cell lines and cytotoxicity 
assays, the inulin-doxorubicin conjugate was determined to be more toxic than free 
doxorubicin at equal doxorubicin concentrations.  
 Doxorobuicin and inulin-doxorubicin conjugate were tested for transport across 
Caco-2/HT29-MTX cell monolayers with and without the presence of unmodified 
P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles. The presence of the 
microparticles did not increase transport across the cell monolayer which is advantageous 
for local, direct delivery to the colon.  
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Chapter 1 
Introduction 
 
1.1  Motivation 
 Cancer is the second leading cause of death in the United States with roughly 
570,000 deaths a year and costs totaling to $263.8 billion in 2010.1 The 5-year survival 
rate for many cancers has been steadily increasing due to improved patient healthcare, 
diagnosis of cancer at earlier stages, and new treatments. Unfortunately, these survival 
rates have come at great sacrifices to the patients including severe side effects during 
treatment and ballooning financial costs. The financial burden is estimated to increase by 
39% by 2020 if current incidence and survival rates continue the same trend as seen in 
the past decade.2 Therefore, there is a need for further advancements or new treatment 
regimens which reduce the side effects of current cancer treatment, improves patient 
compliance, increases patient comfort, and reduces financial costs considerably.   
 Cancer is a disease arising from mutations in genetic material allowing cells to 
acquire the power to proliferate in unregulated and uncontrolled manners.3,4 This 
increased rate of growth for tumor cells allows them to develop into large heterogeneous 
masses competing for space and nutrients with surrounding healthy tissue. The 
environmental front between healthy tissue and tumor tissue is favorable to the tumor as 
it can adapt or has already adapted to survive in hypoxic and low nutrient conditions. 
This ‘survival’ genotype for cancer cells allows them to compete with healthy tissue in 
Darwinian fashion.5,6 Eventually these tumor cells out grow its healthy neighbors, cease 
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an organ’s or tissues function completely, and could result in death if that organ or tissue 
is vital to the human system.  
The invasive nature and difficulty to remove or destroy cancer makes this 
diagnosis feared and heartbreaking for the patient. Cancer’s potential mortality, 
morbidity, and financial burden, has made it a growing research field in the past decade 
(Figure 1.1). The importance of cancer and cancer research has been acknowledged by 
the National Cancer Institute and has developed the Physical Sciences Oncology (PS-OC) 
initiative, which is focused on engaging trans-disciplinary scientific teams from fields of 
mathematics, engineering, physics, and chemistry for the formation of new, non-
traditional approaches to cancer research. This PS-OC initiative has cooperative 
agreements among 12 leading institutions to build the necessary collaborative network, 
infrastructure, and innovative ideas to be successful in cancer research progress. As a 
result of new programs like PS-OC as well as previous cancer research, the 5 year 
survival rate from 1975 to 2003, irrespective of site of origin, gender, or race, has 
increased from 49% to 67% percent.7 While this progress is promising, there are still a 
large number of individuals who suffer from cancer and cancer treatment regimens; thus, 
it is essential to continue the current research efforts and increase these efforts in the 
future.  
1.2 Cancer 
The human cell is the building block which makes living possible, but cell life is 
finite, they become old or damaged, and must be replaced with new cells. Thus our body 
has developed cell replication pathways which are systematic and controlled using a 
series of regulatory genes as stop and go signals to keep the replication in check. Even 
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with the most precise control, the replication process can become disrupted as a result of 
environmental exposures and/or hereditary causes resulting in once pure DNA to become 
littered with mutations.8  
A series of specific mutations known as ‘driver mutations’ will eventually allow 
healthy cells to acquire the hallmarks of cancer: sustained angiogenesis, limitless 
replicative potential, tissue invasion and metastasis, insensitivity to anti-growth signals, 
self-sufficiency in growth signals, and evading apoptosis. 3,4 Research laboratories are 
trying to understand how these hallmarks arise using new high throughput assays and 
improved hardware and software capabilities, with a primary focus on determining what 
steps lead to mutations and how many mutations are necessary before a hallmark is 
acquired. These hallmarks are vital to tumor growth and metastasis and will be discussed 
in detail. 
 The rise of cancer originates from a single cell possessing heritable alterations to 
its genetic material due to the exposure to carcinogens. Most carcinogens are mutagens 
and mutagens are the material which causes modifications to occur among a cell’s 
genetic material. Environmental factors are the primary source for mutagens, but 
heritable genetic mutations due account for approximately 5-10% of cancers.8 Those 
cancers caused by environmental factors can be contributed to tobacco use (25 – 30%), 
diet (25 – 30%), infections (15 – 20%), and obesity (10 – 20%). The remaining 
percentage (10 – 15%) includes a host of factors such as stress, physical activity, and the 
environment which one resides.9-11 Since carcinogens are strongly linked to mutagens, 
the first true evaluation of a substance’s harm to the human body was evaluated by the 
Ames test, developed in the early 1970’s by Bruce Ames. The premise of this procedure 
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was to expose Salmonella (a bacterial strain) to various chemical compounds and test for 
mutagenic activity.12 Increased mutagenic activity was correlated back to increased 
carcinogenic potential and was successful in identifying approximately 50 – 70% of 
known carcinogens. Today’s conventional test for carcinogenicity is long-term exposure 
of the material of interest to rodents. Carcinogens are ranked from group 1 to group 4 
with group 1 defined as an agent or mixture which definitely causes cancer in humans. 
Group 4 is an agent or mixture not likely to be carcinogenic to humans. Group 1 
carcinogens include cigarette smoke, silica, ethylene oxide, and x-radiation.  
1.3 Tumor Initiation, Growth, and Metastasis 
Currently there are more than 100 different types of cancer and 60 different 
organs in the human body were cancer can begin. However, despite the diversity of 
cancers, their initiation, growth, and metastasis are all similar. In each case, it began with 
a series of mutations to the genetic material which caused that cell or cells to become 
unregulated, uncontrolled, and unchecked. As discussed earlier, the cell replication 
process is highly controlled by regulatory genes to keep DNA unaltered and untouched 
during replication. In cancer, these regulatory genes have been divided into two 
categories: oncogenes and tumor suppressor genes.  
Oncogenes are normal genes which have mutated to become constitutively active 
and this activity plays an important role in the acquisition of the hallmark of cancers. 
Tumor suppressor genes are genes that protect the cell from becoming cancerous by 
inhibiting the key steps to genetic mutations. In many cancers, the loss of function, 
reduced activity, or silencing of these tumor suppressor genes is greatly increased as 
compared to its healthy counterpart. Since the discovery of the first oncogene in 1989, 
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there are now over 400 recognized oncogene and tumor suppressor genes as a result of 
the cancer genome project.13  
Cancer is a complex, abnormal growth that involves dynamic changes to its 
genome. Despite its complexity, the same functional developments have been acquired 
by a majority of cancers, but through different pathways. The first of these developments 
is the ability to be self-sufficient in growth signals. In the absence of growth signals, a 
cell will stay quiescent in the G0 phase of the cell cycle and await for the appropriate 
conditions and signaling cascade to move forward through the G1 phase and into the S 
phase (Figure 1.2).14  In a healthy cell, growth factors are secreted and drift to the exterior 
of the cell where surface receptors bind to these growth factors, dimerize, and cross 
phosphorylate causing a cascade of signals to initiate cell growth. Mutagenic cells 
possess oncogenes to insert an overabundance of receptors on the surface which results in 
self-dimerization without growth signals or being overly responsive to ambient levels of 
growth factor which under normal circumstances would not induce signaling.15  
Within the cell cycle, a restriction point must be passed to move from the G1 
phase to the S phase (Figure 1.2). Antigrowth signals help maintain these cells at the 
restriction point by preventing the retinoblastoma protein (pRB) from becoming hyper 
phosphorylated and releasing the E2F transcription factor which expresses a blanket of 
genes to promote forward activity in the cell cycle.16 Mutations to a series of tumor 
suppressor genes are often seen in cancer, such as the p16 protein, where the loss of 
function results in the inability to keep pRb hypophosphorylated. With these 
modifications to cell performance, cancer has acquired a degree of insensitivity to 
antigrowth signals.  
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The acquired traits of insensitivity to antigrowth signals and self-sufficiency in 
growth signals allow the rate of cell proliferation to greatly increase; however, apoptosis, 
programmed cell death, must be avoided or silenced for tumor cell populations to expand. 
Like the cell cycle, apoptosis requires step by step instructions for successfully targeting 
the correct cell and appropriately killing it. For apoptosis to be completed, the 
mitochondria must release a catalyst called cytochrome c which is regulated by an anti-
apoptotic protein called BLC-2. Cancers have learned to develop oncogenic factors to 
upregulate BCL-2, thus sequestering cytochrome c inside the mitochondria, and avoiding 
apoptosis.17   
 Cells are capable of continued replication until they reach the Hayflick limit, 
where they then become unstable and are targeted for apoptosis. This was first discovered 
by Leonard Hayflick in 1961 when he was unable to keep his ex vivo cell cultures alive 
past 50 – 60 passages, indicating that cells have an internal counting mechanism and 
know when mitosis can no longer occur safely.18 Telomeres are found at the end of 
chromosomes, serve as the internal counting mechanism for cell replication, and are 
composed of several thousand repeats of a short 6 base pair sequence. During cell 
replication a small amount of the telomere is snipped off (50 – 150 bp) resulting in the 
slow shortening of the telomere. This shortening is the result of DNA polymerase’s 
inability to attach to the very beginning of the 3’ end during replication of the original 
DNA strand.  
Eventually the telomeres are lost, exposed chromosomal ends fuse to one another, 
enter into an unstable state, and become targeted for apoptosis. As infants, toddlers, and 
adolescents, telomere shortening is offset by telomerase, a combinatorial protein and 
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RNA strand which extends the lost base pairs during replication. Telomerase activity is 
high in early childhood and slowly tapers off to undetectable levels in adulthood. 
However, in ways still being discovered today, 85 – 90% of malignant cells express 
upregulated levels of telomerase.19 Thus it is important to know that cancer cells 
understand the importance of telomere maintenance for limitless replicative potential and 
have developed ways to keep telomerase constitutively active through oncogenes or 
down regulation of tumor suppressor genes.    
The human body has developed an extensive network of blood vessels so that any 
cell in the body resides within 100 µm. This allows for the natural diffusion of oxygen 
and nutrients to keep cells functioning and surviving as well as serve as a route for waste 
removal. Previously discussed hallmarks of cancer allow cancer cells to growth in 
unlimited fashion, but if a solid tumor reaches a critical mass of 106 cells, this 100 µm 
distance is surpassed and the need for new vessels is required. The formation of blood 
vessels can occur through vasculogenesis or angiogenesis. Vasculogenesis is the creation 
of endothelial cells from progenitor cell types and only occurs during development.  
Angiogenesis is the formation of new capillaries sprouting off from existing 
vessels and is the only way new vessels form in the adult. Angiogenesis is tightly 
controlled and largely down regulated in the adult with minor exceptions in the female 
reproductive system and in wound healing. The steps for angiogenesis include (1) the 
degradation of the basement membrane surrounding the endothelial tube; (2) invasion of 
a column of proliferating endothelial cells into the extracellular matrix; and (3) 
differentiation of cells at the trailing edge of the column, changing shape to form a tube, 
and adhering to neighboring cells to prevent leakage (Figure 1.3). Judah Folkman was the 
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pioneer and leading researcher for the influence of angiogenesis in tumor development 
when he discovered that tumor growth in mice was greatly increased in the presence of 
neovascular growth factors.20 The angiogenic switch can be viewed as a see-saw of 
positive and negative signals where upregulating the positive signals (oncogenes) or 
down regulating negative signals (tumor suppressor genes) will turn the switch to the on 
position. There are many documented cancer cases demonstrating upregulation of 
vascular endothelial growth factors and fibroblast growth factors as well as the loss of 
function of the p53 protein which causes angiogenic inhibition levels to fall and 
liberating endothelial cells for vascular growth.          
A majority of these previously mentioned hallmarks of cancer must be obtained or 
in place before tissue invasion and metastasis can occur. The tissue invasion and 
metastasis process accounts for 90% of human cancer deaths.21 The metastatic cascade 
occurs in the following manner:  a primary tumor is formed, local invasion of the 
surrounding tissue, intravasation from the primary tumor site into the blood stream, 
transport through the circulation, arrest in a new tissue or organ, extravasation from the 
blood vessel into the tissue, formation of micro-metastasis, colonization, and formation of 
a macro-metastasis (Figure 1.4).22  
The prediction of metastasis based on the original primary tumor site is 
hypothesized by two observed tendencies, the seed-soil hypothesis and the circulatory 
hypothesis. The seed-soil hypothesis explains the pattern of metastasis based on the 
environment friendliest to those particular cancer cells. In other words, assuming cancer 
cells had equal access to all tissues of the body, they would only settle and proliferate in 
specific tissues with an environment similar to where they came from. The circulatory 
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hypothesis is fairly self-explanatory in that the circulatory flow of blood between organs 
is the primary determinant for the next microvessel system the cancer cell would 
encounter (Figure 1.5).22 For example, primary breast cancer cells metastasize through 
the blood vessels to many organs, but preferentially target the lung, liver, and bone.23 
Approximately two-thirds of the observed metastatic cases confirm the circulatory 
hypothesis. 
In normal, healthy tissue the cells are tethered together using cell-cell adhesion 
molecules (CAMs) to provide structural support and an information pathway between 
cells. E-cadherin is the most widely observed adheren junction in healthy cells and the 
most widely disrupted adheren in cancer. Mutated E-cadherin can cause it to be inactive 
or transcriptionally down-regulated through hypermethylation. Disruption of the E-
cadherin junction with simultaneous secretion of metzincin proteases to degrade 
surrounding extracellular matrix allows cancer cells to become effective in locally 
invading surrounding healthy tissue or endothelial cells of the lymphatic or blood vessels.     
Though not considered a hallmark of cancer, an emerging field of research has 
focused on “cancer stem cells,” which like regular stem cells, are self-renewing and 
relatively undifferentiated. The potential of this research field could prove highly 
important for the future treatment of cancer and hopefully an eventual cure. Using 
colorectal cancer cells, cell-fractioning, and surface cell markers, a specific population of 
cells were sequestered and were capable of generating 45 tumors out of 49 mice injected 
while another set were only capable of 1 tumor our of 47 mice injected.24 Using similar 
methods as used with the colon cancer cell line, similar results for “cancer stem cells” 
have been found in leukemia and breast cancer.25,26 The conclusions drawn from these 
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studies is that even if radiation, surgery, or chemotherapy is highly effective and destroys 
every cancer cell except for one and that one cell is a stem cell, complete regrowth of that 
original tumor is possible. Thus future treatment strategies may take into account the 
importance in targeting specific “cancer stem cells.”   
Cancer is complex and acquires a series of traits that make it difficult to treat and 
completely cure. Previous and ongoing research has greatly revealed the mechanistic 
pathways of cell control and regulation and consequently a growing list of oncogenes and 
tumor suppressor genes have been discovered. It will take collaborative efforts for future 
successes and the National Cancer Institute understands this by developing the Physical 
Sciences Oncology (PS-OC) initiative. As history has demonstrated, the growing 
understanding of cancer will lead to better efforts and reduced mortalities for the fight 
against cancer. 
1.4 Cancer Treatment 
 Cancer therapy is divided into three primary modalities: surgery, radiation 
therapy, and chemotherapy. These methods can be used singularly or in combination to 
maximize the efficacy in destroying all cancer cells. Factors such as the type of cancer, 
the grade (size and invasiveness) of the cancer, the location of the cancer, and the 
patient’s current heath all contribute to which modality or modalities are most appropriate 
for that cancer.    
 Surgery is the oldest form of cancer therapy. In the case of solid tumors, surgery 
will always be the primary therapy of choice and may be supplemented with radiation or 
chemotherapy. Surgery operates by “zero-order” kinetics, meaning killing is not 
proportional to the number of cells initially present, but dependent on the number of cells 
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excised during the operation. Depending on the location of the tumor, percentage of 
healthy tissue removed, and the amount of normal tissue that can be regenerated 
determines the toxicity (morbidity) and risk of death (mortality) for that particular 
operation. For example skin cancers are typically considered low morbidity because the 
tissue can regenerate and the tumor is highly accessible. On the other hand, brain tumors 
are considered high morbidity because brain tissue is unlikely to be replaced and the 
tumor may be very inaccessible.  
Surgery is most effective for lower grade, accessible, well-localized tumors, but is 
considered a marginal therapy. Marginal therapy implies that a surgical procedure 
requires a margin of healthy tissue to be removed surrounding the tumor for best 
outcomes. Improvements in training, surgical techniques, and equipment has advanced 
the field of surgical therapy and also improved patient comfort through minimally 
invasive procedures.  
 Radiation therapy originated from observations that X-rays sterilize rams in the 
1920s. This therapy delivers high-energy photons or charged particles to ionize chemical 
species present in the body, particularly oxygen, into harmful, toxic compounds. Upon 
ionizing radiation, oxygen can form into peroxide, superoxide, or hydroxyl radicals each 
of which induce damage to DNA resulting in cell death. Radiation is most effective for 
well oxygenated tumors, proliferating cells, and tumors relatively unobstructed by 
surrounding tissue or organs.  
Enhancement of this therapy may be achieved by suppressing intracellular 
radioprotective substances such as thiols, inhibiting post-irradiation cellular repair 
processes, placing patients in hyperbaric environments, or using oxygen-mimetic 
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sensitizers.27 However, radiation therapy can fail if the radiation field didn’t encompass 
the entire tumor (geographical miss), part of the tumor did not receive a full dose 
(marginal miss), or the dose required to eradicate the tumor cell divided by the dose that 
yields unacceptable toxicity to surrounding tissue (therapeutic ratio) is close to one. 
Technological advances in imaging, 3-D rendering of tumors, and instruments for 
delivery of radiation has improved the field of radiation therapy and will continue to 
increase toxicity to cancer cells while reducing toxicity to healthy tissue. 
 The potential of chemical agents to be used for cancer therapy was discovered in 
WWI when the use of mustard gas suppressed bone marrow and caused atrophy to lymph 
nodes in soldiers exposed to the toxic gas. Today, chemotherapy has become a routine 
procedure for treating cancer. Like radiation therapy, chemotherapy preferentially targets 
proliferating cells, affects rapidly dividing cells more than slowly dividing cells, has a 
therapeutic ratio close to one, and low blood perfusion reduces its effectiveness. Unlike 
radiation therapy, chemotherapy is generally systemic and not localized which allows for 
a greater chance of targeting metastasis, but at the sacrifice of greater general toxicity to 
healthy tissue.  
 Chemotherapeutic drugs kill cells by disrupting or damaging DNA during cell 
growth and replication and can be divided into schedule independent or schedule 
dependent categories. Schedule independent drugs use ATP depletion, alkylating agents, 
or DNA intercalating agents as mechanisms for cell death. Schedule dependent drugs are 
drugs which must be administered at a certain phase of the cell cycle for it to be effective. 
In this case, prolonged treatment times are required in order for all cells to be exposed 
during specific cell phases. Furthermore, treatment using schedule dependent drugs is 
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often fractionated over a period of time to try exposing all cells at the appropriate cell 
phase. 5-fluorouracil and taxol are popular schedule dependent drugs while doxorubicin 
and cisplatin are popular schedule independent drugs. Advances in chemotherapy have 
been in the development of new drugs as well as modifying existing drugs with targeting 
mechanisms to reduce toxicity. Intravenous administration has been and continues to 
remain as the primary method for delivering chemotherapeutics.     
 Cytoreduction based on radiation or chemotherapy is based on first order kinetics. 
This means the killing of cancer cells is dependent on the number of cells initially present 
and a fraction of cells are killed with each round of treatment. Internal solid tumors are 
typically undetectable until it reaches 1010 cells which is about 1 cm3. Empirically, the 
fractional (or log) kill model most closely resembles behavior of tumors in response to 
chemo or radiation therapy (Figure 1.6).28  
Tumors are heterogeneous groups of cells operating together to form the 
cancerous mass and it is this heterogeneity that may be the reason why fractional killing 
is most applicable. For example, assume a cell is composed of 90% of differentiated 
cancer cells and 10% undifferentiated, cancer stem cells. Upon administration of a 
chemotherapeutic, only the 90% is targeted and destroyed; thus, the remaining 10% is 
capable of tumor regrowth. Cells existing in the quiescent (not actively proliferating) 
state versus the active proliferation state could also contribute to the fractional kill of 
cancer cells with each treatment. 
Traditionally, surgery is completed first, followed by radiation or chemotherapy. 
Surgery reduces tumor burden, increases blood perfusion to the surgically removed site, 
and increases the number of actively proliferating cells. This will enhance the 
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effectiveness of the adjuvant treatment of radiation or chemotherapy. The aggressiveness 
of chemotherapy or radiation is highly dependent on the cancer type and the motivation 
and health of the patient. Furthermore, a balance between a cure for cancer (elimination 
of all malignant cells) and living a full, comfortable, and normal life is highly patient 
dependent.  
For example, a hypothetical patient undergoes three different treatment plans in 
attempt to balance his or hers quest for a cure for cancer versus quality of life.29 In 
scenario one, the patient has surgery, then moderate chemotherapy approximately 2 years 
after surgery, and then passes away at 60 months post-surgery (Figure 1.7A). This 
treatment plan extended the patient’s battle against cancer over a period of 3 years which 
may have resulted in an uncomfortable life for an extended period of time. In scenario 
two, the patient has surgery, followed by immediate, moderate chemotherapy, then passes 
away at 60 months post-surgery (Figure 1.7B). In this case, the patient attempted to 
destroy the cancer in the shortest amount of time possible with moderate discomfort from 
the chemotherapy. In scenario three, the patient has surgery, then immediate, aggressive 
chemotherapy, then passes away at 60 months post-surgery (Figure 1.7C). This treatment 
schedule was planned for a patient who wanted to give the best effort to cure cancer in 
the shortest period of time, regardless of pain and discomfort caused by aggressive 
chemotherapy. These treatment schedules help demonstrate that adjuvant treatment at 
time of surgery decreases time to initial recurrence, but doesn’t greatly impact ultimate 
survival rates. Furthermore, while some improved or new therapies may not affect overall 
mortality statistics, they can dramatically affect quality of life for the patient.  
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For our research purposes it is important to select a specific cancer to 
appropriately tailor our polymer design to account for or exploit features unique to that 
cancer and its environment. For this thesis we will be focused on treating colorectal 
cancer. 
1.5 Colorectal Cancer 
 Colorectal cancer is defined as abnormal tissue growth in the colon or rectum that 
can turn into a large tumor mass. Growth of the tumor is not coordinated with that of 
surrounding healthy tissue and will continue to grow even if the known stimuli are 
removed. Colorectal cancer is the third most common cancer and the third leading cause 
of cancer-related mortality in both men and women in the United States.30 The mortality 
and incidence rates for colorectal cancer have decreased in the last decade due to routine 
examination and screening where the presence of cancer can be found early and removed 
with great success. Colorectal cancer is also the third most commonly diagnosed cancer 
in the world with incidence rates much greater for developed countries than undeveloped 
countries.31 Thus, there is a large motivational factor and immediate need for improved 
treatment options for colorectal patients.  
The exact cause of colorectal cancer is unknown, but many studies have revealed 
several risk factors. Age is considered the largest risk factor for colorectal cancers 
because 80% of diagnosed patients are over the age of 50 with a median age of 70.32 
Studies suggest a diet composed of high red and processed meat intake and low 
consumption of whole grains, vegetables, and fruits paired with a sedentary lifestyle may 
play a role in the development of colorectal cancer.33 It is also suggested long-term 
 16 
 
smoking increases the risk of colorectal cancer.34 Genetic inheritance of colorectal cancer 
has been suggested and is still being studied.35-38  
The detection and diagnosis of colorectal cancer is primarily carried out during a 
colonoscopy. A colonoscopy has become a routine procedure for older patients and it 
examines the entire colon and rectum using a lighted instrument with imaging 
capabilities. As this instrument traverses the colon, the doctor will look for, remove, or 
biopsy any abnormal tissue growths or polyps found. Polyps are noncancerous, abnormal 
growths which protrude from the inner wall of the colon or rectum. Some scientists are 
suggesting cancer of the colon or rectum originates from these polyps.39,40 Cancer 
positive biopsies are followed up with a variety of tests to determine the extent of cancer 
growth. These tests may include a variety of imaging techniques to view tumor size and 
formations, blood analysis to check for cancer markers, and surgery to remove the tumor 
and see how far it has infiltrated surrounding tissue. After these tests, colorectal tumors 
can be categorized in stages from 0 to IV.  
From the apical to basolateral side the colon wall is composed of mucosa, 
submucosa, muscle layers, and serosa with blood and lymphatic vessels spread 
throughout all layers except the mucosa (Figure 1.8).30 In stage 0, abnormal cells and cell 
growth are restricted to only the mucosa. Cells may or may not be cancerous and if 
cancerous are termed carcinoma in situ.  In stage I, cells are cancerous, forming in the 
mucosa and extending into the submucosa. Stage II is separated into three categories: 
Stage IIA, IIB, and IIC.  Cancer that has spread to the serosa is Stage IIA, while cancer 
that has spread through the serosa is Stage IIB. Stage IIC is the same as stage IIB except 
nearby organs have been infected with cancerous cells. Stage III reflects colon cancer 
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which has infiltrated nearby lymph nodes. The number of lymph nodes infected 
determines if it is IIIA, IIIB, IIIC where IIIC has the most lymph nodes infected. In all 
cases of stage III cancer, the infection of nearby organs is highly probable. In stage IV, 
cancer has spread through the entire colon, infected lymph nodes, and spread to all least 
one organ that is not near the colon. 5 year survival rates are inversely proportional to the 
stage of cancer, with a 12% survival rate for patients diagnosed with stave IV colorectal 
cancer. 
1.6  Treatment Strategies for Colorectal Cancer 
 Colon cancer is primarily treated with surgery, chemotherapy, and radiation. 
Surgery is standard treatment for all stages of colon cancer and the invasiveness of the 
procedure depends on the severity of the colon cancer. For early stage colon cancers, the 
cancer can be easily removed by “clipping” the site of interest by a tube through the 
rectum or simultaneously during a colonoscopy. As the tumor size grows and spreads, 
physicians are forced to cut through the abdominal wall to remove the tumor and a small 
amount of surrounding healthy tissue to try to remove all cancerous material. After 
removal, the colon is then resectioned together, thus making the colon slightly shorter. In 
some cases, the size of the tumor removed makes it difficult to resection so a temporary 
and sometimes a permanent opening is created between the colon and a bag placed 
outside of the body to collect the waste.   
For late stage colorectal cancers, chemotherapy and/or radiation are used as 
adjuvant therapy to surgery. Chemotherapy is not widely used for stage II cancers 
because the side effects outweigh the benefits. The most common chemotherapeutic 
delivered to colorectal cancer patients is a combination of fluorouracil (5-FU) and 
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leucovorin (LU). These drugs work synergistically to inhibit DNA synthesis and repair 
through different mechanisms. 5-FU inhibits a critical enzyme (topoisomerase II) 
required for DNA replication and is most effective when cells are actively proliferating 
and undergoing DNA replication. If cells are dormant, do not have the necessary growth 
signals, or the appropriate downstream signaling cascade, the drug effectiveness is 
decreased. Leucovorin further enhances the effect of 5-FU by inhibiting thymidylate 
synthase, an enzyme that becomes phosphorylated for DNA synthesis and repair. 
 Chemotherapeutic agents are currently administered in 6-8 week cycles with one 
infusion per week lasting 2 – 3 hr.. The expense of IV administration for drug alone can 
range from $1,028 for cycle of 5-FU/LV to upwards of $38,000 for other specialized drug 
cocktails.41,42 These expenses do not take into account the cost of surgery to remove the 
tumor, the payment of healthcare to administer the drug, nor the time or work lost as a 
result of receiving these treatments. The current estimated cost per quality-adjusted life 
year gained for colorectal cancer is $100,000.43 At this current rate, coverage policies and 
Medicare may not fiscally support new chemotherapeutics or expensive technologies. If a 
chemotherapeutic could be delivered orally via polymer drug carriers it would make an 
immediate impact for the patient and reduce costs.  
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Figure 1.1. Graphical representation of the number of cancer related publications 
according to Web of Knowledge for the past decade. 
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Figure 1.2. The cell cycle for a normal eukaryotic cell. 
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Figure 1.3. The formation of new blood vessels through angiogenesis. Endothelial 
cells extend pseudopodials to guide capillary sprout, divide, form adjacent vacuoles, and 
fuse together to form new luminal space.  
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Figure 1.4. The metastatic cascade. Primary tumor grows and establishes necessary 
resources to flourish. Then a pioneer cell sprouts off and intravasates into the blood 
stream, circulates, and arrests in distant organs. The cell then extravasates into the local 
tissue, forms micrometastasis, develops blood vessels, and forms into macrometastasis.   
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Figure 1.5. The circulatory hypothesis for metastatic cancer. The formation of 
metastasis usually arises on the organ downstream from primary tumor.  
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Figure 1.6. Absolute versus fractional (log) kill models for cancer cells. Absolute kill 
is associated with surgical removal while log kills model chemotherapeutic treatment.  
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Figure 1.7. Comparison of cancer treatment scenarios and duration to death. Long 
treatment, moderate chemotherapy (A); Short treatment, moderate chemotherapy (B); 
Short treatment, aggressive chemotherapy (C).  
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Figure 1.8. Progression of colon cancer. Normal gastrointestinal tract (A) and stage 0 
(B), stage I (C), stage II (D), stage III (E), stage IV (F) colon cancer. 
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Chapter 2 
Background 
 
2.1  Overview 
 Oral delivery can improve patient compliance and comfort for many therapeutic 
agents. Oral delivery of chemotherapeutic agents is an emerging research field and has 
shown promising results when compared to conventional intravenous administration.1-3 
Designing oral chemotherapeutics to more effectively treat cancer than intravenous 
treatments could revolutionize the fight against cancer, but a new host of obstacles must 
be overcome for proper delivery and oblation of the tumor. Intelligent, highly 
biocompatible polymer carriers can be synthesized to overcome these obstacles and 
transport chemotherapeutic agents to their proper location. In this chapter is discussed the 
mechanisms of action and current routes of administration of many cancer therapeutics. 
Focus is placed on doxorubicin, the chemotherapeutic agent used in this thesis. The 
gastrointestinal tract is a physiologically complex system with parameters such as time, 
pH, and microflora changing throughout. These parameters will be discussed as obstacles 
and potential modalities for colonic drug delivery. A review of current and past work in 
colon delivery will be presented and the potential advantages of a polymer carrier for the 
oral drug delivery of chemotherapeutics discussed.  
2.2  Chemotherapeutics   
 Advances in the understanding of tumor, tumor growth, and tumor development 
has allowed clinicians to improve on which chemotherapeutics are used and better ways 
of targeting the chemotherapeutics to reduce systemic toxicity. Chemotherapeutic agents 
 33 
 
are traditionally given after surgical removal of the tumor because decreased tumor 
burden, increased blood profusion to the surgical site, and increase in the number of 
proliferating cells enhance the effectiveness of the adjuvant therapy. Unfortunately, 
chemotherapy is not always a “full proof” plan because drug resistance cells or cancer 
stem cells may resist current treatments and could result in tumor reoccurrence.4 Thus 
over the years, specific chemotherapeutic regimens for specific cancers have been 
developed, but the route of administration of new drugs still heavily relies on intravenous 
injection. 
  As discussed in Chapter 1, chemotherapeutics can be separated into schedule 
dependent and schedule independent categories. Figure 2.1 illustrates a multitude of 
chemotherapeutic drugs and at what cell cycle phase they are most effective. Using this 
knowledge, treatment plans may use a “cocktail” of chemotherapeutics to provide the 
best chance for tumor destruction. These cocktail treatments serve two functions, to kill 
tumor cells via different mechanisms and to reduce the toxicity effect on healthy cells.  
Log kills are dependent on the present number of tumor cells (see Chapter 1) and 
when chemotherapeutics are combined, the log kills are multiplicative. For example, let 
us assume that drug A gives a 2-log kill and thus kills 99% of tumor cells and leaves 
behind 1%. Drug B will then kill 99% of the remaining 1% and thus 0.01% of the 
original number of tumor cells will remain (4-log kill).5 As for reduced toxicity, each 
chemotherapeutic mechanistically alters or disrupts a part of the cell replication process. 
Using an abundance of one chemotherapeutic could result in increased toxicity to the 
patient. However, using a variety of chemotherapeutics in smaller quantities could just as 
effectively hinder the cell replication process by attacking and destroying many routes of 
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the replication process while reducing toxicity. For example, a cocktail of 5-fluorouracil, 
taxol, and bleomycin would inhibit thymidylate synthase, affect microtubule dynamics, 
and fragment DNA, respectively. Furthermore, a tumor mass is composed of cells at 
different cycles of the replication process and thus combination chemotherapeutics can 
target multiple cell cycle phases (Figure 2.1), increasing the treatment plan success.6  
 The influence of mustard gas on field soldiers in World War I was the first 
evidence that a chemical compound could greatly influence cell death or inability for 
cells to replicate. From these observations stemmed the first anticancer drug, 
mechlorethamine, to be developed and administered to patients.7 Mechlorethamine, is a 
nitrogen mustard alkylating agent that works by crosslinking two strands of DNA 
together and thus preventing cell duplication.8 Since the mechlorethamine was 
discovered, many other chemotherapeutic drugs have been found or synthesized and fall 
in the categories of alkylating agents, anti-metabolites, taxanes, topoisomerase inhibitors, 
and cytotoxic antibiotics.9  
 Chemotherapeutics are given to a patient through intravenous administration. 
Typically, a patient undergoing many rounds of chemotherapy will have a surgically 
installed peripherally inserted center catheter (PICC-line) for easy connection and 
disconnection of the intravenous drip. Intravenous administration is the current method of 
choice due to the inherent hydrophobicity of chemotherapeutics which makes it difficult 
to load large amounts of drug into a small amount of aqueous solution. The patients are 
normally placed on a rotational schedule of chemotherapy once a week for approximately 
4 weeks up to months long.  
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The most common side effects due to the systemic delivery are myelosuppression, 
mucositis, and alopecia.10 Drug dosing is determined by the maximum tolerated dose 
(MTD) before unacceptable toxicity is present and is dependent on the drug. The MTD 
value is than correlated with a patient’s body surface area (determined by weight and 
height) for final optimization of dosing schedule and amount. In its current state, 
chemotherapy has only advanced in terms of new drugs and modifying existing drugs, 
but there is still a need for improved delivery methods, particularly oral delivery for 
patient care, comfort, and reduction in healthcare costs. 
2.3  Doxorubicin 
 Doxorubicin is a red pigmented, wide-spectrum antitumor antibiotic first 
discovered in soil samples taken from Castel Del Monte, an Italian castle. In these soil 
samples existed Streptomyces peucetius, a biologically active microbial metabolite that 
produced a red pigmented substance. This red pigment was extracted, isolated, and an 
antibiotic formed from this bacterium; it is now one of today’s most effective 
anthracycline antibiotic.11  Doxorubicin has been used clinically for the treatment of 
gastric, bladder, leukemia, soft-tissue sarcoma, ovarian, and breast cancers. 
Doxorubicin’s backbone is composed of a series of four 6-carbon ring structures with 
hydroxyl, oxygen, and amino sugar pendent groups attached to this backbone (Figure 
2.2). Doxorubicin has many ionic states and these can play an important role in their 
function and activity against tumor cells (Figure 2.3),12,13 especially in a dynamic pH 
environment such as the gastrointestinal tract during oral transit.  
 Doxorubicin stops cell proliferation and replication by intercalating between 
DNA nucleotides and inhibiting topoisomerase II which blocks DNA synthesis and 
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transcription. Furthermore, anthracylines are known to produce harmful free radicals 
upon metabolism.14 A majority of the binding of doxorubicin to the DNA strands is 
achieved through the alternating single double bond present in the ring structures, but the 
amino sugar can extend into the minor groove of DNA to form a hydrogen bond.15   
Doxorubicin is administered intravenously as single dose injections of 60 – 90 
mg/m2 every 21 to 28 days. A maximum lifetime dose is not to exceed 500 – 600 mg/m2
 
as cumulative cardiotoxicity associated with anthracycline treatment has been reported.16 
Nausea, vomiting, hypersensitivity (fever, chills), and peripheral neurotoxicity have also 
been associated with doxorubicin treatment. 
 Modifications to doxorubicin for improved tumor targeting have been researched 
and FDA approved. Doxil® (ALZA Corporation) is one such modification where 
doxorubicin has been PEGylated and loaded into liposomes. This drug delivery system 
uses the enhanced permeability and retention effect to demonstrate dramatically different 
release profiles as compared to free doxorubicin. While mucosa and skin toxicity remain 
present, alopecia and cardiotoxicity were greatly reduced in Doxil® treatments.17  
LivaTag® is another emerging doxorubicin modified chemotherapeutic. In this 
drug delivery system, poly(isohexyl cyanoacrylate) nanoparticles have been loaded with 
doxorubicin and shown great effectiveness against hepatocellular carcinomas of various 
animals.18 The development of novel polymer systems for the enhanced delivery of 
doxorubicin is growing and will continue to grow as the understanding of cancer and its 
dynamics emerge. 
 Doxorubicin has been selected for use in this thesis for multiple reasons. First, 
doxorubicin has demonstrated great success with a variety of tumors as discussed earlier; 
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however, its current effectiveness for colorectal cancer is limited. Thus, through this 
research, a new polymer system may be able to locally delivery therapeutic concentration 
of doxorubicin to the targeted tumor with reduced toxicity and be used as an alternative 
to tumors which have become multidrug resistant to 5-fluoruoracil and leucovorin. 
Second, doxorubicin possesses a series of double bonds throughout its backbone making 
it easy absorbt and fluoresce at varying wavelengths of light. This allows easy 
characterization of concentration and loading levels using standard spectrometers. Third, 
on the amino sugar group of doxorubicin, is a primary amine which can be modified or 
organically synthesized to include targeting pendent groups or long polysaccharide chains 
for protection through the small intestine and local degradation in the colon. Lastly, from 
a safety standpoint, doxorubicin’s distinct red pigment allows the user and those working 
beside the user to easy identify the presence of doxorubicin.    
2.4  Gastrointestinal Tract Physiology 
 The human gastrointestinal (GI) tract is composed of the following organs: 
stomach, small intestine, large intestine, colon, and rectum. The GI tract’s primary 
purposes are to breakdown and degrade consumed food or drink, extract the appropriate 
nutrients from the food or drink, transport the nutrients to the bloodstream, and prepare 
any undigested items for removal. The complex nature of each organ provides very 
specific roles to the overall digestive process and the balance of parameters such as 
residency time, pH, and microflora are critical for digestive success.   
 The stomach secretes protein-digesting enzymes such as pepsin and strong acids, 
such as hydrochloric acid, to begin the initial degradation of food. Due to secreted 
enzymes and hydrochloric acid, the stomach pH value is between 1 – 2 and the overall 
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environment is hostile to any microbial growth.19 The residence time is reported on 
average to be around 3 hr, but is highly variable depending on the type of food and the 
amount eaten.20 
 The small intestine is the next gastrointestinal organ after the stomach and the 
pyloric sphincter (valve between stomach and small intestine). The small intestine is 
approximately 16 feet long, 1 – 2 inches in diameter, and divided into three regions: the 
duodenum, the jejunum, and the ileum. The duodenum is the first and shortest section, 
the jejunum is the longest section, and the ileum is the last section and connects to the 
colon. The small intestine has approximately 2100 square feet of surface area for 
maximum absorption of nutrients and goblet cells secrete a mucosal lining to help aid in 
transport as well as protect the luminal lining. The small intestinal pH ranges from 5 to 7 
and increases toward the colon.21 The more neutral pH and less contractile nature of the 
small intestine makes it a more hospitable environment for microbial growth and colonies 
exist on the order of 103 – 104 CFU/mL.22 The transit time through the small intestine is 
consistently reported as 3 – 4 hr and during this time pancreatic and liver enzymes help 
further digest what was started by the stomach.23 The remaining undigested contents are 
then emptied into the large intestine.  
The large intestine is composed of the ascending, transverse, descending colon, 
and the rectum. It is approximately 4 – 5 feet long and approximately 2 – 3 inches in 
diameter. The colon is focused on reabsorbing any remaining water, digesting 
polysaccharide chains, and packing contents for removal from the body. The pH of the 
colon is neutral and ranges from 6 – 7.24 The combination of neutral pH and slow moving 
contents provides perfect conditions for microflora to grow and survive with 
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approximately 1012-1013 CFU/mL.22 The microflora is dependent on the long, undigested 
polysaccharide chains for its food and the waste products of the microflora are essential 
nutrients for the human body. The colon has been investigated for protein and drug 
absorption due to long residency times (20 – 30 hr) and lack of degradative enzymes that 
are abundant in the small intestine.25  
 The coordination of these gastrointestinal organs is essential to proper digestion 
and extraction of nutrients for human bodies to properly function. This system typically 
runs properly, but with disease, especially cancer, function can be altered or ceased 
completely. Diseases or cancers can cause changes in residency time, pH environment, 
and amount of microflora colonies. Since time, pH, and microflora are primarily 
mechanisms to exploit for oral delivery to the colon, it is important to account for these 
changes in the diseased or cancerous state.  
2.5 Systems for Oral Delivery of Therapeutics to the Colon 
 A variety of polymer carriers have been researched and reviewed for the delivery 
of therapeutic agents to the colon for the treatment of many diseases including irritable 
bowel syndrome, Crohn’s disease, ulcerative colitis, severe constipation or diarrhea, and 
colorectal cancers. Colonic delivery can be achieved through these primary mechanisms: 
pH,26 time,27 biodegradation,22 and pressure.28,29 Each of these mechanisms has 
advantages and disadvantages for colonic drug delivery and uses the native colonic 
environment as the stimulus or activating agent for the delivery of the drug. Polymer drug 
delivery devices may use one of the above mechanisms or combinations to achieve 
targeted, controlled drug delivery to the colon. 
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Time dependent delivery systems release drugs or therapeutics based on a time 
factor that parallels the transit time of the GI tract. Digestion can proceed in a very time 
dependent fashion, where each stage of digestion can be marked with a specific time 
period; however, GI transit time has high inter- and intra-patient variability and is further 
complicated for diseased patients.30,31 The time delayed systems are usually a three part 
system: 1) a core composed of the drug of interest, 2) an inner semi-permeable polymer 
membrane providing a time dependent release, and 3) an outer enteric coating protecting 
the contents from the low pH and enzymes of the stomach. The inner semi-permeable 
polymer’s composition, structure, and thickness determine the length of time before drug 
is released.  
Furthermore, these semi-permeable membranes can deliver the drug core by 
rupturing, eroding, or diffusing. For example, a blend of carnauba and bee wax combined 
with surfactants was applied in varying thicknesses as an aqueous dispersion to allow 
time dependent diffusion of a core composed of 5-aminosalicylic acid (5-ASA), an anti-
inflammatory drug.32 It was determined a thickness of 5.9 mm allowed water to diffuse 
in, dissolve 5-ASA, and elute out at an appropriate time. Shah et al. used a proprietary 
polymer blend allowing water to influx until hydrostatic pressure causes it to explode and 
release the contained drug33 while Takada and colleagues introduced micropores into  
hydrophobic shells to induce earlier release in the colon.34 
The capsular device is a second type of time dependent delivery device which 
utilizes a drug container, swellable substance, a cap, and water insoluble body (Figure 
2.4).35-37 Time dependent properties can be controlled by the composition of the swellable 
substance or the body of the device can be drilled with various sized pores. Swellable 
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substances have included sodium alginate,38 sucrose,39 sodium starch glycolate,40 and 
hydroxypropylmethyl cellulose.41  It is important to note these polymer membranes could 
become saturated with drug or caps prematurely ejected causing burst effects that result 
in high, local concentrated levels of toxic drug.  
From the stomach to rectum there exists an increasing pH gradient. The distinct 
pH ranges in each location of the GI tract make it possible to deliver a therapeutic agent 
to specific locations. However, like GI transit times, there can be inter- and intra-patient 
variability in pH values which can cause release in undesired locations.30 CODESTM  is a 
polymer device using an enteric coating composed of dimethyl aminoethyl methacrylate, 
butyl methacrylate, and methyl methacrylate which becomes permeable and swells at pH 
> 5.0. In this way, the pH environment of the small intestine will trigger the release of 5-
ASA. Similar systems using acrylic acid,42-44 methacrylic acid,45-49 and their blends with 
vinyl alcohol50,51 have also demonstrated drug delivery to the upper small intestine.  
Eudragit® polymers are probably the most commercial and successful enteric 
coatings focused on using pH sensitivity to delivery loaded contents. Eudragit® is a 
family of ionic, aqueous polymers composed of methacrylic acid and methacrylates. By 
varying the composition of these two monomers and controlling the final structure of the 
coatings, pH sensitivity can be finely tuned to the application of interest. Eudragit® L30,52 
Eudragit® L12.5,53 and Eudragit® S12.554 are formulations which have pH sensitivity of 
5.5 to target upper small intestine, 6.0 to target the lower small intestine, and 7.0 to target 
the colon, respectively. However, these formulations assume average pH values of 
healthy subject and may need to further adjusted or tailored for diseased or cancerous 
patients.  
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 The colon is habitat to more than 400 – 500 different species and predominantly 
includes Bacteriocides, Bifidiobacterium, and Eubacterium.55 Colonic microbes secrete 
enzymes which are capable of fermentation of long carbohydrate chains not digested in 
the small intestine. Therefore, polymer drug carriers or drugs themselves can be 
synthesized or modified to include long carbohydrate chains which are sustainable until 
they reach the colon. The most common structures for interaction with microbes include 
prodrugs, conjugates, and matrices. Prodrugs are pharmacologically inactive substances 
when administered, but through mechanical or chemical alterations becomes an active 
metabolite. Prodrugs are a growing research area, but FDA considers this design strategy 
a new drug entity which extends the time length to approval.56  
Conjugates are typically a therapeutic agent modified with a targeting group such 
as a long polysaccharide chain for local degradation in the colon. Conjugates are not 
pharmacologically inactive, but reduced activity of the therapeutic could result from the 
conjugation and be maintained until that conjugate is degraded. Conjugates, like 
prodrugs, are considered new chemical entities and undergo long FDA approval 
processes. Matrix delivery methods essentially use a drug uniformly dispersed in a 
polymer network which undergoes biodegradation in the colonic environment. The 
matrix method is one of the most popular delivery methods because of its quick FDA 
approval and its matrix template can be used for a variety of different therapeutic agents.    
Prodrugs of 5-aminosalicyclic acid are demonstrating growing importance in the 
treatment of ulcerative colitis or Crohn’s disease which are potential precursors of colon 
cancer.57-60 Conjugate technology is more historic than prodrugs and has been focused on 
using polysaccharides to target the colon.61 Polysaccharides for conjugation can be 
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derived from fungus,62 bacteria,63 or plants64 with dextran (bacteria) being the most 
widely used in the research community.65-67 Matrix delivery devices have included guar 
gum mixed with mebendazole (a therapeutic treatment for roundworms or hookworms),68 
ibuprofen photo-encapsulated within an inulin hydrogel,69 and 5-ASA loaded into 
chitosan-alginate microparticles.70 Due to a large number of different polysaccharides 
and different sizes, a significant wealth of knowledge and understanding is being 
developed by the scientific research community. Furthermore, since the colonic 
environment is not as variable as pH or transit time, this targeting mechanism may prove 
to be more sensitive and reliable. 
2.6  pH-Responsive Hydrogels 
Hydrogels are three-dimensional networks that are insoluble in aqueous 
environments due to physical and/or chemical crosslinks, but still imbibe large amounts 
of water or biological fluids.71 To date, many hydrogels have been synthesized and can 
use triggering mechanisms such as pH, light, heat, electrolyte strength, or even specific 
concentrations levels of proteins.72-74 Since hydrogels can imbibe copious amounts of 
water, they are highly biocompatible making them appropriate for many bioapplications. 
Their potential as biodevices were first discovered when poly(2-hydroxyethyl 
methacrylate) (PHEMA) gels were fabricated into soft contact lenses.75 Hydrogels have 
now been expanded extensively to the fields of drug delivery,76 tissue engineering,77 and 
regenerative medicine.78  Hydrogels can contain homopolymers or copolymers which can 
be arranged in specific or random fashions to elicit desirable physicochemical properties 
appropriate for their application at hand. Common monomers for hydrogel are: 
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poly(ethylene glycol)-dimethacrylate, hydroxyethyl methacrylates, methacrylic acid, 
acrylic acid, and acrylamides.     
pH-Responsive hydrogels include an ionizable pendant group within the polymer 
network and causes swelling in response to pH change. The selection of the pendant 
group can determine if swelling occurs in basic or acid conditions. In either case, in the 
non-swollen state, the polymer network is collapsed and prevents the transport of any 
compounds in or out (Figure 2.5A). However, in the swollen state, the polymer network 
forms many pores which serve as conduits for compounds to diffuse in or out (Figure 
2.5B). This transition from the collapsed to swollen state can be exploited for drug 
delivery where an encapsulated agent can be released in very specific pH environments.  
Anionic hydrogels contain acidic pendant groups and exhibit maximum swelling 
in pH ranges above the pKa of the acid (Figure 2.6). Anionic hydrogels are excellent 
polymer devices for oral drug delivery because at low pH, such as the stomach, the 
network remains collapsed, restricting drug release; upon exiting the stomach and 
entering the small intestine, the pH becomes more neutral, the polymer network swells, 
and the drug is released (Figure 2.7). The opposite swelling behavior is observed for 
cationic hydrogels which contain basic pendant groups (Figure 2.6). Biologically, 
cationic hydrogels can be useful for drug delivery to inflamed tissues where the pH is 
typically more acidic. Basic pendant groups are typically primary, secondary, or tertiary 
amines.   
Peppas and co-workers developed one of the first pH-responsive microgels, 
composed of poly(methacrylic acid) grafted with poly(ethylene glycol) tethers, P(MAA-
g-EG), for the use of oral drug delivery of proteins and peptides (Figure 2.8).79-81 The 
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methacrylic acid contains carboxylate groups with a pKa of 4.8 – 4.9,82,83 and does not 
swell until these values are surpassed. Thus, loaded biomacromolecules are protected 
from the acidic, proteolytic environment of the stomach and subsequently released in the 
more neutral pH environment of the small intestine. To enhance protection and prevent 
premature therapeutic agent release in low pH, the etheric oxygen of the poly(ethylene 
glycol) (PEG) tether was introduced so that its etheric oxygen could hydrogen bond with 
the hydroxyl group of the methacrylic acid (Figure 2.9). Small modifications to the 
hydrogel system such as the PEG tether or introduction of mucoadhesive agents have 
proven useful for oral drug delivery of proteins and peptides.84 
2.7  Oral Chemotherapeutics 
 As discussed at the beginning of this chapter, oral delivery is the gold standard for 
patient compliance and comfort. Chemotherapeutics are currently administered 
intravenously for systemic delivery and requires long profusion times for each treatment, 
can cause trauma when trying to access the bloodstream (needlestick), form clots, and 
bypasses the body’s normal immune defenses. The development of oral 
chemotherapeutics would eliminate the need for intravenous delivery and potentially 
improve patient comfort.85 A small number of chemotherapeutic agents have been orally 
delivered and shown promising results such as lower toxicity and clinical efficacy that is 
equal to or sometime improved when compared to intravenous treatment.86-88  
The advantages of oral chemotherapeutics include patient preference, equivalent 
efficacy to intravenous regimens, favorable safety profiles, and cost-effectiveness.89 
Patient preferences include reduction of hospital or clinical visits, convenience, 
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elimination of surgically implanted cannulas, and greater control over the dosage and 
environment of administered chemotherapeutic agent.90  
Capecitabine (Xeloda®, Roche Ltd, Basel, Switzerland) is an example of an oral 
chemotherapeutic approved by the FDA for metastatic colorectal and breast cancers.91  
Capecitiabine is a prodrug that undergoes a series of enzymatic steps which result in the 
final antineoplastic drug 5-fluoruoracil (Figure 2.10). Either 150 mg or 500 mg 
capecitabine pills are taken twice daily for 14 days and 7 days of rest to complete a full 
21 day cycle. The pill is swallowed, protected from the stomach via an enteric coating, 
and dissolved in the small intestine. The capecitabine is absorbed through the small 
intestinal wall into the blood stream and transported to the liver where the first enzymatic 
step occurs through carboxylesterase. The secondary intermediate is further altered by 
cytidine deaminase found in most tissues and finally converted to 5-fluoruoracil by 
thymidine phosphorylase which is expressed in elevated levels in tumors, but still found 
in healthy tissue. The approval of capecitabine is based on non-inferiority to traditional 
intravenous delivery, but side effects such as increased hand-feet syndrome have been 
noted by the patients. Capecitabine is only employed for late stage metastatic colorectal 
or breast cancers and if a more direct delivery method with reduced side effects is 
developed, treatment of tumors can occur at early stages and reduce the opportunity for 
metastasis.   
Despite these advantages, there are still obstacles that must be overcome for oral 
administration of chemotherapeutics. These obstacles include the delivery of the agent to 
the targeted tumor which can either be transported across the epithelium of the 
gastrointestinal (GI) tract into the bloodstream (breast or liver cancer) or remain in the GI 
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tract for local delivery (colorectal cancer). Potential harm to the stomach and GI tract due 
to the toxicity of the agent as well as the toxic agent being exposed to the low pH and 
degradative enzymes of the stomach must be overcome as well. Chemotherapeutics are 
traditionally hydrophobic structures which makes it difficult for loading and releasing in 
hydrogel systems. While pH-responsive hydrogels may possess the necessary 
characteristics for protecting the chemotherapeutic agent and the GI tract from each 
other, they must be modified with hydrophobic polymer segments for preferential loading 
of hydrophobic agents. Finally, oral formulations give control to the patient, but eliminate 
the ability to quickly halt or lower dosing as with intravenous administration; however, 
this could be avoided by instituting multiple daily doses which maintain therapeutic 
concentration levels for tumor destruction without developing significant toxicity to 
healthy tissue.   
2.8 Proposed System for Oral Delivery of Chemotherapeutics to the Colon  
This thesis focuses on the development and characterization of hydrogel carriers 
for the oral delivery of chemotherapeutic agents. This research will investigate a new 
class of materials comprised of hydrophilic and hydrophobic components to load 
chemotherapeutic agents, protect the stomach from the toxic drug, protect the drug from 
the harsh enzymatic conditions of the stomach, and release the drug in the small intestine 
for transport to the cancer of interest. 
Upon review of the primary mechanisms for colon drug delivery, combining a 
pH-responsive hydrogel carrier with a chemotherapeutic conjugate can provide oral, 
targeted drug delivery to the colon. The pH-responsive hydrogel carrier will provide the 
necessary protection from the harsh environment of the stomach and then release the 
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chemotherapeutic conjugate in the small intestine where the chemotherapeutic conjugate 
will reduce its toxic activity until it reaches the colon where colonic microbes ferment 
polysaccharide chains. 
  Previous work in our laboratory has concentrated on the optimal design of pH 
responsive hydrogels45-49 and had success in the oral delivery of insulin,92-94 calcitonin,95-
97
 and bleomycin.82,98 However, the translation of these polymer systems for their use and 
interaction with hydrophobic, low molecular weight therapeutic agents, such as 
chemotherapeutics, is limited and needs to be optimized or modified for greater success. 
Clearly, a polymer system balanced with hydrophilic-hydrophobic properties may prove 
advantageous for the delivery of hydrophobic, low molecular weight therapeutic agents. 
In this work, we will combine the desirable characteristics of pH-sensitive, 
hydrophilic networks with the hydrophobic thermodynamic behavior of certain 
homopolymers by either synthesizing advanced interpenetrating networks (IPN) or pH-
responsive hydrogels dispersed with hydrophobic nanoparticles. These structures can be 
used to develop amphiphilic polymer structures for bioapplications.99-105 
In IPNs, two homopolymers or copolymers are physically entangled within one 
another, but are not chemically bound; this allows the combinatorial expression of 
properties from each individual polymer network. We will synthesize and characterize 
sequential IPNs composed of a pH-responsive, hydrophilic polymer, P(MAA-g-EG), 
prepared from methacrylic acid (MAA) grafted with poly(ethylene glycol) tethers, and 
hydrophobic poly(n-butyl acrylate) (PBA) (Figure 2.11). The synthetic technique used in 
this work will allow the incorporation of varying amounts of PBA into the P(MAA-g-
EG) hydrogel resulting in IPNs with a distribution of physical properties.  
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Using the P(MAA-g-EG) hydrogel system as previously designed, but assembling 
it in the presence of hydrophobic nanoparticles develops new structures and architectures 
which may lead to significant improvements of materials for oral chemotherapeutic 
delivery. Due to their small nature, nanoparticles can possess unique characteristics 
different from their larger parent counterparts and can be easily incorporated into existing 
polymer structures to elicit new physical and chemical properties.106 Research in the 
nanoparticle field has grown significantly in the last decade and a host of established 
techniques are available to develop nanoparticles of desirable sizes and properties.107,108 
In this second polymer system, P(MAA-g-EG) is polymerized in the presence of 
poly(methyl methacrylate) (PMMA) nanoparticles to form a hydrogel dispersed with 
hydrophobic domains (Figure 2.12). In this way, the degree of hydrophobicity of the final 
polymer carrier can be varied and elicit a distribution of physical properties. These 
polymer carriers paired with a chemotherapeutic conjugate could provide oral, targeted 
drug delivery to the colon and treat early stage colorectal cancers in a direct manner.  
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Figures 
 
 
 
  
 
 
Figure 2.1. Cell-cycle schematic and respective sensitivity to chemotherapeutic 
agents. 
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Figure 2.2. Doxorubicin structure. 
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Figure 2.3. Possible ionic configurations of doxorubicin within the pH range of 4.0 – 
9.0. 
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Figure 2.4. Capsular device utilizing time dependent properties for drug delivery.  
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Figure 2.5. SEM of P(MAA-g-EG) polymer structure. Collapsed state (A) and the 
swollen state (B).  
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Figure 2.6. Swelling of theoretical pH-sensitive polymers. The blue line represents a 
theoretical anionic polymer; the red line represents a theoretical cationic polymer. Both 
polymers have a pKa of about 6. 
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Figure 2.7. Polymer structure in the complexed and swollen state. In low pH the 
polymer structure is collapsed and prevents therapeutic agent release. In neutral to high 
pH the polymer chains become repulsive, form a porous network, and release the 
therapeutic agent.    
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Figure 2.8. pH-Responsive hydrogel system. Poly(methacrylic acid) backbone (blue) 
with poly(ethylene glycol) grafted tethers (purple).  
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Figure 2.9: Graphical representation of complexation between MAA and PEG. (a) 
Complexed state at gastric pH levels due to hydrogen bonding; (b) decomplexed state at 
intestinal pH due to ionic repulsion of oxygen. 
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Figure 2.10. Capecitabine prodrug for metastatic colorectal and breast cancer. 
Prodrug undergoes three enzymatic steps to form the final active chemotherapeutic 5-
fluoruoracil.   
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Figure 2.11. Amphiphilic interpenetrating polymer network. Poly(methacrylic acid) 
backbone (blue) with poly(ethylene glycol) grafted tethers (purple) provide hydrophilic, 
pH-responsive properties while the poly(n-butyl acrylate) (orange) provides hydrophobic 
properties.  
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Figure 2.12. pH-Responsive hydrogel dispersed with hydrophobic nanoparticles. 
Nanoparticles are dispersed and photoencapsulated during the UV-polymerization 
process. 
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Chapter 3 
Objectives 
 
A promising strategy for the oral administration of chemotherapeutics involves 
the use of environmentally – sensitive hydrogels complimented with hydrophobic 
polymers. Environmentally – sensitive hydrogels composed of methacrylic acid (MAA) 
chains grafted with poly(ethylene glycol) (PEG) tethers has been shown to exhibit non-
specific targeting characteristics to the upper small intestine and can be used as delivery 
vehicles for a variety of proteins and peptides. However, in previous studies, the success 
of this family of hydrogels was shown for delivery of hydrophilic therapeutic compounds 
and not hydrophobic chemotherapeutics.  
Thus, the main goal of this thesis was to use these pre-existing environmental – 
sensitive hydrogels, but modify them with hydrophobic moieties that would impart 
preferential association, and will exhibit loading and release of hydrophobic 
chemotherapeutic compounds. The development of these amphiphilic polymer systems 
was made possible through interpenetrating polymer networks or by dispersing 
hydrophobic nanoparticles in the bulk of the hydrogel.    
The objective of this research was to develop a new class of polymer drug 
carriers, which could be optimized by varying the ratio of hydrophobic and hydrophilic 
components, that could promote the protection of and increase loading efficiency of low 
molecular weight, hydrophobic therapeutic agents, particularly chemotherapeutics and 
their conjugate forms. Protection from the enzymatic degradation and low pH of the 
stomach is important in keeping the drug biologically active, while increased loading 
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levels will provide drug concentrations at therapeutic levels appropriate for the treatment 
and reduction of colorectal cancer. The work done focused on the synthesis and 
characterization of polymer carriers and a chemotherapeutic conjugate, the loading and 
release of chemotherapeutic agents and its conjugate form, and the in vitro analysis of 
toxicity and transport kinetics.  
The specific aims of this research project were: 
1. to develop polymer drug carriers for the oral drug delivery of hydrophobic 
therapeutic agents using hydrophilic-hydrophobic interpenetrating networks and 
hydrogels dispersed with hydrophobic nanoparticles; 
2. to design and synthesize a chemotherapeutic conjugate targeted for the colon; 
3. to characterize the polymer system’s swelling properties, ability to load 
hydrophobic therapeutic agents, and in vitro release kinetics in physiological 
relevant conditions; and  
4. to assess the in vitro cytocompatibility of polymer carriers and the transport 
properties across an intestinal epithelial model.  
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Chapter 4 
Synthesis and Characterization of Interpenetrating Polymer Networks 
 
4.1 Introduction 
Novel synthetic techniques have led to significant improvements of materials which can 
be used in biomedical and clinical applications. Of particular interest to us are biomaterials based 
on pH-responsive hydrogels. Hydrogels are three-dimensional networks that are insoluble in 
aqueous environments due to physical and/or chemical crosslinks, but still imbibe large amounts 
of water or biological fluids.1 These networks can be synthesized using biocompatible polymers 
and can be tailored to exhibit desirable physicochemical properties depending on their swollen 
and collapsed states. These properties change drastically at an appropriate pH shift and can be 
used to achieve local and targeted drug, peptide, or protein delivery.  
For these reasons, pH-responsive hydrogels exhibit promising results as polymer carriers 
for oral delivery of a variety of proteins and peptides which are traditionally administered 
parenterally or through subcutaneous injections. The expansion of hydrogel research and the 
evolving nature of pH-responsive hydrogels parallel the large growth of protein and peptide 
drugs synthesized or utilized by pharmaceutical companies. The translation of these polymer 
systems for their use and interaction with hydrophobic, low molecular weight therapeutic agents 
is limited and needs to be optimized or modified for greater success. Clearly, a polymer system 
balanced with hydrophilic-hydrophobic properties may prove advantageous for the delivery of 
hydrophobic, low molecular weight therapeutic agents. 
Previous work in our laboratory has concentrated on the first design of an 
environmentally – sensitive hydrogel composed of methacrylic acid (MAA) and poly(ethylene 
glycol) tethers (referred to as P(MAA-g-EG).2-4  This P(MAA-g-EG) has undergone small 
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changes by subsequent investigators in our group to develop an optimum ratio of MAA and PEG 
that provides the highest degree of complexation and swelling to the highest degree in the 
uncomplexed state.5-9 These hydrogels contains carboxyl groups on the MAA moiety which will 
form a hydrogen bond with the etheric oxygen of the PEG chain forming a tight, collapsed 
network in low pH. In neutral pH, the carboxyl groups become deprotonated causing an 
expanded network due to ionic repulsion. Thus, this pH shift from the stomach (low pH) to the 
upper small intestine (neutral pH) can be used as a physiological trigger for releasing entrapped 
drug. These hydrogels have been used to orally deliver insulin,10-12 calcitonin,13-15 and 
bleomycin.16,17  
For this research, the optimized P(MAA-g-EG) hydrogel will be utilized and modified 
with complimenting hydrophobic properties to form two separate polymer drug carrier systems. 
The first system will use P(MAA-g-EG) networks with the hydrophobic thermodynamic 
behavior of certain homopolymers by synthesizing advanced interpenetrating polymer networks 
(IPN; Chapter 4) and the second system will utilize hydrophobic nanoparticles dispersed 
throughout the P(MAA-g-EG) network during polymerization (Chapter 5). 
In this chapter we discuss the IPN technology. IPNs combine the desirable characteristics 
of pH-sensitive, hydrophilic networks with the hydrophobic thermodynamic behavior of certain 
homopolymers by synthesizing advanced IPNs that can be used to develop amphiphilic polymer 
structures for bioapplications.18-21 In IPNs, two homopolymers or copolymers are physically 
entangled within one another, but are not chemically bound; this allows the combinatorial 
expression of properties from each individual polymer network.  
 The IPNs were synthesized and characterized to determine their potential as oral polymer 
carriers of chemotherapeutics. Characterization included swelling studies to determine pH-
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responsiveness; swelling in sequential solvents and staining to elicit the degree of 
hydrophobicity; and imaging techniques to determine microparticle size and distribution.  
4.2 Materials and Methods 
Materials. Methacrylic acid (MAA), n-butyl acrylate (BA), tetraethylene glycol 
dimethacrylate (TEGDMA),  1-hydroxycyclohexyl phenyl ketone (Irgacure® 184), 3,3-
dimethylglutaric acid (DMGA), Nile Red, dimethyl sulfoxide (DMSO), and ethanol were 
purchased from Sigma–Aldrich (St. Louis, MO). 10× phosphate buffer solution (PBS) and 
sodium chloride were purchased from Fisher Scientific (Fair Lawn, NJ). Poly(ethylene glycol) 
monomethyl ether monomethacrylate (PEGMMA; 1000 g/mol) was from Polysciences Inc. 
(Warrington, PA). All chemicals were used as received except for MAA which was vacuum 
distilled at 54 ºC and 25 mm Hg prior to use to remove the inhibitor hydroquinone. Double 
distilled water was used in all studies. Figure 4.1 illustrates the chemical structures used strictly 
for polymer systems. 
Synthesis of P(MAA-g-EG) Hydrogels. The P(MAA-g-EG) hydrogel was formed by 
free radical UV-initiated polymerization (Figure 4.2). First, MAA and PEGMAA were placed in 
an amber bottle in a 1:1 molar ratio while TEGDMA and Irgacure® 184 were added in the 
amount of 0.75 mol % and 0.5 wt % of total monomer respectively.  A solvent ratio composed of 
50:50 w/w ethanol to water was added in a 50:50 w/w ratio of total monomer to solvent. The 
amber bottle was capped, sonicated for 15 minutes to ensure thorough mixing, and then purged 
with N2 for 30 minutes in a sealed glove box to remove oxygen from the system. The precursor 
solution was pipetted between glass plates (15 cm x 15 cm x .3 cm) separated by a 0.7 mm 
Teflon spacer and exposed to UV light at an intensity of 16 mW/cm2 (Dymax 2000-EC Light 
Curing System, Torrington, CT) for 30 minutes to form a hydrogel film. The resulting film was 
78 
 
removed from the glass plates and washed with deionized water for 7 days to remove unreacted 
components. The washed film was punched into 18 mm discs for incorporation of the second 
hydrophobic network, 10 mm discs for swelling studies, or crushed into 75 – 500 µm particles 
for loading/release studies. Both discs and particles were dried in vacuum at 30 °C for 1 week. 
Synthesis of IPNs of P(MAA-g-EG) and PBA. The IPN was formed by a sequential 
free radical UV-initiated polymerization in the presence of the first P(MAA-g-EG) hydrogel 
(Figure 4.3). A solution composed of BA, TEGDMA, and Irgacure® 184 was prepared using the 
same molar ratios as above but without PEGMMA. The solvent composed of ethanol and water 
was adjusted from 50:50 to 80:20, 75:25, or 70:30 (w/w). This procedure was used for the 
production of IPNs with increasing PBA content: 80/20 IPN, 75/25 IPN, 70/30 IPN. All IPNs 
were synthesized in the following manner: an 18 mm dried P(MAA-g-EG) disc was placed in a 
solution of 80:20, 75:25, or 70:30 (w/w) ethanol to water, BA, TEGDMA, and Irgacure® 184 and 
shaken for 24 hours to allow the disc to reach equilibrium. The resulting P(MAA-g-EG) disc, 
swollen with hydrophobic monomer, was purged with N2 for 45 minutes to remove oxygen, 
blotted to remove excess soaking solution, placed on an open-faced Teflon square (8 cm x 8 cm), 
and exposed to UV light at an intensity of 16 mW/cm2 (Dymax BlueWave 200 UV Curing Spot 
Lamp, Torrington, CT) for 45 minutes. The amphiphilic IPNs were washed in 30% (w/w) 
ethanol in water for several days and either punched into discs or crushed into particles (75 – 500 
µm) for future use. Both particles and discs were dried in vacuum at 30 °C for 1 week. 
Characterization of P(MAA-g-EG) and IPNs. Solvent influence during IPN formation. 
It is predicted that adjusting the solvent ratios of ethanol to water during the formation of the 
PBA network could influence the degree of hydrophobicity of the IPN. Thus, 10 mm P(MAA-g-
EG) discs were dried and allowed to undergo swelling in 100/0, 80/20, 75/25, 70/30 ratios of 
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ethanol to water for 24 hours. The resulting equilibrium weight swelling ratio (g swollen / g 
polymer) was determined. 
Hydrophobic staining. Hydrophobic staining was used to determine the presence of the 
PBA network in the IPNs. The following protocol was adapted to stain polymer discs: a 20 
mg/mL stock solution of Nile Red, a hydrophobic dye, was prepared by dissolving in methanol. 
75 µL of the stock solution was dissolved in 8 mL of double distilled water and combined with 
120 mL of 1× PBS. P(MAA-g-EG) and IPN discs were soaked for 24 hours in 60 mL of the 
aforementioned Nile Red solution and washed multiple days with water.22 
Contact Angle Measurements. Surface analysis was carried out by measuring contact 
angles on a goniometer (Rame-Hart Goniometer Model No. 100) using DROPimage software to 
analyze the influence of PBA on the IPN surface. Samples were pre-swollen in water for 24 
hours, removed and placed on a standard microscope slide, and the surface dried with a Kim 
Wipe. Static contact angle measurements, θ, of distilled/deionized water droplets at the IPN-air 
or P(MAA-g-EG)-air interface were measured at room temperature (Figure 4.4). A 5 µL sessile 
drop of water was measured at 10 sec after deposition on the polymer surface. The reported static 
angle measurements are an average of six measurements where three measurements were taken 
on each of two samples. 
 Hydrophobic Swelling Ratio. P(MAA-g-EG) and IPN discs were subject to sequential 
equilibrium weight swelling experiments in two different swelling agents to characterize the 
PBA content in the bulk of the IPNs. First, dry discs were swollen to equilibrium in water, qw, 
and the equilibrium weight swelling ratio determined. The discs were then dried again and 
reswollen to equilibrium in isopropanol, qi, and the equilibrium weight swelling ratio 
determined. The ensuing ratio of qw divided by qi was correlated to the hydrophobicity of the 
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polymer systems.23 Solubility parameters of isopropanol and PBA are similar and thus the 
ensuing ratio of qw divided by qi should decrease with increasing PBA content. 
  Swelling Studies. Dynamic and equilibrium swelling studies were used to study the pH-
responsive behavior of P(MAA-g-EG) and IPNs. Swelling studies utilized 0.1 M 
dimethylglutaric acid (DMGA) buffers ranging from pH 3.2 to 7.6. Sodium chloride was added 
to control ionic strength. 10 mm IPN or P(MAA-g-EG) discs were punched from hydrated 
samples and dried. The dried discs were placed in approximately 100 mL of the 0.1 M DMGA 
buffers housed in a swelling chamber (Figure 4.5). The swelling chamber provided the swelling 
media to uniformly penetrate the sample from all directions as opposed to one surface and the 
edges as done before. For dynamic swelling conditions, the same polymer disc was subjected 
first to a pH of 3.2 for 12 minutes, removed, blotted, weighted, and then placed in the DMGA 
buffer of the next highest pH for another 12 minutes. This was repeated until a pH of 7.6 was 
reached. All samples were thermostated to physiological conditions (37 °C). The swelling ratio, 
q, was calculated as the swollen weight divided by the dry weight of the polymer disk. 
Equilibrium swelling was completed utilizing the same buffer series as above except discs 
remained in one pH level for 24 hours. The swollen discs were weighted and equilibrium weight 
swelling ratio determined as mentioned above. 
 For mesh analysis studies, the mass of the polymer disc were additionally 
measured in n-heptane, a non-solvent, using a hanging basket scale apparatus (Figure 4.6). 
Through this extra measurement, polymer volume fractions in the relaxed, dry, and swollen state 
can be determined and used in calculating mesh sizes.  
Measurements of sample values in the “relaxed state” (i.e., in the state immediately after 
polymerization but before swelling) were taken just after polymerization, dry measurements after 
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10 days in vacuum or once no mass loss could be detected, and swollen measurements were 
made after a 24 hours equilibrium swelling study utilizing the same buffer series as above. 
For IPNs, the relaxed and dry measurements were taken before incorporating the second 
network and the swollen measurements were performed after the second network was 
incorporated into the final drug delivery carrier.   
 Scanning Electron Microscopy (SEM). P(MAA-g-EG) and IPN microparticles were 
prepared as previously described and kept in vacuum until ready for imaging. Microparticles 
were placed directly on carbon tape covered aluminum stubs and sputter coated (Cressington 208 
Benchtop Sputter Coater) with an 8 nm thick layer of platinum/palladium for improved image 
quality. Images were obtained with a SEM (Supra 40 VP, Carl Zeiss Inc.) operating at 5 kV and 
working distances between 2 and 10mm.  
 Differential Scanning Calorimetry (DSC). The glass transitions temperatures (Tg) were 
determined by differential scanning calorimetry (DSC, Mettler Toledo DSC 1). The cell was 
calibrated using an indium standard and sample weight was ~ 15 mg. After equilibration at 100 
°C for 5 minutes the sample was heated to 200 °C for 10 minutes to remove any residual solvents 
in the sample. The sample was then thermostated to -100 °C for 5 minutes and then reheated to 
200 °C. All heating and cooling rates were ± 20 °C/min and Tg was measured on the second heat. 
4.3 Results and Discussion 
Amphiphilic interpenetrating networks were developed through sequential free radical 
UV-initiated polymerization of two sets of monomers. The hydrophilic P(MAA-g-EG) network 
was formed first, followed by polymerization of the hydrophobic PBA network within the 
P(MAA-g-EG) network. The ensuing IPNs were characterized using hydrophobic staining, 
contact angles measurements, swelling experiments, and imaging to verify and determine the 
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influence the PBA network had on the polymer carriers properties and their potential as oral 
delivery devices for hydrophobic agents. 
Characterization of P(MAA-g-EG) and IPNs. Solvent influence during IPN formation. 
P(MAA-g-EG) discs were placed in varying ratios of ethanol to water and the resulting P(MAA-
g-EG) equilibrium swelling ratios increased with increasing water content (Figure 4.7). The 
increasing water content increases the deprotonation of the carboxyl group of the polymer and 
thus the hydrogel is capable of swelling more. An increase in swelling provides the means of 
incorporating more PBA during the second polymerization process. Ratios of 60:40 and 50:50 
ethanol to water were also tested and demonstrated similar trends in the equilibrium swelling 
ratio, but were insufficient to fully dissolve butyl acrylate during the second polymerization. 
Hydrophobic Staining. P(MAA-g-EG) and IPNs were placed in the Nile Red solution for 
24 hours. P(MAA-g-EG) samples remained clear and translucent while IPN samples were 
stained hazy pink indicating the presence of the PBA network in the IPNs (Figure 4.8). The 
intensity of the pink hue was not distinguishable between IPN samples and thus could not 
quantitate an increasing or decreasing degree of hydrophobicity between samples.  
Contact Angle Measurements. Polymer discs were equilibrated in water for 24 hours 
before being subjected to contact angle measurements using 5 µL sessile drops. Static drops were 
placed on the sample surface and the angle formed between the droplet and the surface, θ, was 
determined (Figure 4.4). For pure P(MAA-g-EG) discs, contact angles measured approximately 
52°. For the IPN samples, contact angles measured 64°, 73°, and 105° for the 80/20, 75/25, 70/30 
IPNs, respectively (Table 1). This gradual increase in contact angle measurements is indicative 
of increasing hydrophobicity on the surface of the IPNs.  
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Hydrophobic Swelling Ratio. The equilibrium weight swelling ratio in water, qw, divided 
by the equilibrium weight swelling ratio in isopropanol, qi, was employed to determine the 
influence of PBA in the bulk of the IPNs and is defined as the hydrophobic swelling ratio. 
Isopropanol and Butyl acrylate homopolymers have been computed to have solubility 
parameters, δ, of 8.8 and 9.0 (cal/cm3)1/2, respectively, making them compatible solvents (Sigma-
Aldrich). P(MAA-g-EG) hydrophobic swelling ratio was determined to be 1.34 and indicates that 
swelling in water is much greater than swelling in isopropanol. This is to be expected as 
P(MAA-g-EG) is hydrophilic due to the presence of the methacrylic acid and contains no 
hydrophobic polymers. As for the IPNs, all hydrophobic swelling ratio values were less than 
1.34 which indicates swelling of PBA in isopropanol is greater than water. The hydrophobic 
swelling ratio progressively decreases from 0.96 for the 80/20 IPN to 0.80 for the 70/30 IPN 
(Table 1). This gradual decrease in the hydrophobic swelling ratio indicates an increasing 
presence of PBA content in the bulk of the IPN. The same set of IPN discs were then subjected 
to the same procedure but were soaked in isopropanol first followed by water. The same trend 
was demonstrated for the reverse procedure where IPN discs had lower swelling ratios as 
compared to the pure P(MAA-g-EG). It can be concluded this hydrophobic swelling ratio is not 
independent on past swelling conditions, but dependent on the amount of PBA present in the 
IPN. These results paired with the contact angle measurements led to the conclusion that our 
synthetic technique allowed us to control the amount of hydrophobic content in the IPN on the 
surface and in the bulk. 
Swelling Studies. Swelling experiments illustrated the pH-responsive behavior of the 
polymer drug carrier systems in simulated physiological fluids, specifically the effect of 
introducing a PBA network into the P(MAA-g-EG) hydrogel samples. For dynamic and 
84 
 
equilibrium swelling experiments, minimal swelling occurred in gastric conditions (low pH) due 
to the anionic nature of the P(MAA-g-EG) network. Because the P(MAA-g-EG) network 
contains a carboxyl group with a pKa value of 4.8-4.9, swelling is minimized until these values 
are surpassed.24,25   
For all dynamic swelling experiments, the swelling ratios of the IPNs were greater than 
P(MAA-g-EG) (Figure 4.9). The larger swelling ratios of the IPNs is a result of carboxyl groups 
deprotonating were it is believed the presence of the second PBA network induced a more open 
structure in which water could more freely penetrate and deprotonate these carboxyl groups. For 
equilibrium weight swelling experiments, the equilibrium swelling ratio diminished as the 
amount of PBA content increased (Figure 4.10). The increasing presence of the PBA network 
influences the number of physical macromolecular entanglements between both networks, alters 
free volume for polymer chain movement, and reduces or shields ionic repulsion between 
deprotonated carboxyl groups, all which reduce equilibrium weight swelling ratios. Alternative 
modifications to the original P(MAA-g-EG) hydrogel have been completed previously in our lab 
and also shown variation in swelling behavior.26,27  
Mesh Analysis. Measurements of the volume fraction of the IPNs in the relaxed and 
swollen state were determined to gain insight into whether these polymer carriers could be useful 
for loading and releasing hydrophobic, therapeutic agents. The volume fraction of the polymer in 
the relaxed state (υ2,r) was calculated using Equation 4.1.  
, = ,	
,,	
,			                                                                                                                                                                              (4.1) 
where the subscripts ‘r’ and ‘d’ represent the relaxed and dry states, respectively. The volume 
fraction of the polymer in the swollen state (υ2,s) was calculated using Equation 4.2.  
, = ,	
,,	
,		                                                                                                                     (4.2) 
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where Wa and Wh are the weights in air and n-heptane and the subscripts ‘s’ and ‘d’ represent the 
swollen and dry states, respectively. The equilibrium polymer volume fractions in the swollen 
state were compared for the P(MAA-g-EG) and IPNs (Figure 4.11). For all polymer carriers, the 
swelling ratio and the volume fraction of the polymer in the swollen state are inversely related. 
This is an expected trend for υ2,s because as the polymer carrier swells it imbibes more water 
mass; thus, the fraction of polymer volume decreases in relation to the volume of the imbibed 
water.  
In acidic conditions, υ2,s is greater as compared to neutral conditions and is advantageous 
for oral drug delivery because less solvent has penetrated the polymer carrier and any 
encapsulated therapeutic agent is protected.  If solvent were to significantly penetrate the IPNs or 
P(MAA-g-EG), premature drug release could occur. Premature drug release reduces the amount 
of drug delivered to the targeted site, exposes the drug to the harmful enzymes of the stomach, 
and exposes the stomach to the toxicity of the drug.  
Using the values of υ2,s and υ2,r, the molecular weight between crosslinks, Mc, could be 
determined using the Peppas-Merrill equation (Equation 4.3). The Peppas-Merrill equation does 
not account for ionic units present in the polymer system, but since the equation uses the ratio of 
ionic to neutral components, this analysis technique is acceptable. 

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 −
 ὐ	, 	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,
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                                                                                (4.3) 
The volume fraction of the polymer in the relaxed state, υ2,r , and the volume fraction of 
the polymer in the swollen state, υ2,s , were used as determined above. V1 is the molar volume of 
the swelling solution which is primarily composed of water and thus determined to be 18.1 
cm3/mol. 
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 The term ὐ was determined using equation 4.4 and is the specific volume of the polymer 
calculated using Wa,d, Wa,h, and the density of n-heptane (ρh). 
ὐ = 	 )
 ∗
,	,

,                 (4.4) 
The Flory interaction parameter, χ, is a parameter indicating how well the polymer and solvent 
interact. Values above 0.5 indicate favorable interactions and values below 0.5 indicate 
unfavorable interactions between the polymer and the solvent. For these studies, χ1 was 
calculated as weighted average of the Flory interaction parameter of methacrylic acid28,29 given 
by Equation 4.5 and poly(ethylene glycol) (0.44).  
+ = 0.44 + 0.6,               (4.5) 
In these experiments, χ1 was greater than 0.5 at pH < 5.8 and lower than 0.5 at pH > 5.8. Since 
the Flory interaction parameters indicate favorable thermodynamic interaction for values lower 
than 0.5, investigation of mesh analysis focused on pH conditions greater than 5.8.  The term Mn 
is the number average molecular weight of the same hydrogel system without crosslinker and 
was determined to be 20,000 kDa by gel permeation chromatography (Agilent 1200 Series 
operating with Viscotek I-Series column) of samples prepared under exactly the same conditions 
of preparation. This value is in good reasonable agreement to those previously published in our 
lab. 30-32 
 With all values independentyly determined for Equation 4.3, Mc could calculated and 
then used to compute the mesh size (ξ), or the linear distance between adjacent crosslinks using 
Equation 4.6. 
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Here, Mr is the molecular weight of the repeating unit (86 g/mol) of poly(methacrylic 
acid), Cn is the Flory characteristic ratio (14.6 for PMAA30,33) and ‘l’ is the length of the bond 
along the polymer backbone (1.54 Å for vinyl polymers). 
Calculated mesh sizes are plotted in Figure 4.12 for hydrogels swollen at pH values 
ranging from 3.6 to 7.2. Mesh sizes varied from 312 Å to 349 Å and P(MAA-g-EG) exhibited  
the largest mesh size at 349 Å. The relatively large P(MAA-g-EG) mesh sizes are due to the 
absence of the PBA network which can increase entanglement of molecular chains or retard 
water uptake due to PBA’s hydrophobicity. The mesh sizes at pH 7.2 of the 80/20 IPN (336 Å) 
was similar to that of P(MAA-g-EG) while the 75/25 IPN (223 Å) and 70/30 IPN (225 Å) were 
more significantly reduced .For the mesh size calculations there seems to be a critical amount of 
PBA to be incorporated into the polymer system to more greatly influence mesh size. For 
example, the 75/25 IPN and 70/30 IPN are similar in sizes while the 80/20 IPN and P(MAA-g-
EG) are similar in size. The Peppas-Merrill equation is based on a balance of thermodynamic and 
elastic forces in a swollen network for computed mesh sizes to be valid. At pH values less than 
4.2, computed mesh values ranged from 7 to 8 Å; however, υ2,s values ranged from 0.70 to 0.77 
indicating an insufficiently hydrated polymer for mesh analysis. Thus, these reported mesh 
values at low pH only indicate that the polymer is collapsed. As indicated in Figure 4.13, the Mc 
values were calculated as ~8000 g/mol for the IPNs which corresponds to 3 crosslinks per chain.   
 Scanning Electron Microscopy (SEM). P(MAA-g-EG) and IPN discs were synthesized, 
crushed and sieved between 75 and 500 µm, and imaged by SEM. The surface features and bulk 
morphologies between the IPN and P(MAA-g-EG) were determined by high magnification 
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imaging. No differences between the two polymer carriers could be determined. However, the 
SEM imaging verified the size as sieved and the distribution of sizes of each sample. Figure 
4.14A and Figure 4.14B are P(MAA-g-EG) and 70/30 IPN, respectively, and give an example of 
what the surface and cross sections of the samples look like after polymerization and 
purification.  
Differential Scanning Calorimetry (DSC). Glass transition temperatures were determined 
from heat flow versus temperature thermograms for PBA, P(MAA-g-EG), and IPN samples. The 
glass transition was determined by the minimum peak of the 1st derivative of the thermograph.    
Pure PBA samples generated a Tg value of -49 °C and is in agreement with reported literature 
(Figure 4.15).34,35 P(MAA-g-EG)’s exhibited a glass transition at 170 °C (Figure 4.15). P(MAA-
g-EG) also exhibited a large broad endothermic shift at 250 °C as a result of dehydration and 
anhydride formation at high temperatures (not pictured). These two temperatures are in 
agreement with previous publications.36,37 Interpenetrating polymer networks are composed of 
two separate networks and thus glass transitions can be either presented as a large broad 
transition which spans the two glass transitions of the separated networks or as two separate 
glass transitions where the temperatures have been shifted inward.38 All IPNs demonstrated two 
glass transitions at – 46 °C and 118 °C corresponding to the PBA and P(MAA-g-EG) network 
respectively (Figure 4.15 and Figure 4.16). It has been previously discussed that inward shifts of 
glass transitions are a result of immiscible polymers.39,40 PBA and P(MAA-g-EG) are immiscible 
polymers and the inward shift of these two glass transition temperatures are expected.  
4.4 Conclusions 
IPNs composed of P(MAA-g-EG) and PBA networks were formed by a  sequential free 
radical UV-initiated polymerization technique. First, the P(MAA-g-EG) network was formed, 
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dried, and swollen in the presence of the monomeric form of PBA. By controlling the solvent 
conditions of ethanol and water, three IPN structures were formed with increasing PBA content. 
By developing IPNs with hydrophilic and hydrophobic properties an oral polymer drug carrier 
for chemotherapeutics may be possible.  
The IPN structures demonstrated incremental increases in hydrophobic content through 
contact angle measurements and hydrophobic swelling ratios. Equilibrium and dynamic swelling 
experiments indicated there was little to no swelling at pH values below 5; however, an increase 
in swelling occurs for pH values above 5. At pH below 5 the carboxyl groups of PMAA remain 
protonated and hydrogen bond with etheric oxygen on the PEG chains to form a complexed, 
collapsed network. At pH above 5, carboxyl groups deprotonate and break hydrogen bonding 
leading to the formation of a porous polymer structure due to ionic repulsion. Pore size of the 
polymer structure was ranged from 225 to 349 Å with P(MAA-g-EG) having the largest. Even 
though pore sizes at low pH are not valid values, the data does indicate the polymer network is 
collapsed and capable of entrapping loaded therapeutics. The swelling studies and mesh size 
calculations demonstrate that the shift from the stomach to the upper small intestine can be used 
as a physiological trigger to deliver therapeutic compounds.   
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Figures 
 
 
 
Figure 4.1. Monomers and photocatalyst in the synthesis of P(MAA-g-EG) and PBA 
networks. (a) Methacrylic acid, (b) tetraethylene glycol dimethacrylate, (c) Irgacure® 184, (d) 
ethylene glycol monomethyl methacrylate (1000 g/mol), and (e) n-butyl acrylate. 
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Figure 4.2. Synthesis of P(MAA-g-EG) hydrogel. Hydrophilic monomers, crosslinkers, and 
photoinitiators were combined into a beaker, sonicated, and polymerized between glass slides.   
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Figure 4.3. Synthesis of IPN. The P(MAA-g-EG) discs were swollen in the presence of 
hydrophobic monomers, crosslinkers, photoinitiators, and solvents. After swelling, the disc was 
removed, placed on a Teflon sheet, and UV-crosslinked.  
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Figure 4.4. Contact Angle Measurement.  
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Figure 4.5. Swelling chamber for pH-responsive studies. 
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Figure 4.6. Hanging basket apparatus. Polymer discs were placed in a wire basket suspended 
in n-Heptane, but still attached to the scale. 
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Figure 4.7.  P(MAA-g-EG) hydrogel swelling in solvents with varying ratios of 
ethanol to water by weight percent. 100/0 (   ), 80/20 (   ), 75/25 (   ), and 70/30 (   ). 
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Figure 4.8. Nile Red staining of P(MAA-g-EG) and IPNs. From left to right, P(MAA-g-EG), 
80/20 IPN, 75/25 IPN, 70/30 IPN. 
 
103 
 
 
 
 
  
0
1
2
3
4
5
6
7
3 4 5 6 7 8
D
yn
a
m
ic
 
W
ei
gh
t S
w
el
lin
g,
 
q 
(g/
g)
pH
Figure 4.9. pH-Dependent dynamic weight swelling ratio profiles for P(MAA-g-EG) 
and IPNs. P(MAA-g-EG) (    ), 80/20 IPN (    ), 75/25 IPN (    ), and 70/30 IPN (    ). 
104 
 
 
Figure 4.10. pH-Dependent equilibrium weight swelling ratio profiles for P(MAA-g-
EG) and IPNs. P(MAA-g-EG) (    ), 80/20 IPN (    ), 75/25 IPN (    ), and 70/30 IPN (    ). 
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  Figure 4.11. Polymer volume fraction in swollen state as function of pH for 
P(MAA-g-EG) and IPNs. P(MAA-g-EG) (    ), 80/20 IPN (    ), 75/25 IPN (    ), and 
70/30 IPN (    ). 
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Figure 4.12. Mesh size calculations as function of pH for P(MAA-g-EG) and IPNs. 
P(MAA-g-EG) (    ), 80/20 IPN (    ), 75/25 IPN (    ), and 70/30 IPN (    ). 
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Figure 4.13. Molecular weight between crosslinks, Mc, as a function of IPN formulation.  
Mc decreased with increasing PBA content.  
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Figure 4.14. SEM images of P(MAA-g-EG) and 70/30 IPN. (a) P(MAA-g-EG) and (b) 70/30 
IPN.  
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Figure 4.15. Differential scanning calorimetry for PBA, P(MAA-g-EG), and 70/30 IPN. The 
glass transition temperature, Tg, was determined for PBA, P(MAA-g-EG), and 70/30 IPN.  
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Figure 4.16. Differential scanning calorimetry for 80/20 IPN and 75/25 IPN. The glass 
transition temperature, Tg, was determined for 80/20 IPN, and 75/25 IPN.  
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Tables 
 
Formulation Surface Contact Angle (°) 
Hydrophobic 
Swelling Ratio 
(Water then 
Isopropanol) 
Hydrophobic 
Swelling Ratio 
(Isopropanol then 
Water) 
P(MAA-g-EG) 52 ± 2 1.32 ± 0.01 1.32 ± 0.01 
80/20 IPN 64 ± 1 1.18 ± 0.03 1.18 ± 0.04 
75/25 IPN 73 ± 3 1.15 ± 0.04 1.16 ± 0.03 
70/30 IPN 105 ± 1 0.75 ± 0.10 0.92 ± 0.12 
 
 
Table 4.1. Surface contact angle and hydrophobic swelling ratio for P(MAA-g-EG) and 
IPNs. 
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Chapter 5 
Synthesis and Characterization of Hydrogels Dispersed with Hydrophobic 
Nanoparticles 
 
5.1  Introduction 
Using traditional synthetic techniques for polymer development, but assembling 
them into new structures or architectures may lead to significant improvements of 
materials which can be used in biomedical and clinical applications. pH-Responsive 
hydrogels can be synthesized with biocompatible polymers exhibiting anionic or cationic 
properties. This allows the hydrogel networks to be tailored or modified to exhibit 
desirable physicochemical properties appropriate for their application at hand.1 Of 
particular interest is the synthesis of polymer carriers which are responsive to specific pH 
ranges, resulting in drastic property changes from the collapsed to swollen state. These 
drastic changes can be used to achieve local and targeted drug, peptide, or protein 
delivery.  
Oral drug delivery systems based on pH-responsive hydrogels have the potential 
to replace parenteral or subcutaneous injections. However, these hydrogels are 
hydrophilic by design and their translation for use and interaction with hydrophobic, low 
molecular weight therapeutic agents is limited and needs to be optimized or modified for 
greater success. It is proposed that these hydrogels can be balanced with opposing 
hydrophobic properties which may prove advantageous for the delivery of hydrophobic, 
low molecular weight therapeutic agents. 
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In Chapter 4, interpenetrating polymer networks composed of poly(methacrylic 
acid), poly(ethylene glycol), and poly(n-butyl acrylate) were evaluated as potential colon 
drug delivery devices. In this chapter, we propose a second polymer system for colon 
drug delivery composed of a pH-responsive hydrogel containing hydrophobic 
nanoparticles. In this way, the desirable characteristics of pH-sensitive, hydrophilic 
networks with hydrophobic nanoparticles can be used to develop amphiphilic polymer 
structures for biomedical applications.2-5 Nanoparticles can possess unique characteristics 
different from their larger parent counterparts and can be easily incorporated into existing 
polymer structures to elicit new physical and chemical properties.6 Research in the 
nanoparticle field has also grown significantly in the last decade and a host of established 
techniques is available to develop nanoparticles of desirable sizes and properties.7,8 In 
this chapter, we synthesized and characterized polymer carriers composed of a pH-
responsive, hydrophilic polymer, P(MAA-g-EG), prepared from methacrylic acid (MAA) 
grafted with poly(ethylene glycol) tethers, and hydrophobic poly(methyl methacrylate) 
(PMMA) nanoparticles. 
The optimal design of P(MAA-g-EG) hydrogels has been determined by our 
laboratory previously and discussed in Chapter 4.9-13 By photoencapsulating PMMA 
nanoparticles during the UV polymerization process using P(MAA-g-EG) hydrogels, the 
degree of hydrophobicity can be varied in the final polymer carrier and elicit a 
distribution of physical properties.  
The hydrogels dispersed with nanoparticles were synthesized and characterized to 
determine their potential as oral polymer carriers of chemotherapeutics. Characterization 
included swelling studies to determine pH-responsiveness, analysis of PMMA 
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nanoparticles, and imaging techniques to determine how nanoparticles where 
photoencapsulated.  
5.2 Materials and Methods 
Materials. Methacrylic acid (MAA), methyl methacrylate (MMA), tetraethylene 
glycol dimethacrylate (TEGDMA), 1-hydroxycyclohexyl phenyl ketone (Irgacure® 184), 
ammonium persulfate (APS), 3,3-dimethylglutaric acid (DMGA), Nile Red, dimethyl 
sulfoxide (DMSO), and ethanol were purchased from Sigma–Aldrich (St. Louis, MO). 
10× phosphate buffer solution (PBS) and sodium chloride were purchased from Fisher 
Scientific (Fair Lawn, NJ). Poly(ethylene glycol) monomethyl ether monomethacrylate 
(PEGMMA; 1000 g/mol) was from Polysciences Inc. (Warrington, PA). All chemicals 
were used as received except for MAA which was vacuum distilled at 54 ºC and 25 
mmHg prior to use to remove the inhibitor hydroquinone. Double distilled water was 
used in all studies. Figure 5.1 illustrates the chemical structures used strictly used for 
synthesizing the P(MAA-g-EG) hydrogels with PMMA nanoparticles.   
 Synthesis of PMMA Nanoparticles. A surfactant-free emulsion polymerization 
(SFEP) technique for the formation of PMMA nanoparticles was adapted for this polymer 
carrier (Figure 5.2).14 MMA monomer and TEGDMA crosslinker were added to a round 
bottom flask containing water and the thermal initiator ammonium persulfate. MMA and 
APS were added in the amount of 0.56 M and 8 mM based on total solution volume while 
TEGDMA was added in the amount of 0.6 mol% based on MMA content. The 
polymerization was carried out for 3 hr at 75 °C in a temperature controlled water bath 
under magnetic stirring. Cross-linked PMMA nanoparticles were cooled down to room 
temperature, dialyzed for 1 week in water, and lyophilized for 3 days.  
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Synthesis of P(MAA-g-EG) Hydrogels Dispersed with PMMA Nanoparticles. 
The P(MAA-g-EG) hydrogel dispersed with PMMA nanoparticles was formed by free 
radical UV-initiated polymerization (Figure 5.3). First, MAA and PEGMAA were placed 
in an amber bottle in a 1:1 molar ratio while TEGDMA and Irgacure® 184 were added in 
the amount of 0.75 mol% and 0.5 wt% of total monomer respectively.  A solution 
composed of 50:50 (w/w) ethanol to water was added in a 50:50 (w/w) ratio of total 
monomer to solvent. To this solution were added PMMA nanoparticles in the amount of 
1, 2.5, or 5 wt% of the combined weight of MAA and PEG. The amber bottle was 
capped, sonicated for 15 min to ensure thorough mixing, and then purged with N2 for 30 
min in a sealed glove box to remove oxygen from the system. The precursor solution was 
pipetted between glass plates (15 cm x 15 cm x .3 cm) separated by a 0.7 mm Teflon 
spacer and exposed to UV light at an intensity of 16 mW/cm2 (Dymax 2000-EC Light 
Curing System, Torrington, CT) for 30 min to form a hydrogel film with nanoparticles. 
The resulting sample of hydrogel containing nanoparticles was washed several days with 
water and either punched into discs or crushed into particles (75 – 150 µm) for future use. 
Both particles and discs were dried in vacuum at 30 °C for 1 week. P(MAA-g-EG) 
hydrogels containing 1, 2.5, or 5 wt% PMMA nanoparticles will be identified as P(MAA-
g-EG)-1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5.0NP.  
Characterization of Hydrogels Dispersed with PMMA Nanoparticles. SEM 
Imaging of PMMA Nanoparticles, P(MAA-g-EG), and P(MAA-g-EG) containing 
nanoparticles . Scanning electron microscopy (SEM, Supra 40 VP, Carl Zeiss Inc.) was 
used to characterize the PMMA nanoparticles, to approximate their nanoparticle 
diameter, uniformity, dispersion after being encapsulated in P(MAA-g-EG) hydrogels, 
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and the stability of encapsulation in the swollen P(MAA-g-EG) network. Pure PMMA 
nanoparticles were dissolved in a small amount of ethanol, dropped onto a carbon taped 
aluminum stub and the solvent allowed to fully evaporate. All other samples were 
vacuum dried for 1 week and placed directly onto carbon taped aluminum stubs.  
The surface and cross section of P(MAA-g-EG) and P(MAA-g-EG) containing 
nanoparticles samples were imaged in the collapsed and swollen state by placing discs in 
0.1 N HCl and 1× PBS (pH 7.4), respectively, for 24 hr, frozen in liquid N2, and 
lyophilized until dry.15 To determine if nanoparticles were being released during 
swelling, a P(MAA-g-EG)-5.0NP disc was cycled between 0.1 N HCl and 1× PBS 5 
times to represent the collapsed and swollen states the polymer would experience. SEM 
images were taken before and after the cyclic swelling. All samples were coated with an 
8 nm thick layer of platinum/palladium for improved image quality. Image analysis of 
PMMA nanoparticles was performed using ImageJ software and reported diameter sizes 
are of n = 800.    
Hydrophobic staining. Hydrophobic staining was used to determine the presence 
of the PMMA nanoparticles in the polymer carrier. The following protocol was adapted 
to stain polymer discs: a 20 mg/mL stock solution of Nile Red, a hydrophobic dye, was 
prepared by dissolving in methanol. 75 µL of the stock solution was dissolved in 8 mL of 
double distilled water and combined with 120 mL of 1× PBS. P(MAA-g-EG), P(MAA-g-
EG)-1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5.0NP discs were soaked for 24 
hr in 60 mL of the aforementioned Nile Red solution and washed 5 days with water.16 
 PMMA nanoparticle characterization. The average hydrodynamic diameters, 
polydispersity indices (PDI), and zeta potential of the PMMA nanoparticles were 
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measured using dynamic light scattering (DLS, NanoZS, Malvern Instruments). Particle 
size and zeta potential measurements were conducted by resuspending polymerized 
particles in 1× PBS at 0.1 mg/mL and measuring at 25 °C. The values reported are the 
average of 10 individual runs. To investigate the influence pH would have on particle 
sizes and zeta potentials, the DLS instrument was equipped with an autotitrator. 
Measurements of particle diameter and zeta potential were determined for the pH range 
from 2.0 to 7.5 in 0.5 increments and the values reported are the average of 2 runs with 
each run an average of 15 measurements.  
Swelling Studies. Dynamic and equilibrium swelling studies were used to study 
the pH-responsive behavior of P(MAA-g-EG) and P(MAA-g-EG) containing 
nanoparticles. Swelling studies utilized 0.1 M 3,3-dimethyl glutaric acid (DMGA) buffers 
ranging from pH 3.2 to 7.2. Sodium chloride was added to control ionic strength. 10 mm 
P(MAA-g-EG) or P(MAA-g-EG) containing nanoparticles discs were punched from 
hydrated samples and dried. The dried discs were placed in approximately 100 mL of the 
0.1 M DMGA buffer solutions housed in the same swelling chamber as discussed before 
(Figure 4.5). For dynamic swelling conditions, the same polymer disc was subjected first 
to a pH of 3.2 for 12 min, removed, blotted, weighted, and then placed in the DMGA 
buffer of the next highest pH for another 12 min. This was repeated until a pH of 7.6 was 
reached. All samples were thermostated to physiological conditions (37 °C). The swelling 
ratio, q, was calculated as the swollen weight divided by the dry weight of the polymer 
disc. Equilibrium swelling was completed utilizing the same buffer series as above except 
discs remained in one pH level for 24 hr. The swollen discs were weighted and the 
equilibrium weight swelling ratio determined as mentioned above. 
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Rheometry. Rheological measurements were performed on P(MAA-g-EG) and 
P(MAA-g-EG)-5.0NP samples to determine if PMMA nanoparticles were physically 
entangled or crosslinked into the P(MAA-g-EG) hydrogel during polymerization. A TA 
Instruments rheometer (AR 2000EX) was equipped with parallel plate geometry (plate 
diameter of 8 mm) and operated at 25 °C. Samples were equilibrated in water for 24 hr, 
then punched into 8 mm x 0.6 mm discs, dried, and placed on the parallel plates. By 
oscillating at 1 Hz, applying a normal force of 0.2 N, and strain sweeping from 10 to 
0.01%, the linear viscoelastic range was determined. To compute storage modulus, G’, 
the strain computed from the previous experiment was kept constant, a normal force of 
0.2 N was applied, and the frequency swept from 1 to 0.2 Hz.    
5.3 Results and Discussion 
New polymer carriers composed of a pH-responsive P(MAA-g-EG) hydrogel 
containing PMMA nanoparticles were synthesized. PMMA nanoparticles were formed 
using a conventional surfactant free emulsion polymerization procedure. The PMMA 
nanoparticles were then added to the monomer solution of MAA, PEG, TEGDMA, 
Irgacure® 184, and encapsulated during a free radical UV-initiated polymerization 
process. The ensuing polymer carriers’ swelling behavior was analyzed and the size and 
distribution of nanoparticles throughout the hydrogel evaluated to determine their 
potential as oral delivery devices for hydrophobic therapeutic agents.  
Characterization of Hydrogels Dispersed with PMMA Nanoparticles. SEM of 
PMMA Nanoparticles, P(MAA-g-EG), and P(MAA-g-EG) containing nanoparticles. Dry 
nanoparticles were spherical, uniform, and their diameters were determined to be 212 ± 
21 nm (Figure 5.4). SEM images illustrated nanoparticles were present on the surface and 
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in the bulk of the P(MAA-g-EG) hydrogels (Figure 5.5) and existed as small aggregates 
(1 – 5 µm) resulting in micro-domains of predominantly hydrophobic material (Figure 
5.6). These micro-domains were formed by nanoparticles which were not fully dispersed 
in the aqueous solution before UV polymerization. It has been reported that as a result of 
the drying process of the nanoparticles, significant hydrogen bonding occurs and makes it 
difficult to re-disperse them in aqueous media or even organic solvents.17 SEM images 
demonstrated the increase in PMMA nanoparticles in the bulk film as weight percentage 
of PMMA increased during polymerization of the P(MAA-g-EG) hydrogel (Figure 5.7) 
At pH values above the pKa of carboxyl groups on the MAA moiety, the 
hydrogels form nanoporous networks allowing therapeutic agents to flow in or out based 
on the diffusional gradient. Figure 5.8 shows high porosity of the P(MAA-g-EG)-5.0NP 
sample and how these pores can serve as the transport mechanism for therapeutic agent 
loading and release. Similar porous networks were imaged for P(MAA-g-EG)-1.0NP, 
P(MAA-g-EG)-2.5NP, and P(MAA-g-EG).  
Since these proposed polymer carriers undergo the transition from the collapsed 
to swollen state it is important to determine if PMMA nanoparticles remain embedded in 
the P(MAA-g-EG) hydrogel during swelling cycles. Though PMMA is a material 
commonly used in biomaterials, keeping nanoparticles embedded within the hydrogel 
would eliminate the risk of nanoparticles to be freely floating in the GI tract. Due to their 
size (212 nm), free PMMA nanoparticles could penetrate mucosal surfaces of the GI 
tract; however they were too large to transport by the paracellular route into the 
bloodstream where the gap between cells is 2 – 4 nm.18-20 P(MAA-g-EG)-5.0NP samples 
were transferred between 1× PBS and 0.1 N HCl to represent the swelling cycle the 
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material would experience when leaving the stomach and entering the upper small 
intestine.  
This procedure was repeated multiple times and SEM images were taken before 
and after the swelling cycles. PMMA nanoparticles are viewed as 2-D spheres implanted 
on the flat, cross-sectional surface of the P(MAA-g-EG)-5.0NP sample before 
undergoing swelling (Figure 5.9A). After the swelling cycles, PMMA nanoparticles were 
not released, but maintained within the hydrogel after swelling cycles (Figure 5.9B). The 
images appear rough and mountainous with the appearance of debris on the P(MAA-g-
EG) hydrogel surface. However, upon closer investigation this debris is in fact many 
PMMA nanoparticles clustered together, but still contained within the P(MAA-g-EG) 
matrix (Figure 5.9B insert).  
Characterization of PMMA Nanoparticles in P(MAA-g-EG) Hydrogels. The 
existence of the PMMA nanoparticles in the P(MAA-g-EG) hydrogel was confirmed by 
soaking in Nile Red for 24 hours. P(MAA-g-EG) samples remained clear and translucent 
while P(MAA-g-EG) containing nanoparticles increased in pink opaqueness with 
increasing PMMA nanoparticle content (Figure 5.10).  
   The z-average hydrodynamic diameters in neutral 1× PBS (pH 7.4) were 
determined to be 199 ± 4 nm and narrowly distributed (PDI:  0.17). These values support 
the particle diameter as determined by SEM and confirm that PMMA nanoparticles do 
not undergo any appreciable swelling in the presence of aqueous solutions. Z-average 
hydrodynamic diameters were also measured across the pH range 2 to 7.5. The particles 
did not undergo any appreciable swelling across this pH range (Figure 5.11). This is 
expected, as these particles are hydrophobic and do not possess any ionic groups which 
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would be pH-dependent and cause swelling. The zeta potential of these nanoparticles 
measured -34 ± 1 mV and are considered stable because particles with zeta potentials 
above 30 mV or below -30 mV maintain their repulsive forces while dispersed.21,22 Zeta 
potentials were measured over the pH range 2 to 7.5 (Figure 5.12). The values fluctuated 
between 0.1 – 7.0 % of the value measured in 1× PBS (-34 ± 1 mV) indicating that 
particles would remain stable in the physiological conditions from the stomach to the 
colon.  
Swelling Behavior of P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles. 
Swelling experiments were completed to study the pH-responsive behavior of the 
polymer drug carriers in simulated physiological fluids and the effects of introducing 
hydrophobic PMMA nanoparticles into the P(MAA-g-EG) hydrogel. Dynamic swelling 
experiments illustrated no significant differences between P(MAA-g-EG) and P(MAA-g-
EG) containing nanoparticles (Figure 5.13). The nanoparticles did not disrupt enough 
hydrogen bonds in the low pH conditions to allow premature swelling or swelling rate 
differences as compared to the PBA network in the IPN structures in Chapter 4. 
Equilibrium weight swelling ratios decreased with the increasing amount of PMMA 
nanoparticle content (Figure 5.14). The increasing presence of the PMMA nanoparticles 
reduces or shield ionic repulsion between deprotonated carboxyl groups and physically 
reduces the volume for polymer chain movement. Furthermore, as the weight percent of 
PMMA nanoparticles increases, the space once occupied by a water molecule is replaced 
by a PMMA nanoparticle and results in the reduction of water uptake into the polymer 
structure. Each of these items can contribute to the reduction of equilibrium weight 
swelling ratios. The volume fractions of the polymer carrier in the swollen state, υ2,s, 
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additionally illustrates that at low pH the total swollen weight is primarily polymer 
weight and at neutral conditions the swollen weight is primarily water weight (Figure 
5.15). Equation 5.1 was used to calculated υ2,s,  
  
, =
,	
,
,	
,		
                                                                                                              (5.1) 
 
where Wa and Wh are the weights in air and n-heptane and the subscripts ‘s’ and ‘d’ 
represent the swollen and dry states, respectively.  
Rheometry. P(MAA-g-EG) samples were subjected to strain sweeps from 10% to 
0.01% to determine the linear viscoelastic range. The linear viscoelastic range existed for 
strains below 0.5% and a strain of 0.25% was chosen as the static strain during frequency 
sweep experiments. The storage modulus, G’, was computed for P(MAA-g-EG) and 
P(MAA-g-EG)-5.0NP for frequencies between 1 and 0.2 Hz. P(MAA-g-EG)-5.0NP had 
significantly lower values as compared to the P(MAA-g-EG) across all frequencies 
(Figure 5.18). 
 PMMA nanoparticles were purified post polymerization to prevent possible 
crosslinking into the P(MAA-g-EG). If these nanoparticles were to have crosslinked into 
the hydrogel structure this would increase its G’ value due to the presence of increased 
crosslinks as compared to the pure P(MAA-g-EG) sample. However, since these results 
show significant decrease in G’ values, it was confirmed the nanoparticles were 
physically encapsulated and not crosslinked. The associated G’ values were between 80 – 
180 kPa. 
5.4 Conclusion 
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By encapsulating hydrophobic PMMA nanoparticles during the UV 
polymerization of P(MAA-g-EG), we were able to develop hydrogel samples with 
amphiphilic properties. The amount of PMMA nanoparticles in the hydrogel systems 
affected the degree of hydrophobicity of the system and consequently influenced the 
physical and mechanical properties of the hydrogels. 
Using this synthetic technique, it was easy to control the degree of hydrophobicity 
of the systems by incorporating more or fewer nanoparticles during the UV-
polymerization process. The surfactant-free polymerization process allowed PMMA 
nanoparticles to be developed into uniform, spherical particles with approximately 212 
nm diameters. The removal of surfactants from nanoparticle synthesis techniques can be 
difficult; however, this synthetic scheme eliminates surfactants all together.  
The nanoparticles were uniformly dispersed in the P(MAA-g-EG) hydrogel and 
existed in small hydrophobic micro domains due to aggregation during the lyophilization 
process. As the nanoparticle content increased during polymerization, the presence of 
nanoparticles on the cross-sectional surface of the polymer carriers also increased. 
PMMA nanoparticles were physically encapsulated and not crosslinked into the P(MAA-
g-EG) hydrogel and are contained within the hydrogel system even after multiple 
swelling and de-swelling cycles.   
Swelling experiments indicated no hydrogen bonding disruption due to the 
presence of nanoparticles in low pH conditions. However, in more neutral pH 
environments the presence of the nanoparticles prevented equilibrium swelling ratios to 
reach the same values as the pure P(MAA-g-EG) hydrogel, but were still closer to the 
P(MAA-g-EG) control as compared to the IPNs.  
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This could prove valuable in drug delivery since nanoparticle containing 
hydrogels can introduce hydrophobic properties for improved uptake of hydrophobic 
compounds while still maintaining the necessary equilibrium swelling ratios to allow 
encapsulated therapeutics to be released in neutral environments such as the small 
intestine or colon.  These amphiphilic polymer carriers could prove useful in the oral 
drug delivery of hydrophobic chemotherapeutics. 
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Figures 
 
 
 
Figure 5.1: Monomers and photocatalyst in the synthesis of P(MAA-g-EG) and 
P(MAA-g-EG) containing nanoparticles. (a) Methacyrlic acid (MAA), (b) tetraethylene 
glycol dimethacrylate (TEGDMA), (c) Irgacure® 184, (d) poly(ethylene glycol) 
monomethyl methacrylate (1000 g/mol), (e) methyl methacrylate (MMA), and (f) 
ammonium persulfate (APS). 
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Figure 5.2. Synthesis of PMMA nanoparticles. Monomers, crosslinker, thermal 
initiator, and immiscible solvent were placed in round bottom flask and reacted for 3 hr. 
Resulting nanoparticles were dialyzed and lyophilized.  
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Figure 5.3. P(MAA-g-EG) hydrogel dispersed with PMMA nanoparticles. PMMA 
nanoparticles were added to a solution of monomers, crosslinker, photoinitiator, and 
solvents. The solution was sonicated, and photopolymerized to form a P(MAA-g-EG) 
hydrogel with PMMA nanoparticles.   
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Figure 5.4. SEM of PMMA nanoparticles. PMMA nanoparticles were synthesized 
using a surfactant free emulsion polymerization technique. Resulting nanoparticles were 
uniform and measured approximately 212 nm.  
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Figure 5.5. SEM of nanoparticles in P(MAA-g-EG)-2.5NP. PMMA nanoparticles were 
contained within the P(MAA-g-EG) hydrogel during polymerization. The PMMA 
nanoparticles can be seen on the surface and cross-section of P(MAA-g-EG)-2.5NP 
samples indicating the nanoparticles are dispersed throughout the hydrogel.  
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Figure 5.6. Cross-section SEM of nanoparticles in P(MAA-g-EG)-5.0NP. PMMA 
nanoparticles are uniformly distributed throughout hydrogel, but exist as small aggregates 
sized between 1 – 5 µm. Pictured above is P(MAA-g-EG)-5.0NP. 
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Figure 5.7. Weight percent of PMMA nanoparticles increased in P(MAA-g-EG) 
hydrogel. The figures above illustrate the increased presence of nanoparticle in the 
P(MAA-g-EG) hydrogel corresponds to the increase of nanoparticle content during 
polymerization: (A) P(MAA-g-EG)-1.0NP, (B) P(MAA-g-EG)-2.5NP, and (C) P(MAA-
g-EG)-5.0NP. 
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Figure 5.8. SEM of swollen and collapsed state of P(MAA-g-EG)-5.0NP. P(MAA-g-
EG)-5.0NP samples were swollen in 1× PBS, frozen in liquid nitrogen, and lyophilized to 
remove solvent to reveal a porous structure at neutral pH (A) and compared to its 
collapsed state (B). The porous structure in the top figure illustrates how therapeutic 
agents can diffuse out or in depending on concentration gradient.  
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 Figure 5.9. PMMA nanoparticles physically entangled in P(MAA-g-EG) hydrogel. 
P(MAA-g-EG)-5.0NP samples were imaged after vacuum drying for 3 days (A) and 
compared to the same sample after cycling between 1× PBS and 0.1N HCl 5 times (B).  
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Figure 5.10. Nile Red staining of P(MAA-g-EG) and compositions of P(MAA-g-EG) 
containing nanoparticles. From left to right, P(MAA-g-EG), P(MAA-g-EG)-1NP, 
P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5.0NP.  
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Figure 5.11. PMMA nanoparticle average diameter with respect to varying pH. 
Average diameters of PMMA nanoparticles were measured for the pH range of 2 to 7.5 in 
0.5 increments. Values were normalized to the average diameter measurements taken at 
pH 7.4 in 1× PBS (199 nm).  
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Figure 5.12. PMMA nanoparticle zeta potential with respect to varying pH. Zeta 
potentials were measured for the pH range of 2 to 7.5 in 0.5 increments. Values were 
normalized to the zeta potential measurements taken at pH 7.4 in 1× PBS (-34 mV).  
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 Figure 5.13. pH-Dependent dynamic weight swelling ratio profiles for P(MAA-g-
EG) and compositions of P(MAA-g-EG) containing nanoparticles. 
P(MAA-g-EG) (    ), P(MAA-g-EG)-1.0NP (    ), P(MAA-g-EG)-2.5NP (    ), and 
P(MAA-g-EG)-5.0NP (    ).  
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Chapter 6 
Doxorubicin Release Studies from Interpenetrating Polymer Networks and 
Hydrogels Dispersed with Hydrophobic Nanoparticles 
 
6.1  Introduction 
Loading and release experiments were used to determine if a polymer delivery 
system loaded with therapeutic agents could be designed to perform in a desirable way 
and with a specified release profile. The results from these studies were evaluated and 
correlated to their performance in vivo.  
For this thesis, the loading of low molecular weight, hydrophobic compounds 
such as chemotherapeutics could prove essential to improving future cancer treatments. It 
is a concern that unmodified polymer carriers which only exhibit hydrophilic properties 
would demonstrate low loading efficiencies, have difficulties keeping the 
chemotherapeutic entrapped within the polymer matrix, and deliver payloads below the 
needed concentration for therapeutic effects. However, by developing new polymer 
systems with hydrophobic properties such as IPNs in Chapter 4 and P(MAA-g-EG) 
containing PMMA nanoparticles in Chapter 5, loading levels could increase and 
subsequent release of chemotherapeutics maybe controlled and targeted to the site of 
interest. 
Doxorubicin is a chemotherapeutic which utilizes an anthracycline antibiotic to 
intercalate between DNA, forming harmful radicals, and ending in cell death.1 
Doxorubicin works against a variety of cancer types including lymphomas, breast, lung, 
and gastric cancers. This particular chemotherapeutic is a low molecular weight, 
149 
 
hydrophobic compound which is primarily administered intravenously to patients. 
Despite its success, patients can only receive maximum lifetime doses before known 
cumulative cardiotoxicity begins.2 For these reasons and others specified in Chapter 2, a 
new method of delivery of this cytotoxic substance is needed to prevent side effects, 
increase targeting to the tumor site to reduce cardiotoxicity, and improve patient 
compliance. 
Doxil® and LivaTag® are new drugs which are FDA approved (Doxil®) or 
currently in clinical trials (LivaTag®) that take advantage of the leaky vasculature of 
tumors.3,4 Doxil® encapsulates doxorubicin in a closed lipid sphere (liposome) which 
helps reduce cardiotoxicity while LivaTag® utilizes a TransdrugTM nanoparticle 
technology designed specifically for intracellular targeting. By using liposomes or 
nanoparticles, reduction in side effects and targeting to the tumor site has increased, 
respectively. However, these new drugs are still administered intravenously. Studies 
toward developing oral delivery of doxorubicin are just emerging and knowledge of oral 
drug delivery of chemotherapeutics is still premature.  
Kalaria et al., has investigated the use of biodegradable nanoparticles for the oral 
delivery of doxorubicin.5 These nanoparticles, composed of poly(D,L-lactide-co-
glycolide) were loaded with doxorubicin through a double emulsion polymerization and 
demonstrated a biphasic release with 20% of drug released initially and the remaining 
80% released over a couple of weeks. However, lower loading efficiencies (2.5 – 10%) 
require larger amounts of polymer to sustain the proper therapeutic levels. Poly(amido 
amine) dendrimers, lipid nanocarriers, and surface functionalized chitosan nanoparticles 
have also been developed to enhance bioavailability of doxorubicin for oral drug 
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delivery.6-8 These projects are focused on transmembrane transport of doxorubicin from 
the GI tract to the bloodstream to treat a variety of cancers whereas this project is focused 
on direct, local delivery of doxorubicin to the colon to treat colon cancers.  
In our laboratory we have focused on developing P(MAA-g-EG) anionic 
complexation hydrogels for the oral delivery of a variety of proteins and other small and 
large molecular weight therapeutic agents. By varying the monomer composition, 
crosslink density, crosslinker length, and PEG chain length, a variety of polymer carriers 
with unique loading and release properties were developed. These formulations have 
shown great success with loading and releasing proxyphylline, insulin, insulin-transferrin 
bioconjugates, vitamin B12, theophylline, bleomycin, vancomycin, and other 
compounds.9-17 The potential for P(MAA-g-EG) hydrogels to load and release 
hydrophobic compounds is limited, unless the hydrogel is modified with hydrophobic 
properties.  For these studies we focused on using a single P(MAA-g-EG) formulation 
and modified it with either poly(n-butyl acrylate) (PBA) into interpenetrating polymer 
networks or with poly(methyl methacrylate) (PMMA) nanoparticles embedded into the 
P(MAA-g-EG) hydrogel during polymerization. By adding these new hydrophobic 
polymers to the existing hydrophilic network, we may be able to more preferentially 
associate with hydrophobic compounds such as chemotherapeutics. 
IPN and P(MAA-g-EG) containing nanoparticles possess ionizable groups and 
hydrogen bonding through ethylene glycol tethers which allow polymers to be swollen or 
collapsed at different pHs. These swollen and collapsed states can be exploited for the 
loading and release of low molecular weight chemotherapeutics. For loading and release 
studies we used doxorubicin as the selected chemotherapeutic. Fluorescein was also 
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utilized for loading and release because it served as a model hydrophobic agent as well as 
a chemotherapeutic analogue due to its similar hydrophobicity, molecular weight, and 
chemical structure to several chemotherapeutics.18,19 The following studies demonstrate 
that P(MAA-g-EG) modified with PBA or with PMMA nanoparticles are capable of 
entrapping doxorubicin or fluorescein and releasing these compounds. Release profiles 
were generated in neutral, low, and two – step pH conditions.  
6.2  Materials and Methods 
Materials. P(MAA-g-EG), 80/20 IPN, 75/25 IPN, 70/30 IPN, P(MAA-g-EG)-1.0NP, 
P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5.0NP polymer formulations were synthesized using 
the procedures described in Chapter 4 and 5. Dimethyl sulfoxide (DMSO) and fluorescein were 
purchased from Sigma – Aldrich (St. Louis, MO). 10× phosphate buffer solution (PBS), sodium 
chloride, and hydrochloric acid were purchased from Fisher Scientific (Fair Lawn, NJ).  
Doxorubicin was purchased from Selleck Chemicals (Houston, TX). Double distilled water was 
used in all studies.  
Loading Studies. Doxorubicin loading of P(MAA-g-EG) and IPNs. Doxorubicin was 
loaded by equilibrium partitioning in the following manner: a stock solution of doxorubicin was 
prepared in 2 wt.% DMSO in 1× PBS (pH 7.4) at a concentration of 0.25 mg/mL. First, 
doxorubicin was weighed and placed into the bottom of a glass beaker equipped with a Teflon stir 
bar. Doxorubicin was first dissolved in DMSO, then water was added, and lastly 10× PBS 
resulting in a final 1× PBS solution. The order of added solvents prevented doxorubicin from 
precipitating out of solution. A 5 mg/mL concentration of P(MAA-g-EG) or IPN crushed 
particles (75 – 500 µm) to doxorubicin stock solution was allowed to stir slowly for 2 hr. The 
doxorubicin loaded particles were filtered and rinsed with water to remove any surface absorbed 
doxorubicin. A fluorescent plate reader (Biotek Synergy-HT, Winooski, VT), operating at a 485 
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nm excitation and 590 nm emission wavelengths, determined the concentration levels and 
calculated the loading efficiency as follows: 
 
		
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where Co is the initial doxorubicin concentration and Cf is the final doxorubicin 
concentration remaining in the solution. Concentration levels were determined by a 
calibration curve of serial dilutions of doxorubicin ranging from 0.05 µg/mL to 100 
µg/mL. 
Doxorubicin loading of P(MAA-g-EG) and P(MAA-g-EG) containing 
nanoparticles. Loading studies utilized the same doxorubicin loading procedure as above 
except P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles were sized between 
75 – 150 µm and used. 
Fluorescein loading of P(MAA-g-EG) and IPNs. Fluorescein was loaded by 
equilibrium partitioning in the following manner: a fluorescein stock solution was made 
with 2 wt.% DMSO in 1× PBS (pH 7.4) to a final concentration of 0.145 mg/mL. A 5 
mg/mL concentration of P(MAA-g-EG) or IPN crushed particles (75 – 500 µm) to 
fluorescein stock solution was allowed to stir for 24 hr. Then the particles were collapsed 
by adding 1 N HCl to entrap fluorescein within the network, filtered, and rinsed with 
water and 0.1 N HCl to remove any surface absorbed fluorescein. The fluorescent plate 
reader was operated at 485 nm excitation and 590 nm emission wavelengths to determine 
the concentration levels and calculate the loading efficiency using equation 6.1. 
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Concentration levels were determined by a calibration curve of serial dilutions of 
fluorescein ranging from 0.1 µg/mL to 143 µg/mL. 
Fluorescein loading of P(MAA-g-EG) and P(MAA-g-EG) containing 
nanoparticles. Loading studies utilized the same fluorescein loading procedure as above 
except P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles were sized between 
75 – 150 µm and used. 
Release Studies. Doxorubicin release of P(MAA-g-EG) and IPNs. Release experiments 
were performed on a rotary mixer (Glas-Col, Terre Haute, IN) adapted with a cardboard rotary 
wheel which could firmly hold 5 mL vials and operated at 15 rpm (Figure 6.1A). The mixer was 
then placed inside a dry oven (Fisher Scientific Isotemp Incubator Model 525D, Pittsburgh, PA) 
thermostated to 37 °C (Figure 6.1B). For all doxorubicin release experiments, a 1.5 mg sample of 
doxorubicin loaded P(MAA-g-EG) or IPN microparticle was added to a 5 mL vial containing 3 
mL of 1× PBS (pH 2.0 or 7.4). For doxorubicin release in neutral pH, 1× PBS (pH 7.4) was used 
and over the duration of 6 hr, samples were taken and replaced to maintain sink conditions. 
Doxorubicin release in low pH was conducted in the same manner as neutral pH except 1× PBS 
was adjusted to a pH of 2.0 using 1N HCl. 
To mimic the physiological conditions and residence time in the stomach and small 
intestine, doxorubicin was released using a two-step pH change from low pH (2.0) to high pH 
(7.0).20 Doxorubicin loaded microparticles were first placed in 1× PBS at pH 2.0. After 90 min, 
5N NaOH was added to increase the pH to 7.0 where release continued for 6 hr. Samples were 
obtained as above. The mass of doxorubicin released was determined by the fluorescent plate 
reader and reported as follows: 
 
	 = /∞ ∗ 100                                                                              (6.2) 
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where Mt is mass released at a given time and M∞ is total mass released.  
Doxorubicin release of P(MAA-g-EG) and P(MAA-g-EG) containing 
nanoparticles. Release studies utilized the same doxorubicin release procedure as above 
except P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles were sized between 
75 – 150 µm and used. Due to their small size, the particles were allowed to settle in the 3 
mL vial before sampling to prevent uptake during sampling. Uptake during sampling 
could result in artificially high results due to loaded particle releasing in sample 
collection reservoirs.  
Fluorescein release of P(MAA-g-EG) and IPNs. Release experiments were 
performed on a dissolution apparatus (Distek Dissolution System 2100B, North 
Brunswick, NJ) operating at 100 rpm and 37 °C (Figure 6.2A). For all fluorescein release 
experiments a 10 mg sample of fluorescein loaded P(MAA-g-EG) or IPN microparticles 
was added to a 100 mL vessel containing 30 mL of 1× PBS (pH 2.0 or 7.4; Figure 6.2B). 
Release studies were conducted in neutral, low, and two – step pH condition. The mass of 
fluorescein released was determined by the fluorescent plate reader and reported using 
equation 6.2.  
Fluorescein release of P(MAA-g-EG) and P(MAA-g-EG) containing 
nanoparticles. Release studies utilized the same fluorescein release procedure as above 
except P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles were sized between 
75 – 150 µm and used.  
6.3  Results and Discussion 
Loading Studies. Loading was completed by equilibrium partitioning between 
the stock doxorubicin or fluorescein solution and crushed microparticles of P(MAA-g-
155 
 
EG), IPN, or P(MAA-g-EG) containing nanoparticles. The microparticles were red or 
green at the completion of the study indicating the loading of doxorubicin or fluorescein, 
respectively, and were also clumped together and had to be re-crushed for release studies. 
Overall, the loading process was consistent and easy to complete. 
Doxorubicin loading in P(MAA-g-EG) and IPNs. The loading of doxorubicin was 
dependent on the hydrophobic and hydrophilic ratio among the IPNs and P(MAA-g-EG) 
(Table 6.1). P(MAA-g-EG) had a loading efficiency of 48 ± 1% and the 75/25 had the 
highest at 55 ± 2%. The 75/25 IPN possesses the appropriate amount of hydrophobic 
PBA content while still swelling appreciably to imbibe the highest amount of 
doxorubicin. P(MAA-g-EG), which displays the greatest swelling ratio (Chapter 4), 
allows it to still have a high loading level as compared to the other IPNs, but does not 
possess the hydrophobic content to reach the loading levels of the 75/25 IPN. The 80/20 
IPN’s small hydrophobic content and the 70/30 IPN’s low swelling level contributed to 
their reduced loading levels. Weight percent loading ranged from 1.5 – 2.8% and is 
defined as the mg of doxorubicin per mg of polymer. 
Doxorubicin loading in P(MAA-g-EG) and P(MAA-g-EG) containing PMMA 
nanoparticles. The amount of nanoparticles present in the P(MAA-g-EG) hydrogel 
appeared to correspond to the loading efficiencies of doxorubicin. Loading efficiencies 
ranged from 49 – 64% and increased with increasing PMMA nanoparticle content (Table 
6.2). The P(MAA-g-EG)-5.0NP contained the highest weight percentage of nanoparticles 
which resulted in the highest loading efficiency of 64 ± 1%. P(MAA-g-EG)-2.5NP also 
demonstrated a high loading level of 63 ± 3%. P(MAA-g-EG)-2.5NP’s higher degree of 
swelling (Chapter 5) allowed doxorubicin to imbibe more into the polymer network as 
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compared to P(MAA-g-EG)-5.0NP. P(MAA-g-EG) possessed the lowest loading level 
due to the absence of hydrophobic nanoparticles. Weight percent loading ranged from 2.4 
– 3.1% and is defined as the mg of doxorubicin per mg of polymer. 
Fluorescein loading in P(MAA-g-EG) and IPNs. Fluorescein was initially used as 
a model chemotherapeutic to quickly characterize the polymer systems and fine tune 
loading and release procedures before a more expensive and dangerous chemotherapeutic 
(doxorubicin) was used. The polymer carrier’s structure and ratio of hydrophilic to 
hydrophobic components caused different loading efficiencies (Table 6.3).  P(MAA-g-
EG) had a loading efficiency of 37 ± 2% and the 75/25 IPN had the highest at 44 ± 2%. 
75/25 IPN’s degree of hydrophobicity and equilibrium swelling ratio are balanced 
appropriately for increasing the loading potential of fluorescein. We concluded that the 
absence of the hydrophobic network resulted in reduced loading levels in the P(MAA-g-
EG) as compared to the 75/25 IPN. However, the higher equilibrium weight swelling 
ratio of P(MAA-g-EG) allowed it to still maintain high loading levels. On the other hand, 
the 80/20 IPN’s small amount of hydrophobic content and the 70/30 IPN’s reduced 
swelling levels contributed to lower loading levels. Weight percent loading ranged from 
0.9 – 1.3% and is defined as the mg of fluorescein per mg of polymer.  
Loading Fluorescein in P(MAA-g-EG) and P(MAA-g-EG) containing 
nanoparticles. The presence of nanoparticles in the hydrogel caused different loading 
efficiencies. Loading efficiencies ranged from 39 – 51% and increased with increasing 
PMMA nanoparticle content (Table 6.4). The highest efficiency achieved by the P(MAA-
g-EG)-5.0NP, 51 ± 1%, was due to the highest weight percentage of nanoparticles present 
in the P(MAA-g-EG) hydrogel. The absence of the hydrophobic nanoparticles resulted in 
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the reduced loading level for P(MAA-g-EG) as compared to the P(MAA-g-EG) 
containing nanoparticles. However, the high equilibrium weight swelling ratio of 
P(MAA-g-EG) allowed it to still maintain loading levels close to the P(MAA-g-EG)-
1.0NP and P(MAA-g-EG)-2.5NP. Nanoparticles present in the hydrogel allow the 
hydrogel to exhibit hydrophobic properties which preferentially associate with the 
hydrophobic fluorescein compound and improve loading levels. Weight percent loading 
ranged from 1.1 – 1.4%. 
Release studies. Doxorubicin release studies were completed on the rotary mixer 
placed inside a 37 °C incubation oven for small sample analysis while fluorescein release 
studies were completed on a dissolution apparatus. In each case, doxorubicin or 
fluorescein loaded particles slowly swelled and released their contents as indicated by the 
red or green tint of the solution. The release procedure for the rotary mixer required more 
prep time and more careful attention to protocol as compared to the dissolution apparatus.    
Doxorubicin release of P(MAA-g-EG) and IPNs. Release studies were completed 
in neutral pH, low pH, and two – step pH conditions. In neutral pH, 86 – 90% 
doxorubicin released occurred over the course of 4 hr for P(MAA-g-EG), 80/20 IPN, 
75/25 IPN, and 70/30 IPN (Figure 6.3). Because the pH of the release media is greater 
than the pKa value of MAA, the polymer carriers can swell and develop pores large 
enough for doxorubicin to diffuse out and into the surrounding solution.  
To simulate the gastrointestinal pH conditions and transit time, a two – step pH 
model was employed. First, doxorubicin loaded particles were released in pH 2.0 (1× 
PBS) for 90 min and then increased to pH 7.0 (1× PBS) for an additional 6 hr.  IPNs 
released approximately 30 – 70% of doxorubicin in the low pH conditions as compared to 
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P(MAA-g-EG)’s 20% (Figure 6.4). After transitioning from the low pH to neutral pH 
conditions, the remaining amount of doxorubicin loaded in the IPNs and P(MAA-g-EG) 
were slowly released over 4 hr (Figure 6.4). The large amount of doxorubicin in the low 
pH conditions is unfavorable and appeared to be dependent on the degree of 
hydrophobicity. Recalling from Chapter 4, the 70/30 IPN had the highest degree of 
hydrophobicity, the 75/25 IPN the next highest, and the 80/20 IPN the lowest. In the low 
pH conditions of the two-step pH release of doxorubicin, the 80/20 IPN demonstrated the 
least amount of released (30%) while the 75/25 IPN and 70/30 IPN released 64% and 
70%, respectively. These large burst effects for the IPNs as compared to the P(MAA-g-
EG) initially indicated surface loading of doxorubicin. To further investigate, a 75/25 IPN 
doxorubicin loaded sample was exposed to a continuous drip of 1× PBS for 30 min which 
is sufficient enough to remove surface absorbed doxorubicin but insufficient enough to 
fully release all doxorubicin from the core of the particle. The results of the 75/25 IPN 
with and without the 30 min washed are presented in Figure 6.5. 75/25 IPN particles 
washed for 30 min released 42% of doxorubicin as compared to 64% of unwashed 75/25 
IPN particles. Despite the washing step, there was still a large burst effect of doxorubicin 
in low pH conditions.  
Thus, the theory of surface absorbed doxorubicin was complimented with a new 
theory. During the formation of the second hydrophobic PBA network, the P(MAA-g-
EG) network is swollen in a ratio of ethanol to water. As the amount of water is increased 
in this ratio, the P(MAA-g-EG) network exhibits a higher degree of swelling resulting in 
a higher degree of hydrophobicity upon polymerization of the butyl acrylate monomer. 
However, as a result of this degree of swelling and polymerization permanent pores could 
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have formed into the polymer structure of the PBA network. These pores would be 
formed by the presence of the PBA network and its ability to inhibit the first P(MAA-g-
EG) network from fully collapsing on itself in low pH conditions. Thus with increasing 
PBA content, larger pores or increased number of pores maybe formed during the 
synthesis technique. Therefore, even in the collapsed state of the IPN structure, there is 
could still be a porous structure which could allow doxorubicin to prematurely release in 
low pH conditions as a function of hydrophobicity. The premature release of doxorubicin 
in low pH conditions could potentially expose the stomach lining to harmful levels of 
doxorubicin as well as the delivery of insufficient amounts of doxorubicin to treat colon 
cancer.  
Release studies in low pH conditions were extended to 2 hr to further investigate 
the premature release of the 75/25 IPN and compared to P(MAA-g-EG) (Figure 6.6). 
After 2 hr, the 75/25 IPN had released 64% of its encapsulated doxorubicin while 
P(MAA-g-EG) only released 24%. There was no statistical increased in doxorubicin 
release in longer low pH conditions, but these results reiterate doxorubicin would be 
prematurely released in the stomach in quantities which could prove harmful to healthy 
cells while reducing the amount of chemotherapeutic capable of being delivered to the 
tumor site. Due to these observations, the focus of the thesis moved from the IPNs to the 
P(MAA-g-EG) hydrogel containing PMMA nanoparticles. Final concentration levels 
ranged from 9.11 – 26.66 µg/mL with P(MAA-g-EG) and 75/25 IPN being the lowest 
and highest, respectively.   
Doxorubicin release of P(MAA-g-EG) and P(MAA-g-EG) containing PMMA 
nanoparticles. In neutral pH, 90 – 95% of doxorubicin released occurred over the course 
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of 4 hr for P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles (Figure 6.7).  
These release profiles are expected since the pH of the release media is greater than the 
pKa value of MAA.  
The two – step pH model was used to relate in vitro behavior to in vivo behavior. 
First, doxorubicin loaded particles were released in pH 2.0 (1× PBS) for 90 min and then 
increased to pH 7.0 (1× PBS) for an additional 6 hr. P(MAA-g-EG) and P(MAA-g-EG) 
containing nanoparticles all released less than 27% of doxorubicin in the low pH 
conditions (Figure 6.8). After the pH was increased from 2.0 to 7.0, the remaining 
amount of doxorubicin released was completed within 3 hr for P(MAA-g-EG) and 
P(MAA-g-EG)-1.0NP and within 4 hr for P(MAA-g-EG)-2.5NP and P(MAA-g-EG)-
5.0NP. P(MAA-g-EG)-2.5NP and P(MAA-g-EG)-5.0NP contain more hydrophobic 
nanoparticles which preferentially associate with hydrophobic doxorubicin, resulting in 
the delayed release in the pH 7.0 as compared to P(MAA-g-EG) and P(MAA-g-EG)-
1.0NP.  
Release studies in low pH conditions were extended to 2 hr for P(MAA-g-EG) 
and P(MAA-g-EG)-5.0NP samples to provide a reflection of doxorubicin release for 
longer gastric transit times in the stomach (Figure 6.9). P(MAA-g-EG) and P(MAA-g-
EG)-5.0NP both released 32% after 2 hr in low pH conditions indicating minimal 
increase in doxorubicin release for longer gastric transit times. Overall, P(MAA-g-EG) 
and P(MAA-g-EG) containing nanoparticles had reduced doxorubicin release in low pH 
conditions as compared to the IPNs. Final concentration levels ranged from 17.59 – 23.36 
µg/mL with P(MAA-g-EG)-5.0NP being the highest.   
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Fluorescein release of P(MAA-g-EG) and IPNs. In neutral pH, maximum release 
occurred after 2 hr with over 90% of fluorescein released for both IPNs and P(MAA-g-
EG) (Figure 6.10). For the two – step pH release, IPNs released a maximum of 13% of 
the total amount released whereas P(MAA-g-EG) released nearly 21% before the pH 
increase (Figure 6.11). The PBA network binds or restrains fluorescein from releasing 
from the surface or bulk of the IPN due to hydrophobic interactions while P(MAA-g-
EG)’s lack of hydrophobicity causes a larger burst effect in low pH conditions. Release 
profiles of P(MAA-g-EG) and 75/25 IPN in low pH reconfirmed this burst effect 
observation (Figure 6.12). 
An immediate increase in the amount of fluorescein released was observed for all 
polymers after the pH changed from 2.0 to 7.0. Maximum drug release was achieve at 2 
and 4 hr for IPNs and P(MAA-g-EG), respectively (Figure 6.11). P(MAA-g-EG)’s slower 
swelling response to pH shift (Chapter 4) explains the slower release rate as compared to 
IPNs. Final fluorescein concentrations ranged from 2.37 – 4.7 µg/mL. 
Fluorescein release of P(MAA-g-EG) and P(MAA-g-EG) containing PMMA 
nanoparticles. In neutral pH, P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles 
reached maximum fluorescein release by 2 hr with over 90% of fluorescein released 
(Figure 6.13). Since the media was maintained at a pH of 7.4 and the pKa value of MAA 
is 4.8 – 4.9, the polymer carriers have developed the necessary porous structure for 
fluorescein to diffuse out into the surrounding solution.  
P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles fluorescein release 
reached a maximum of 18% in low pH conditions, while P(MAA-g-EG) released nearly 
half of its loaded fluorescein (Figure 6.14). The hydrophobicity imparted by the presence 
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of the PMMA nanoparticles allows preferential association with fluorescein to reduce its 
release in low pH conditions compared with the P(MAA-g-EG) hydrogel. Fluorescein 
release was performed in low pH conditions for 2 hr to expand on the observations seen 
in the low pH conditions during the two – step pH change (Figure 6.14). It is clear in low 
pH conditions, P(MAA-g-EG) released more fluorescein as compared to the P(MAA-g-
EG)-5.0NP (Figure 6.15). 
After 90 min, the pH was stepped from 2.0 to 7.0 and an immediate increase in 
the amount of fluorescein released was observed for all polymer carriers and reached a 
maximum in 2 hr (Figure 6.14). At pH 7.0, P(MAA-g-EG) exhibited a faster release rate 
than the P(MAA-g-EG) containing nanoparticles. This can be explained by the presence 
of fluorescein at or near the surface of the polymer as a result of the diffusional front 
already initiated in low pH conditions. Final fluorescein concentrations ranged from 3.29 
to 6.63 µg/mL. 
6.4  Conclusion 
IPNs and P(MAA-g-EG) containing nanoparticles were subjected to the loading 
of doxorubicin, a low molecular weight, hydrophobic chemotherapeutic. Release studies 
were extensively utilized in neutral, low, and two-step pH conditions to properly evaluate 
these polymer carriers’ potentials as oral chemotherapeutic delivery vehicles.  
For the IPN system, doxorubicin loading efficiencies ranged from 47 – 56% and 
were dependent on the IPNs ability to swell in combination with the proper amount of 
hydrophobic PBA content. The 75/25 IPN demonstrated the highest loading levels as a 
result of the proper balance of swelling and PBA content. Release studies show IPNs 
release more doxorubicin than P(MAA-g-EG) at low pH. For the IPN system, as the 
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amount of hydrophobic content increased, the more doxorubicin was released in low pH. 
This is contributed to the development of a porous structure caused by the PBA network. 
The PBA network restrains the P(MAA-g-EG) network, preventing it from fully 
collapsing in low pH conditions. The inability to reduce hydrophobic agent release in low 
pH can be detrimental in bioapplications, specifically for oral delivery. For example, 
premature release of a chemotherapeutic agent could result in toxicity to the stomach. 
Furthermore, protecting the chemotherapeutic agent during transit through the stomach 
increases the amount capable of releasing in colon as well as its mechanism for 
destroying tumors. When the pH shifted from low to neutral, the remaining amount of 
encapsulated doxorubicin was released within 4 hr and resulted in final doxorubicin 
concentrations between 9.11 – 26.66 µg/mL. Due to the premature doxorubicin release in 
the low pH, the remainder of the thesis was focused on P(MAA-g-EG) containing 
PMMA nanoparticles. 
For the P(MAA-g-EG) containing PMMA nanoparticles, loading levels were 
increased from 49% for the P(MAA-g-EG) to 64% for P(MAA-g-EG)-5.0NP and  
increased with increasing nanoparticle content. For release studies, P(MAA-g-EG) and 
P(MAA-g-EG) containing nanoparticles kept doxorubicin release below 27% in low pH 
conditions. After shifting the pH from low to neutral, the remainder of doxorubicin was 
released over 3 hr for P(MAA-g-EG) and P(MAA-g-EG)-1.0NP and 4 hr for P(MAA-g-
EG)-2.5NP and P(MAA-g-EG)-5.0NP. The larger amount of nanoparticles present in the 
latter couple helped extend doxorubicin release over 4 hr which could help improve more 
local release to the colon for colon cancer. Final doxorubicin concentrations were 17.59 – 
23.36 µg/mL with P(MAA-g-EG)-5.0NP being the highest. The P(MAA-g-EG)-5.0NP 
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polymer formula was selected for investigation with cell studies, transport studies, and 
loading and release with doxorubicin conjugate because of its higher loading levels and 
extended release profiles.  
Due to doxorubicin’s toxicity and expense, the loading and release experiments 
were optimized using fluorescein, a fluorescent dye, as a model chemotherapeutic. For 
the IPN system and the P(MAA-g-EG) containing nanoparticles,  fluorescein served as a 
good model for doxorubicin. In all polymer formulations the loading levels of fluorescein 
were reduced as compared to doxorubicin which can be due to fluorescein’s increased 
hydrophobicity as compared to doxorubicin. The trends demonstrated during fluorescein 
loading were also exhibited with doxorubicin loading. For example, the 75/25 IPN had a 
balance of hydrophobic and hydrophilic components to achieve the highest loading of 
fluorescein which is also seen with doxorubicin. For P(MAA-g-EG) containing 
nanoparticles, fluorescein loading increased with increasing nanoparticle content, which 
was also seen with doxorubicin.  
As for release studies, fluorescein appeared to be more influenced by the presence 
of hydrophobic polymers as compared to doxorubicin. In the two – step pH release 
model, IPN and P(MAA-g-EG) containing nanoparticles released less fluorescein in the 
low pH conditions as compared to the P(MAA-g-EG) samples. Furthermore, the amount 
of fluorescein released in the low pH conditions was less than the amount of doxorubicin 
released in low pH conditions for all polymers. In conclusion, fluorescein serves as an 
excellent model chemotherapeutic and good way to optimize experimental conditions; 
however, its performance is not exactly replicated by the chemotherapeutic doxorubicin 
in every experimental scenario.   
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Figures 
 
 
Figure 6.1. Apparatus for doxorubicin release studies. (A) Incubation oven set to 37 
°C, (B) rotary mixer equipped with cardboard sample holder, and (C) 5 mL release vial 
for doxorubicin loaded particles and 1× PBS.  
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Figure 6.2. Dissolution apparatus for fluorescein release studies. (A) Temperature 
controlled water bath, paddles attached to rotary mixer, and (B) dissolution vessel for 
fluorescein loaded particles and 1× PBS.  
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Figure 6.3. Doxorubicin release of P(MAA-g-EG) and IPNs in neutral pH 
conditions. Doxorubicin loaded P(MAA-g-EG), 80/20 IPN, 75/25 IPN, and 70/30 IPN 
crushed particles (70 – 500 µm) were released in 1× PBS (pH 7.4) for 6 hr. Doxorubicin 
release is expressed as Mt/M∞. Curves generated are n = 3 and error bars represent error 
propagation due to ratio of Mt/M∞.  
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Figure 6.4. Doxorubicin release of P(MAA-g-EG) and IPNs in two – step pH 
conditions. Doxorubicin loaded P(MAA-g-EG), 80/20 IPN, 75/25 IPN, and 70/30 IPN 
crushed particles (70 – 500 µm) were released in 1× PBS (pH 2.0) for 90 min. Then the 
pH was increased to 7.0 by adding 5 N NaOH and release continued for 6 hr. 
Doxorubicin release is expressed as Mt/M∞. Curves generated are n = 3 and error bars 
represent error propagation due to ratio of Mt/M∞. 
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Figure 6.5. Doxorubicin release of 75/25 IPN with and without washing in two – step 
pH conditions. 75/25 IPN crushed particles (70 – 500 µm) were washed with water for 
30 min to remove surface absorbed doxorubicin and compared to a 75/25 IPN unwashed 
sample. Both samples were released in 1× PBS (pH 2.0) for 90 min. Then the pH was 
increased to 7.0 by adding 5 N NaOH and release continued for 6 hr. Doxorubicin release 
is expressed as Mt/M∞. Curves generated are n = 3 and error bars represent error 
propagation due to ratio of Mt/M∞. 
 
173 
 
 
Figure 6.6. Doxorubicin release of P(MAA-g-EG) and IPNs in low pH conditions. 
Doxorubicin loaded P(MAA-g-EG), 80/20 IPN, 75/25 IPN, and 70/30 IPN crushed 
particles (70 – 500 µm) were released in 1× PBS (pH 2.0) for 2 hr to evaluate longer 
gastric transit times.  Doxorubicin release is expressed as Mt/M∞. Curves generated are n 
= 3 and error bars represent error propagation due to ratio of Mt/M∞. 
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Figure 6.7. Doxorubicin release profiles of P(MAA-g-EG) and compositions of 
P(MAA-g-EG) containing nanoparticles in neutral pH conditions. Doxorubicin 
loaded P(MAA-g-EG), P(MAA-g-EG)-1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-
EG)-5.0NP crushed particles (75 – 150 µm) were released in 1× PBS (pH 7.4) for 6 hr. 
Doxorubicin release is expressed as Mt/M∞. Curves generated are n = 3 and error bars 
represent error propagation due to ratio of Mt/M∞. 
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Figure 6.8. Doxorubicin release profiles of P(MAA-g-EG) and compositions of 
P(MAA-g-EG) containing nanoparticles in two – step pH conditions. Doxorubicin 
loaded P(MAA-g-EG), P(MAA-g-EG)-1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-
EG)-5.0NP crushed particles (75 – 150 µm) were released in 1× PBS (pH 2.0) for 90 min. 
Then the pH was increased to 7.0 by adding 5 N NaOH and release continued for 6 hr. 
Doxorubicin release is expressed as Mt/M∞. Curves generated are n = 3 and error bars 
represent error propagation due to ratio of Mt/M∞. 
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Figure 6.9. Doxorubicin release profiles of P(MAA-g-EG) and compositions of 
P(MAA-g-EG) containing nanoparticles in low pH conditions. Doxorubicin loaded 
P(MAA-g-EG), P(MAA-g-EG)-1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5.0NP 
crushed particles (75 – 150 µm) were released in 1× PBS (pH 2.0) for 2 hr to evaluate 
longer gastric transit times.  Doxorubicin release is expressed as Mt/M∞. Curves 
generated are n = 3 and error bars represent error propagation due to ratio of Mt/M∞. 
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Figure 6.10. Fluorescein release of P(MAA-g-EG) and IPNs in neutral pH 
conditions. Fluorescein loaded P(MAA-g-EG), 80/20 IPN, 75/25 IPN, and 70/30 IPN 
crushed particles (70 – 500 µm) were released in 1× PBS (pH 7.4) for 6 hr. Fluorescein 
release is expressed as Mt/M∞. Curves generated are n = 3 and error bars represent error 
propagation due to ratio of Mt/M∞. 
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Figure 6.11. Fluorescein release of P(MAA-g-EG) and IPNs in two – step pH 
conditions. Fluorescein loaded P(MAA-g-EG), 80/20 IPN, 75/25 IPN, and 70/30 IPN 
crushed particles (70 – 500 µm) were released in 1× PBS (pH 2.0) for 90 min. Then the 
pH was increased to 7.0 by adding 5 N NaOH and release continued for 6 hr. Fluorescein 
release is expressed as Mt/M∞. Curves generated are n = 3 and error bars represent error 
propagation due to ratio of Mt/M∞. 
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Figure 6.12. Fluorescein release of P(MAA-g-EG) and IPNs in low pH conditions. 
Fluorescein loaded P(MAA-g-EG), 80/20 IPN, 75/25 IPN, and 70/30 IPN crushed 
particles (70 – 500 µm) were released in 1× PBS (pH 2.0) for 2 hr to evaluate longer 
gastric transit times.  Fluorescein release is expressed as Mt/M∞. Curves generated are n = 
3 and error bars represent error propagation due to ratio of Mt/M∞.  
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Figure 6.13. Fluorescein release profiles of P(MAA-g-EG) and compositions of 
P(MAA-g-EG) containing nanoparticles in neutral pH conditions. Fluorescein loaded 
P(MAA-g-EG), P(MAA-g-EG)-1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5.0NP 
crushed particles (75 – 150 µm) were released in 1× PBS (pH 7.4) for 6 hr. Fluorescein 
release is expressed as Mt/M∞. Curves generated are n = 3 and error bars represent error 
propagation due to ratio of Mt/M∞. 
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Figure 6.14. Fluorescein release profiles of P(MAA-g-EG) and compositions of 
P(MAA-g-EG) containing nanoparticles in two – step pH conditions. Fluorescein 
loaded P(MAA-g-EG), P(MAA-g-EG)-1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-
EG)-5.0NP crushed particles (75 – 150 µm) were released in 1× PBS (pH 2.0) for 90 min. 
Then the pH was increased to 7.0 by adding 5 N NaOH and release continued for 6 hr. 
Fluorescein release is expressed as Mt/M∞. Curves generated are n = 3 and error bars 
represent error propagation due to ratio of Mt/M∞. 
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Figure 6.15. Fluorescein release profiles of P(MAA-g-EG) and compositions of 
P(MAA-g-EG) containing nanoparticles in low pH conditions. Fluorescein loaded 
P(MAA-g-EG), P(MAA-g-EG)-1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5.0NP 
crushed particles (75 – 150 µm) were released in 1× PBS (pH 2.0) for 2 hr to evaluate 
longer gastric transit times.  Fluorescein release is expressed as Mt/M∞. Curves generated 
are n = 3 and error bars represent error propagation due to ratio of Mt/M∞. 
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Tables 
 
 
  
Table 6.1. Doxorubicin loading efficiency and weight percent loading for P(MAA-g-
EG) and IPNs (75 – 500 µm). 
Formulation 
Loading Efficiency  
(%) 
Wt. loading  
(%) 
P(MAA-g-EG) 47 ± 1 2.3 
80/20 IPN 30 ± 5 1.5 
75/25 IPN 56 ± 2 2.8 
70/30 IPN 40 ± 3 2.0 
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Table 6.2. Doxorubicin loading efficiency and weight percent loading for P(MAA-g-
EG) and P(MAA-g-EG) containing nanoparticles (75 – 150 µm). 
Formulation 
Loading Efficiency  
(%) 
Wt. loading  
(%) 
P(MAA-g-EG) 49 ± 2 2.4 
P(MAA-g-EG)-1.0NP 57 ± 1 2.8 
P(MAA-g-EG)-2.5NP 63 ± 3 3.1 
P(MAA-g-EG)-5.0NP 64 ± 1 3.1 
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Table 6.3. Fluorescein loading efficiency and weight percent loading for P(MAA-g-EG) 
and IPNs (75 – 500 µm). 
Formulation 
Loading Efficiency  
(%) 
Wt. loading  
(%) 
P(MAA-g-EG) 37 ± 2 1.1 
80/20 IPN 30 ± 2 0.9 
75/25 IPN 44 ± 2 1.3 
70/30 IPN 21 ± 6 1.0 
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Table 6.4. Fluorescein loading efficiency and weight percent loading for P(MAA-g-EG) 
and P(MAA-g-EG) containing nanoparticles (75 – 150 µm). 
Formulation 
Loading Efficiency  
(%) 
Wt. loading  
(%) 
P(MAA-g-EG) 38 ± 2 1.1 
P(MAA-g-EG)-1.0NP 41 ± 3 1.2 
P(MAA-g-EG)-2.5NP 43 ± 1 1.2 
P(MAA-g-EG)-5.0NP 51 ± 1 1.4 
187 
 
Chapter 7 
Mucoadhesive Behavior and Biocompatibility of Interpenetrating Polymer 
Networks and Hydrogels Dispersed with Hydrophobic Nanoparticles 
 
7.1  Introduction 
 When developing new polymer materials for oral drug delivery it is important to 
evaluate their biocompatibility and especially how these materials will interact with the 
GI tract.1 The way polymers interact with biological systems, especially for drug delivery 
applications, can affect drug absorption and distribution. Cytotoxicity studies can be 
employed to determine if the synthesized material is safe and nontoxic to healthy cells, so 
that homeostatic conditions can be maintained during drug delivery. Mucoadhesive 
studies can help determine how the drug delivery system interacts with the intestinal 
mucosa. A favorable interaction with the mucosa allows for the drug delivery system to 
reside longer in the upper small intestine which improves bioavailability of therapeutic 
agents. Neutral or negative interaction of the polymer materials with the mucosa would 
allow that drug delivery system to travel further down the GI tract for drug release in the 
lower small intestine or colon.  
 A variety of cytotoxic and mucoadhesive experiments are available to choose 
from for in vitro characterization. Direct contact, extract dilution, and agar diffusion are 
three common assays to evaluate the toxicity of synthesized polymer materials.2 The 
most common, direct contact, cytotoxicity experiment utilizes a compound called 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-terazolium 
(MTS) paired with an electron-coupling reagent (phenazine ethosulfate; PES). These 
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combined chemicals are bioreduced by cells to form a dark formazan product 
(determined via UV / VIS spectrophotometry) which is directly proportional to the 
number of living cells.3,4 This MTS assay is an effective and quick method to analyze the 
cytocompatiblity of nanoparticle and microparticle polymer systems. 
 Since oral drug delivery devices interact with the GI tract, it is important to assess 
biocompatibility of the synthesized materials with viable cell culture models. The 
intestinal lumen is composed of a monolayer of columnar epithelium which is covered 
with microvilli, i.e., cylindrical membrane protrusions which greatly increased the 
surface area for nutrient and drug absorption.5,6  
The intestinal lumen also contains goblet cells which secrete mucin to form a 
chemical barrier from harmful substances. These two types of cells are modeled in cell 
cultures with Caco-2 and HT29-MTX cultures. Caco-2 cells are derived from a human 
colorectal adenocarcinoma and when grown expresses an apical brush border and 
intestinal enzymes. Caco-2 cell models also form tight junctions similar to the intestinal 
epithelium.7,8 These tight junctions both in cell culture models and in native GI tract are 
critical for cellular signaling and controlling the transport of molecules from the apical to 
basolateral side of the lumen. The formation of the tight junctions and their importance 
will be further discussed in Chapter 9.  
Caco-2 cells do not secrete mucus, thus HT29-MTX cell cultures are evaluated 
separately or co-cultured with Caco-2 to obtain an accurate model of the GI tract.9 HT29-
MTX cells are also human colorectal adenocarcinomas, are a goblet cell subline, and also 
form tight junctions. The combination of these two cell lines provides a close model to 
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the GI tract and is utilized for cytotoxicity studies and transport studies (Chapter 9). 
SW620, a colorectal adenocarcinoma, serves as the colon tumor model. 
Cytotoxicity of P(MAA-g-EG), IPNs, and P(MAA-g-EG) containing hydrophobic 
nanoparticles was tested against varying concentration levels and lengths of exposure to 
Caco-2, HT29-MTX, and SW620 cell lines. Varying concentrations of doxorubicin were 
also exposed to all cell lines to determine IC50 values.   
Mucoadhesion is a phenomenon describing the molecular interactions between 
mucus or a mucosal surface and a polymer. It is characterized by the attractive force 
between the polymer and native GI tissue surfaces.10-12 Increased attractive forces may 
allow polymer samples to reside in the upper small intestine for a prolonged period of 
time and allow for more local, direct delivery to that particular location.13  
The mucosal layer is composed of glycoproteins of high molecular weight of 
which 70 – 90% are carbohydrates.14 In the upper small intestine the thickness of mucus 
is between 10 and 400 µm and the presence of acidic side chains in the glycoprotein 
makes charge interactions important when designing the polymer drug delivery system.15-
17
 Mucoadhesive polymers which have been previously investigated have included 
hydrophilic polymers such as poly(N-vinyl-2-pyrrolidone), methyl cellulose, hydroxyl 
propyl cellulose, and other cellulose derivatives.18-20 Hydrogels with anionic groups such 
as Carbopol® or polyacrylates demonstrate mucoadhesive properties as well as hydrogels 
containing cationic groups such as a chitosan.21-23 
There is a variety of testing methods and materials for determining the 
mucoadhesive properties of polymer materials. The mucosal surface of the human GI 
tract can be modeled by using dry porcine mucin which has been reconstituted and 
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adhered to a variety of substrates or plates for testing purposes. A more physiologically 
relevant model can be obtained by using fresh porcine small intestine acquired from a 
local slaughterhouse and used within 2 – 4 hr of harvest. Flow chambers, waterfall, 
tensile, and fluorescence adherence are a variety of experiments which utilize 
reconstituted mucin or fresh porcine tissue to determine mucoadhesion. In the waterfall 
experiments polymer particles are adhered to reconstituted mucin or fresh porcine tissue 
and then placed at an angle (45 - 90°). Water from a reservoir at the top flows across the 
apparatus until the last particle is washed away. The amount of water or time to remove 
the last attached particle corresponds to the degree of mucoadhesion.24,25 The flow model 
operates similarly, but operates horizontally with a pump pushing water across the 
polymer and the mucin or fresh tissue.26-28 For tensile experiments, the material or model 
tissue is mounted to a tensiometer (such as an Instron) and touched to a mounted material 
or model tissue, allowed some time to adhere, and then retracted from each other and the 
forces measured.29-31 If the material under investigation can be tagged with a fluorescent 
molecule, fluorescent adherence experiments can be completed. In these experiments, the 
fluorescing polymer material is put in contact with mucin or fresh tissue, allowed to 
adhere, washed, and then read on a UV / VIS spectrometer. The increase in fluorescence 
is indicative of increased mucoadhesion.32-34  
Previously it has been demonstrated that P(MAA-g-EG) can increase 
mucoadhesion due to the presence of the grafted PEG chains.35-39 Grafted PEG chains of 
molecular weight 1000 demonstrated increased mucoadhesive while molecular weight 
chains of 100,000 exhibited limited mucoadhesive capacity. Long chains could result in 
extensive entanglements within the hydrogel and thus reduce the necessary mobility for 
191 
 
pendent groups to penetrate the mucin surface.40 On the other hand, the shorter PEG 
chains possess enough mobility and length to penetrate the mucin surface and anchor the 
polymer particle to the upper small intestine to increase residence time of targeted drug 
release.   
For the purpose of this thesis, maximum payload and direct delivery to the colon 
would prove advantageous; thus incorporating a secondary hydrophobic network utilizing 
interpenetrating polymer networks or by incorporating hydrophobic nanoparticles into the 
P(MAA-g-EG) polymer system, could be reduce mucoadhesion. This allows these 
modified polymer systems to travel further down the GI tract and deliver the drug in 
closer proximity to the colon. P(MAA-g-EG), 75/25 IPN, and P(MAA-g-EG)-5.0NP 
discs were subjected to mucoadhesion testing. Using the tensile technique, samples were 
placed on fresh, excised porcine small intestine and the maximum force of detachment 
and work of adhesion computed.     
7.2  Materials and Methods 
 Materials. P(MAA-g-EG), 80/20 IPN, 75/25 IPN, 70/30 IPN, P(MAA-g-EG)-
1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5.0NP were synthesized using the 
procedures described in Chapter 4 and 5. Dulbecco’s Modified Eagle’s Medium 
(DMEM), Roswell Park Memorial Institute Medium (RPMI), and fibronectin were 
purchased from Sigma – Aldrich (St. Louis, MO). Fetal bovine serum (FBS) and trypsin 
with EDTA were obtained from Hyclone (South Plainfield, NJ). 1× Phosphate Buffered 
Saline (PBS) without calcium or magnesium, penicillin, and streptomycin were from 
MediaTech (Manassas, VA). The cell proliferation MTS assay was purchased from 
Promega (Madison, WI). Doxorubicin was purchased from Selleck Chemicals (Houston, 
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TX). Caco-2, SW620 cells, and Leibovitz’s media (L-15) were obtained from American 
Type Culture Collection (ATCC, Rockwell, MD) and HT29-MTX cells were a gift from 
Dr. Thecla Lesuffleur, INSERM, Paris, France. 
General Cell Culture. Caco-2 and HT29-MTX cells were maintained in DMEM 
containing 4.5 g/L glucose, 1% non-essential amino acids, 100 U/mL penicillin, 100 
µg/mL streptomycin, 2.7 g/L sodium bicarbonate, and 10% by volume of heat-inactivated 
FBS. Cells were grown in T-75 vented flasks (Corning, Corning, NY) in a 5% CO2 and 
95% humidity environment maintained at 37 °C. 
SW620 cells were initially maintained in L-15 containing 100 U/mL penicillin, 
100 µg/mL streptomycin, 10% by volume of heat-inactivated FBS, and 2 mM L-
glutamine. These cells were grown in T-75 plug capped flasks (Corning, Corning, NY) 
because L-15 media is to be used without additional CO2. The temperature was 
maintained at 37 °C. After two passages, SW620 cells were switched from L-15 media to 
RPMI-1640 with 2.7 g/L sodium bicarbonate and supplemented with 100 U/ml penicillin, 
100 µg/ml streptomycin, and 10% by volume of heat-inactivated FBS. SW620 cells were 
then grown in T-75 vented flasks in a 5% CO2 and 95% humidity environment 
maintained at 37 °C. 
Media was changed every other day for all cell lines and passaged until 80% 
confluency was reached. To passage cells, cells were rinsed three times with 5 mL of 1× 
PBS, then rinsed with 2 mL of 0.25 – 0.5% trypsin with 0.2% EDTA. Cells were then 
incubated with 3 mL of the trypsin/EDTA solution for 6 to 8 min, diluted with 6 mL of 
fresh media, gently centrifuged down, and resuspended in 5 mL of fresh media for 
seeding and counting.  
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Caco-2 cells were seeded at a density of 3.0 × 103 cells/cm2 and used between 
passages 68 and 78. HT29-MTX cells were seeded at a density of 2.0 × 104 cells/cm2 and 
used between passages 10 to 20. SW620 cells were seeded at a density of 1.0 × 103 
cells/cm2 and used between passages 90 to 100.  
Cytocompatiblity. Cytocompatiblity experiments were performed in a 96-well 
plate (Nunc, Rochester, NY). 96-well plates were first incubated in fibronectin for 1 hr at 
a concentration of 1 µg/cm2. The fibronectin was removed and the cells immediately 
plated. Caco-2 cells were seeded at a density of 2.0 × 104 cells/cm2, HT29-MTX seeded 
at a density of 3.0 × 104 cells/cm2, and SW620 seeded at 1.5 × 104 cells/cm2. Cells were 
incubated for 48 hr before testing. 
IPN and P(MAA-g-EG) dry microparticles, sized between 75 and 500 µm, were 
weighed out individually and added to the 96-well plates which had the growth medium 
removed and replaced with 200 µl of 1× PBS in each well. For P(MAA-g-EG) and 
P(MAA-g-EG) containing hydrophobic nanoparticles sized between 75 and 150 µm, dry 
particles were swollen in 1× PBS overnight and then pipetted into the 96-well plate after 
the growth medium had been removed. Concentrations for P(MAA-g-EG), IPNs, and 
P(MAA-g-EG) containing nanoparticles ranged from 1 to 5 mg/mL. The microparticles 
were incubated with the cells for 2 hr at 37 °C and 5% CO2. The microparticle 
suspensions were aspirated from each well and the wells rinsed with 1× PBS three times.  
Cytotoxicity was also evaluated for long-term exposure utilizing a 5 mg/mL 
concentration for P(MAA-g-EG), 75/25 IPN, and P(MAA-g-EG)-5.0NP. These 
formulations were selected due to their high loading efficiency and release properties as 
demonstrated in Chapter 6.  The same procedures were utilized as above except the 75/25 
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IPN dry microparticles (75 – 500 µm) were placed in fresh growth media instead of 1× 
PBS. For P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles (75 – 150 µm), 
they were swollen in growth media overnight instead of 1× PBS. The microparticles were 
incubated with the cells for 24, 12, and 6  hr at 37 °C and 5% CO2. The microparticles 
suspensions were aspirated from each well and the wells rinsed with 1× PBS three times.            
    MTS assays (CellTiter 96® Aqueous One Solution Cell Proliferation Assay) 
were used to determine cell viability. A 2 mL sample of the CellTiter 96® reagent was 
added to 10 mL of DMEM or RPMI for Caco-2/HT29-MTX or SW620 cells lines 
respectively. A sample size of 120 µL was added to each well and incubated for 2 – 3 hr 
at 37 °C and 5% CO2. Viable cells reduced the MTS tetrazolium compound into a 
colored formazan product. The colored formazan product is detectable at 490 nm using a 
UV/VIS microplate reader (Bio-TEK Synergy HT, Winooksi, VT). Cell viability was 
determined by comparing experimental cells to control cells which were not exposed to 
microparticles. 
IC50 Values. IC50 values represent the concentration of a drug or substance that is 
required for 50% inhibition or death in vitro.
 
An IC50 value can then be paired with the 
release studies completed in Chapter 6 to determine the amount of drug loaded polymer 
to be administered for therapeutic effects. To determine IC50 values for doxorubicin, 
Caco-2, HT29-MTX, and SW620 were plated into 96-well plates as discussed above. 
After 48 hr of growth, all cell lines were exposed to concentrations of doxorubicin 
dissolved in DMEM or RPMI media ranging from 100 to 0.01 µM for 4 hr. The 
doxorubicin was removed from the cells, rinsed three times with 1× PBS, and finally 
195 
 
incubated with fresh media. After 96 hr, the media was removed and the MTS assay 
completed as discussed above.   
     Mucoadhesion. Mucoadhesion testing was carried out on P(MAA-g-EG), 75/25 
IPN, and P(MAA-g-EG)-5.0NP discs using a texture analyzer (TA.XT plus, Stable Micro 
Systems, UK) with a 5 kg load cell (Figure 7.1) and a mucoadhesive testing rig (Figure 
7.2a). Sample discs were allowed to swell and equilibrate in 1× PBS adjusted to a pH of 
7.0 for 24 hr. Sample discs (10 mm in diameter) were dabbed dry on one side and 
attached to aluminum cylindrical probes (10 mm x 60 mm) using super glue and allowed 
to adhere for 10 min (Figure 7.2b-c). The prepped samples were kept in the original 1× 
PBS (pH 7.0) solution until used.  
Porcine GI tract tissue (upper small intestine) was obtained immediately after 
slaughter at the local slaughterhouse (Taylor Meats, Texas). The GI tract was initially 
rinsed with tap water at the slaughterhouse to remove non-digested food from the lumen, 
rinsed a second time with 1× PBS (pH 7.0), and stored in 1× PBS (pH 7.0) at 37 °C until 
tested. All tissues samples were used within 2 – 4 hr of slaughter.  
Figure 7.3 illustrates the mucoadhesive test. The rectangular tissue samples were 
cute in the longitude direction to form a rectangular tissue sample (50 mm x 20 mm) and 
clamped onto the mucoadhesive rig which was immersed 1× PBS (pH 7.0) and 
thermostated to 37 °C. The probe and disc were attached to the texture analyzer, the 
polymer sample was lowered at a rate of 5 mm/min until a force of 5 g was sensed, then 
proceeded to lower at 0.1 mm/min until a force of 50 g was applied to the tissue surface.  
After 5 min of static loaded force, the probe was withdrawn at a rate of 0.1 mm/min until 
it was fully detached from the tissue sample. Using texture analyzer software (Texture 
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Exponent 32) the maximum detachment force (Fmax) and the work of adhesion (Wad) 
could be computed using the maximum peak and the area under the force versus distance 
curve, respectively. These parameters were used to compare the mucoadhesion of 
P(MAA-g-EG), 75/25 IPN, and P(MAA-g-EG)-5.0NP.  
7.3  Results and Discussion 
 Cytocompatiblity. Caco-2, HT29-MTX, and SW620 cells were plated in fibronectin 
coated 96-well plates and exposed to varying concentration of microparticles for 2, 6, 12, or 24 
hr. The viable cells were determined by MTS assay and UV/VIS plate reader operating at 490 nm 
absorbance. P(MAA-g-EG), IPNs, and P(MAA-g-EG) containing nanoparticles were tested at the 
following  concentrations: 1 mg/mL, 2.5 mg/mL, and 5 mg/mL. No significant decrease in cell 
viability was observed for all polymer systems (Figure 7.4 – 7.9). Cell viability appeared low 
(80%) for HT29-MTX exposed to 5 mg/mL of P(MAA-g-EG) (75 – 150 µm) (FIGURE 7.7), but 
visual inspection showed a small sheet of cells dislodged during the washing step.  
 No cytotoxic effect was observed after incubation of P(MAA-g-EG), 75/25 IPN, and 
P(MAA-g-EG)-5.0NP at 5 mg/mL for 24, 12, and 6 hr (Figures 7.10 – 7.12). No toxic effects for 
the HT29-MTX with P(MAA-g-EG) at 5 mg/mL address any further concerns for the toxicity 
seen in the 2 hr study. These microparticles are not intended to cross the GI tract into the 
bloodstream; therefore, investigating long term exposure at 24, 12, and 6 hr could relate to the 
residence time of microparticles in small intestine and colon. The lack of toxicity indicates these 
microparticles should be biocompatible with human physiological systems.  
 P(MAA-g-EG)’s biocompatibility has been extensively studied in previous 
research and these results are in agreement. P(MAA-g-EG), utilizing the polymerization 
technique as in this thesis, proved to be non-toxic at concentrations less than 10 
mg/mL.41-44 However, the original P(MAA-g-EG) hydrogel has been modified with 
poly(butyl-acrylate) to form the interpenetrating network or photopolymerized around 
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poly(methyl methacrylate) nanoparticles. The incorporation of these new materials could 
have influenced their cytotoxicity. From these studies, it can be determined that the 
addition of PBA or PMMA at these concentration levels did not harm the cells. The non-
cytotoxic response of PMMA into the P(MAA-g-EG) hydrogel was to be expected as this 
material has a successful history with medical devices including FDA approved PMMA 
bone cement for implants. PBA’s use in the medical community is significantly reduced 
as compared to PMMA. Limited information is known about PBA and its 
biocompatibility with biological systems. However, that does not mean PBA’s potential 
for use in the medical community should be eliminated. PBA has been utilized for drug 
delivery applications in the formation of  matrices for paclitaxel release45 or to form 
shape-memory suture wound closures46 and have also been shown to be biocompatible.  
 IC50 Values. The IC50 data for the three cell lines treated with varying 
concentrations with doxorubicin are presented in Figure 7.13. Caco-2, HT29-MTX, and 
SW620 demonstrated different sensitivities to doxorubicin. HT29-MTX and Caco-2 cell 
lines demonstrated 2 – 3 times more resistance to doxorubicin as compared to SW620. 
HT29-MTX demonstrated resistance to doxorubicin until a 25 µM concentration of 
doxorubicin in culture media was reached at which point viability was reduced to 50%. 
After this value was reached, HT29-MTX cell lines continued to decrease in viability 
with the lowest viability of 28% reached at 100 µM doxorubicin. Caco-2 slowly 
decreased in viability with increasing doxorubicin concentration, but overall 
demonstrated the most resistance at the higher doxorubicin concentrations.  
Caco-2 cells were at 56% viability at 100 µM doxorubicin. Doxorubicin was most 
toxic to the SW620 cell line with a IC50 value of 5 µM doxorubicin and falling to 17% 
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viable cells at 100 µM. Doxorubicin’s effectiveness is dependent on cell division and the 
data illustrated in Figure 7.13 corresponds accordingly to the Caco-2 which replicates the 
slowest, SW620 which replicates the fastest, and HT29-MTX which is in between. These 
results are in agreement with previous research investigating the effectiveness of 
doxorubicin against Caco-2, HT29-MTX, and SW620 cell lines.47-49 
  Mucoadhesion. The mucoadhesion of a pure P(MAA-g-EG) hydrogel was 
compared to  the 75/25 IPN and P(MAA-g-EG)-5.0NP. The 75/25 IPN and P(MAA-g-
EG)-5.0NP where chosen because they demonstrated high loading efficiencies and 
release profiles appropriate for oral drug delivery.  In the results obtained from these 
experiments (Figure 7.14) the IPN demonstrated the highest degree of adhesion and the 
P(MAA-g-EG)-5.0NP the lowest degree of adhesion. The incorporation of hydrophobic 
properties was expected to decrease the interaction of the polymer systems with the 
mucin surface which is dominantly hydrophilic due to the presence of carbohydrates.  
However, the 75/25 IPN demonstrated increased adhesion as compared to the 
pure P(MAA-g-EG) despite possessing hydrophobic properties. It is hypothesized that 
the increased adhesion of the 75/25 IPN is due to mobile ethylene glycol tethers. During 
the formation of the PBA network in the IPN, the first P(MAA-g-EG) network is swollen 
in a solution of water and butyl acrylate monomer and then exposed to UV light. The 
presence of this second PBA network can cause a porous network to form as well as limit 
the hydrogen bonding interaction between ethylene glycol chains and unionized hydroxyl 
groups on the methacrylic acid. More mobile tethers and decrease in the potential 
bonding gives ethylene glycol tethers an improved chance for diffusion into the mucin 
layer and thus increase adhesion as compared to the unmodified P(MAA-g-EG) 
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counterpart. P(MAA-g-EG)-5.0NP hydrophobic properties prevented favorable 
interactions between itself and the mucin layer and thus demonstrated decreased 
adhesion.  
7.4  Conclusions 
Cytotoxicity and mucoadhesive experiments were conducted as in vitro 
assessments of P(MAA-g-EG), IPNs, and P(MAA-g-EG) containing nanoparticles. 
Cytotoxicity was completed on Caco-2 and HT29-MTX cell lines which represented a GI 
tract model while SW620 operated as a tumor model. For all polymer systems a 2 hr 
exposure at varying concentrations was completed as well as a 24 , 12, and 6 hr exposure 
for P(MAA-g-EG), 75/25 IPN, and P(MAA-g-EG)-5.0NP using a concentration of 5 
mg/mL. All MTS assays indicated all material were cytocompatible at different 
concentrations and exposure times.  IC50 values were also determined for Caco-2, HT29-
MTX, and SW620 cell models. Doxorubicin is a harmful therapeutic agent and toxicity 
even for the Caco-2 and HT29-MTX (GI tract model) is to be expected. However, the 
primary focus of the IC50 experiments were to determine the necessary concentration 
levels of doxorubicin to effectively kill 50% of SW620 cells, our tumor model. A 
doxorubicin concentration of 5 µM is sufficient for killing half of the SW620 cells.  
Mucoadhesion experiments indicated that the 75/25 IPN possessed the greatest 
adhesion and the P(MAA-g-EG)-5.0NP the least. Due to the polymerization method for 
the 75/25 IPN, a more porous network and reduced ability of hydrogen bonding between 
the methacrylic acid and ethylene glycol tethers allows ethylene glycol tethers to be 
mobile and diffuse into the mucin surface. P(MAA-g-EG)-5.0NP hydrophobic content 
brought unfavorable interactions with the dominantly  hydrophilic mucin surface and thus 
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adhered less than the P(MAA-g-EG) hydrogel. Based on these studies, both IPNs and 
P(MAA-g-EG) containing nanoparticles can serve as a good system for oral drug 
delivery, but P(MAA-g-EG) containing nanoparticles may prove more advantageous for 
targeting the colon.  
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Figures 
 
 
Figure 7.1 Mucoadhesive testing platform.  Fresh porcine tissue was stretched across 
the submersible mucoadhesive rig and thermostated to 37°C in 1× PBS adjusted to pH 
7.0. Samples of interest were attached to the cylindrical probe, brought into contact with 
the tissue, and slowly removed to determine force to de-adhere sample/porcine tissue 
interface.  
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Figure 7.2. Mucoadhesive testing apparatus and accessories. (a) Mucoadhesive 
submersible testing rig, (b) cylindrical probe and 75/25 IPN sample, and (c) 75/25 IPN 
sample super glued to cylindrical probe.  
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Figure 7.3. Mucoadhesion testing procedure. (A) Probe lowered to tissue at 10 
mm/min until 50 g force applied, (B) 50 g static force applied and held for 5 min, (C) 
Probe retracted at 10 mm/min until polymer sample and tissue detach.     
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Figure 7.4. Effect of 2 hr P(MAA-g-EG) and IPN exposure on Caco-2 cell 
proliferation. Caco-2 cells were seeded at 2.0 × 104 cells/cm2 and cultured in a 96-well 
plate for 48 hr. P(MAA-g-EG), 80/20 IPN, 75/25 IPN, and 70/30 IPN dry microparticles, 
sized between 75 – 500 µm, were added to Caco-2 cells with 1× PBS and incubated for 2 
hr. Concentrations tested were 1 mg/mL, 2.5 mg/mL, and 5 mg/mL. Error bars represent 
error propagated over control cells. n = 6 – 8. 
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Figure 7.5. Effect of 2 hr P(MAA-g-EG) and P(MAA-g-EG) containing 
nanoparticles exposure on Caco-2 cell proliferation. Caco-2 cells were seeded at 2.0 × 
104 cells/cm2 and cultured in a 96-well plate for 48 hr. P(MAA-g-EG), P(MAA-g-EG)-
1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5.0NP microparticles, sized between 
75 – 150 µm, were swollen in 1× PBS 24 hr before being added to Caco-2 cells for 2 hr. 
Concentrations tested were 1 mg/mL, 2.5 mg/mL, and 5 mg/mL. Error bars represent 
error propagated over control cells. n = 6 – 8. 
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Figure 7.6. Effect of 2 hr P(MAA-g-EG) and IPN exposure on HT29-MTX cell 
proliferation. HT29-MTX cells were seeded at 3.0 × 104 cells/cm2 and cultured in a 96-
well plate for 48 hr. P(MAA-g-EG), 80/20 IPN, 75/25 IPN, and 70/30 IPN dry 
microparticles, sized between 75 – 500 µm, were added to HT29-MTX cells with 1× PBS 
and incubated for 2 hr. Concentrations tested were 1 mg/mL, 2.5 mg/mL, and 5 mg/mL. 
Error bars represent error propagated over control cells. n = 6 – 8. 
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Figure 7.7. Effect of 2 hr P(MAA-g-EG) and P(MAA-g-EG) containing 
nanoparticles exposure on HT29-MTX cell proliferation. HT29-MTX cells were 
seeded at 3.0 × 104 cells/cm2 and cultured in a 96-well plate for 48 hr. P(MAA-g-EG), 
P(MAA-g-EG)-1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5.0NP microparticles, 
sized between 75 – 150 µm, were swollen in 1× PBS 24 hr before being added to HT29-
MTX cells for 2 hr. Concentrations tested were 1 mg/mL, 2.5 mg/mL, and 5 mg/mL. 
Error bars represent error propagated over control cells. n = 6 – 8. 
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Figure 7.8. Effect of 2 hr P(MAA-g-EG) and IPN exposure on SW620 cell 
proliferation. SW620 cells were seeded at 1.5 × 104 cells/cm2 and cultured in a 96-well 
plate for 48 hr. P(MAA-g-EG), 80/20 IPN, 75/25 IPN, and 70/30 IPN dry microparticles, 
sized between 75 – 500 µm, were added to SW620 cells with 1× PBS and incubated for 2 
hr. Concentrations tested were 1 mg/mL, 2.5 mg/mL, and 5 mg/mL. Error bars represent 
error propagated over control cells. n = 6 – 8. 
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Figure 7.9. Effect of 2 hr P(MAA-g-EG) and P(MAA-g-EG) containing 
nanoparticles exposure on SW620 cell proliferation. SW620 cells were seeded at 1.5 × 
104 cells/cm2 and cultured in a 96-well plate for 48 hr. P(MAA-g-EG), P(MAA-g-EG)-
1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5.0NP microparticles, sized between 
75 – 150 µm, were swollen in 1× PBS 24 hr before being added to SW620 cells for 2 hr. 
Concentrations tested were 1 mg/mL, 2.5 mg/mL, and 5 mg/mL. Error bars represent 
error propagated over control cells. n = 6 – 8. 
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Figure 7.10. Effect of the long term exposure of 5 mg/mL of P(MAA-g-EG), 75/25 
IPN, and P(MAA-g-EG) containing nanoparticles on Caco-2 cell proliferation. Caco-
2 cells were seeded at 2.0 × 104 cells/cm2 and cultured in a 96-well plate for 48 hr. 75/25 
IPN dry microparticles (75 – 500 µm) were added to Caco-2 cells with fresh media for 
24, 12, and 6 hr. P(MAA-g-EG) and P(MAA-g-EG)-5.0NP microparticles, sized between 
75 – 150 µm, were swollen in fresh media 24 hr before being added to Caco-2 cells for 
24, 12, and 6 hr. Concentration of all formulas was 5 mg/mL. Error bars represent error 
propagated over control cells. n = 6 – 8. 
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Figure 7.11. Effect of the long term exposure of 5 mg/mL of P(MAA-g-EG), 75/25 
IPN, and P(MAA-g-EG) containing nanoparticles on HT29-MTX cell proliferation. 
HT29-MTX cells were seeded at 3.0 × 104 cells/cm2 and cultured in a 96-well plate for 
48 hr. 75/25 IPN dry microparticles (75 – 500 µm) were added to HT29-MTX cell with 
fresh media for 24, 12, and 6 hr. P(MAA-g-EG) and P(MAA-g-EG)-5.0NP 
microparticles, sized between 75 – 150 µm, were swollen in fresh media 24 hr before 
being added to HT29-MTX cells for 24, 12, and 6 hr. Concentration of all formulas was 5 
mg/mL. Error bars represent error propagated over control cells. n = 6 – 8. 
  
219 
 
 
Figure 7.12. Effect of the long term exposure of 5 mg/mL of P(MAA-g-EG), 75/25 
IPN, and P(MAA-g-EG) containing nanoparticles on SW620 cell proliferation. 
SW620 cells were seeded at 1.5 × 104 cells/cm2 and cultured in a 96-well plate for 48 hr. 
75/25 IPN dry microparticles (75 – 500 µm) were added to SW620 cell with fresh media 
for 24, 12, and 6 hr. P(MAA-g-EG) and P(MAA-g-EG)-5.0NP microparticles, sized 
between 75 – 150 µm, were swollen in fresh media 24 hr before being added to SW620 
cells for 24, 12, and 6 hr. Concentration of all formulas was 5 mg/mL. Error bars 
represent error propagated over control cells. n = 6 – 8. 
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Figure 7.13. Cell viability of Caco-2, HT29-MTX, and SW620 against varying 
concentrations of doxorubicin. Caco-2, HT29-MTX, and SW620 cells were seeded at 
2.0 × 104 cells/cm2, 3.0 × 104 cells/cm2, and 1.5 × 104 cells/cm2, respectively, and 
cultured in a 96-well plate for 48 hr. Doxorubicin in concentrations ranging from 100 to 
0.01 µM was placed on the cell lines for 4 hr and then rinsed three times with 1× PBS. 
Fresh growth media was finally placed on the cells and allowed to grow for 96 hr. Error 
bars represent error propagated over control cells. n = 6 – 8 ± SD. 
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Figure 7.14. Mucoadhesion for P(MAA-g-EG), 75/25 IPN, and P(MAA-g-EG)-5.0NP 
using fresh porcine small intestine. Fresh porcine small intestine was obtained from a 
local slaughterhouse. The small intestine was rinsed and stretched across a mucoadhesive 
rig. P(MAA-g-EG), 75/25 IPN, or P(MAA-g-EG)-5.0NP discs were mounted to 
aluminum stubs and attached to a tensile tester. The sample disc was brought into contact 
with the tissue until a force of 50 g was reached. This force was maintained for 5 min and 
then the sample slowly removed from the tissue and the resistance to removal 
corresponded to mucoadhesion. n = 3 – 4 ± SD. 
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Chapter 8 
Synthesis, Characterization, Loading, and Release of an Inulin-Doxorubicin 
Conjugate 
 
8.1  Introduction 
 For the treatment of colon cancer it is important to deliver the chemotherapeutic 
agent to the correct target and in quantities sufficient enough to destroy the tumor. 
Currently, this thesis has explored the loading and release of doxorubicin using polymer 
systems composed of P(MAA-g-EG), IPN, or P(MAA-g-EG) containing nanoparticles. 
Doxorubicin in its free and active form would be released in the small intestine and have 
the possibility of causing harm to healthy cells as it travels to the colon. Therefore, it is 
important to modify the doxorubicin to reduce its activity or inactivate its toxic ability 
until it reaches the colon. Then utilizing colon specific environmental factors, such as 
change in pH or the drastic increase in microflora content, the doxorubicin may then 
return to its active and toxic form.   
The pH change from the small intestine to the colon is small and gradual and 
investigating methods to reduce activity or inactivate doxorubicin using pH change 
would be difficult. However, the microflora content in the colon is magnitudes higher 
(1011 – 1013 CFU/mL) than the small intestine (103 – 104 CFU/mL) and is the mechanism 
which will be explored in this thesis for targeting doxorubicin to the colon.1 These 
microflora primarily decompose starches, especially polysaccharide chains that were 
unable to be digested by the small intestine. Microflora includes Bacteroids, 
Bifidobacteria, Eubacteria, Enterobacteria and Enterococci.2 Therefore, doxorubicin can 
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be modified to include carbohydrate chains which are sustainable until they reach the 
colon.  
For this thesis, we developed a chemotherapeutic conjugate composed of inulin, a 
polysaccharide chain, chemically attached to the chemotherapeutic doxorubicin. Inulin 
naturally occurs in many plants such as onion, garlic, and chicory and consists of a 
mixture of oligomers and polymers containing 2 to 60 β, 2-1 linked D-fructose molecules 
(Figure 8.1).3 Inulin was specifically selected for this application because native chicory 
inulin typically has an average degree of polymerization of 12,4  making it much smaller 
than other polysaccharides. Furthermore, inulin shows a prebiotic effect on colonic 
microflora, is FDA approved, non-toxic, and primarily hydrolyzed in the colon by 
Bifidobacteria.5-9 Doxorubicin possesses a primary amine for chemical attachment to 
inulin. Through a two – step synthesis technique we can develop a chemotherapeutic 
conjugate which can be loaded into the polymer drug carrier, release in the upper small 
intestine, and travel to the colon where microflora can digest the inulin chain, and allow 
doxorubicin to become more active in the colon.  
Inulin has been previously used for drug delivery applications, but current 
literature revealed no inulin-doxorubicin conjugate as proposed in this thesis. Inulin has 
been conjugated to CoB12 vitamin, noradrenaline, and cysteine and has shown the 
conjugate can increase drug stability to light, temperature, hydrolysis, and chemical 
agents.10 However, these same inulin conjugates demonstrate very short serum half-life 
with rapid and complete urinary elimination.  The use of inulin as a conjugate must be 
justified by direct targeting to the colon to outweigh its insufficiency to avoid quick 
elimination by the urinary system. Besides conjugates, inulin has been extensively 
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utilized as a matrix component for drug delivery due to its biodegradability in the 
presence of specific enzymes of the colon.11,12 Inulin has be incorporated into Eudragit 
RS films to resist degradation in the upper small intestine, but be digested in human fecal 
medium.13 Inulin has also been chemically modified to include methacrylate groups for 
developing crosslinked hydrogels by free radical polymerization which were varied by 
feed rates of inulin and crosslinker.14,15 The final inulin hydrogel compositions were 
subject to enzymatic digestibility utilizing inulinase derived from Aspergillus niger. 
Length of inulinase exposure, inulinase concentration, and crosslink density of the inulin 
hydrogel influenced the rate of degradation of the drug delivery system.16  
Inulin conjugated to doxorubicin were formed by a two – step process: (1) 
carboxymethylation of an inulin chain and (2) attachment of doxorubicin through its 
primary amine using N-Hydroxysulfosuccinimide (sulfo-NHS) and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) chemistry. The resulting inulin-doxorubicin 
conjugate was characterized using acidimetric titrations, colorimetric assays and a 
doxorubicin concentration curve. The inulin-doxorubicin conjugate was loaded and 
released using the P(MAA-g-EG)-5.0NP as developed in Chapter 5.  
8.2 Materials and Methods 
 Materials. Inulin from dahlia tubers, solid sodium hydroxide 20 – 40 mesh beads 
(NaOH), chloroacetic acid 99+% A.C.S. grade, phenolphthalein, and phenol were 
purchased from Sigma – Aldrich (St. Louis, MO). Glacial acetic acid, anhydrous 
methanol, nitric acid, acetone, 1N hydrochloric acid, 10× PBS, sulfuric acid, and ethanol 
were purchased from Fisher Scientific (Fair Lawn, NJ). N-Hydroxysulfosuccinimide 
(sulfo-NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) were from 
225	  
	  
Thermo Scientific (Rockford, IL). Doxorubicin was purchased from Selleck Chemicals 
(Houston, TX). The P(MAA-g-EG)-5.0NP polymer carrier was synthesized as described 
in Chapter 5. Double distilled water was used in all studies.  
 Synthesis of an Inulin-Doxorubicin Conjugate. Carboxymethylation of Inulin. 
The first step to conjugate doxorubicin to inulin was to carboxymethylate the inulin 
(CMI) (Figure 8.2).17 First the inulin molecular weight was determined by gel permeation 
chromatography (Waters, Milford, MA) and used to calculate the proper number of 
monomeric units for the carboxymethylation reaction. Next, 3.4 g of inulin (~20 mmol of 
monomeric units) was dissolved in 25 mL of distilled water and then cooled down in an 
ice bath. To the cooled inulin solution, was added 6.4 g of solid NaOH (160 mmol) and 
stirred until the NaOH was completely dissolved. To the basic inulin solution was added 
7.5 g of solid monochloro acetic acid and stirred until it was fully dissolved. This total 
reaction mixture was placed in a 60 °C water bath, stirred at 130 rpm, and reacted for 120 
min. The reaction was cooled and glacial acetic acid was added dropwise until 
neutralized as determined by pH paper. The neutralized solution was precipitated in 400 
mL of well-stirred methanol, filtered, washed twice with absolute methanol, and dried in 
a vacuum oven (25 mmHg) at 60°C for 24 hr. The resulting product was dialyzed in 
water using 500 – 1000 molecular weight cut off dialysis bags (Spectra/Por®, Rancho 
Dominguez, CA) for 24 hr with the water changed twice in the 24 hr period. The final 
solution was freeze dried (Labconco Freezone 4.0, Kansas City, MO).    
CMI is obtained in the form of a sodium salt (i.e. carboxylate) and must be 
converted completely into its free acid form to determine the degree of substitution (DS). 
To convert the –COOH groups to their free form it is necessary to wash it with an acid 
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reagent. The first step followed this procedure: 1 g of precipitated CMI was added to 14 
mL of the acid reagent which was composed of anhydrous methanol and 70% (v/v) nitric 
acid (10:1) in an Erlenmeyer flask. This solution was covered and shaken for 3 – 4 hr at 
room temperature. The precipitated product was filtered by vacuum and washed several 
times with methanol until the filtrate reached neutrality as determined by pH paper. The 
wet, free acid form of CMI was dried in a vacuum oven (25 mmHg) at 60 °C for 24 hr.  
The second step used acidimetric titration to determine the final degree of 
substitution of the CMI. A 1% (w/v) of CMI in water was formed by dissolving 0.2 g of 
the free acid form of CMI in 20 mL of water. To this solution was added 10 µL of 2% 
(w/v) phenolpthalein in ethanol and 5 mL of 0.1 N NaOH. Using a burette, the exact 
amount of 0.1 N HCl was measured that turned the pink solution, due to phenolphthalein, 
to clear. The degree of substitution was determined by using equation 8.1 and 8.2. 
Equation 8.1 was used to determine the millequivalents of –COOH groups per gram of 
CMI and defined as “A”: 
 ! = !"  !"  !"#$  ×  !!"#$ ![!"  !"  !"#  ×  !!"#]!"#$%  !"  !"#                                                                     (8.1) 
 
Using “A” as defined above, the DS, defined as the average number of sodium 
carboxymethyl groups per anhydrofructose units, could be determined by equation 8.2. 
 !" = !.!"#  ×  !!![!.!"  ×  !]                                                                                                             (8.2) 
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where 0.162 is derived from the molecular weight of the anhydrofructose unit of inulin 
and 0.08 from the net increase in the weight of the fructose unit for each carboxymethyl 
group substituted.17  
Carboxymethylated inulin conjugated to doxorubicin using sulfo-NHS and EDC 
chemistry. Sulfo-NHS and EDC is used to prepare amine-reactive esters of the 
carboxylate groups located on the CMI to react with the primary amine of the 
doxorubicin (Figure 8.3). First, 10 mg of CMI were dissolved in 500 µL of distilled 
water. Then 1:12 and 1:10 molar equivalence of CMI to sulfo-NHS and CMI to EDC, 
respectively, were added to the CMI dissolved in water. After 1 hr of mixing, 
doxorubicin was added to the solution at a 1:1 molar equivalence. After an additional 2 hr 
of mixing, the inulin-doxorubicin conjugate was dialyzed in a 2,000 molecular weight cut 
off cassettes (Thermo Scientific) for 2 days to remove unreacted doxorubicin, CMI, 
sulfo-NHS, and EDC. The final purified solution was placed on the freeze dryer for three 
days.  
Characterization of an Inulin-Doxorubicin Conjugate.  Doxorubicin present in 
the inulin-doxorubicin conjugate. The degree of substitution of the CMI limits the 
amount of doxorubicin which can react and chemically bond to the inulin backbone. To 
determine the amount of doxorubicin present in the inulin-doxorubicin conjugates a 
doxorubicin calibration curve was formed and compared to an inulin-doxorubicin sample. 
Pure doxorubicin was dissolved in water to a final concentration of 62.5 µg/mL and 
serially diluted to 0.0015 µg/mL. Inulin-doxorubicin conjugates were dissolved in water 
at the following concentrations: 250 µg/mL, 170 µg/mL, and 40 µg/mL. The average of 
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these three determined the amount of doxorubicin present in the inulin-doxorubicin 
conjugate.  
Colorimetric assay.  A colorimetric assay for reducing sugars contained in inulin 
was completed to determine the presence of inulin in the conjugate. Inulin-doxorubicin 
conjugate samples were dissolved in 250 µL of water to form 0.5 mg/mL, 0.25 mg/mL, 
and 0.1 mg/mL concentrations for testing. CMI (unconjugated) was dissolved in 250 µL 
of distilled water to form a calibration curve ranging from 5 mg/mL to 5 µg/mL. To all 
samples and standards were added 150 µL sulfuric acid and 30 µL of 5% (v/v) phenol in 
water. The solutions were incubated at 90 °C and shaken at 600 rpm for 30 min to form a 
yellow solution and black precipitate. The black precipitate was centrifuged down for 
samples containing no doxorubicin and doxorubicin containing samples were filtered 
using a 0.22 µm syringe filter (Millipore, Billerica, MA). All samples were imaged at 490 
nm using the UV/VIS spectrometer (Biotek Synergy-HT, Winooski, VT). A pure 
doxorubicin sample was also completed at a concentration level equal to the amount of 
doxorubicin present in the inulin-conjugate sample as determined above. In addition to 
the doxorubicin sample, EDC and sulfo-NHS were run and all were used to subtract out 
background from UV/VIS reading. 
Loading Studies. Inulin-doxorubicin conjugate loading of P(MAA-g-EG)-5.0NP. 
The inulin-doxorubicin conjugate was loaded by equilibrium partitioning in the following 
manner: a stock solution of inulin-doxorubicin conjugate was prepared in 1× PBS (pH 
7.4) at a concentration of 0.25 mg/mL. First, the inulin-doxorubicin conjugate was 
weighed and placed into the bottom of a glass beaker equipped with a Teflon stir bar. The 
inulin-doxorubicin conjugate was first dissolved in water and then 10× PBS resulting in a 
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final 1× PBS solution. A 5 mg/mL concentration of P(MAA-g-EG)-5.0NP (75 – 150 µm) 
to inulin-doxorubicin conjugate stock solution was allowed to stir slowly for 2 hr. The 
inulin-doxorubicin conjugate loaded particles were filtered and rinsed with water to 
remove any surface absorbed doxorubicin. The UV/VIS spectrometer operating at a 485 
nm excitation and 590 nm emission wavelengths, determined the concentration levels and 
calculated the loading efficiency as follows: 
 
!"#$%&'  !""#$#%&$' = !!!!!!! ∗ 100                                                                         (8.3) 
 
where Co is the initial inulin-doxorubicin conjugate concentration and Cf is the final 
inulin-doxorubicin conjugate concentration remaining in the solution. Concentration 
levels were determined by a calibration curve of serial dilutions of the inulin-doxorubicin 
conjugate ranging from 0.0038 µg/mL to 125 µg/mL. 
Release Studies. Inulin-doxorubicin conjugate release from P(MAA-g-EG)-
5.0NP. Release experiments were performed on a rotary mixer (Glas-Col, Terre Haute, 
IN) adapted with a cardboard rotary wheel which could firmly hold 5 mL vials and 
operated at 15 rpm. The mixer was then placed inside a dry oven (Fisher Scientific 
Isotemp Incubator Model 525D, Pittsburgh, PA) thermostated to 37 °C. For all inulin-
doxorubicin conjugate release experiments, a 1.5 mg sample of inulin-doxorubicin 
conjugate loaded P(MAA-g-EG)-5.0NP was added to a 5 mL vial containing 3 mL of 1× 
PBS (pH 2.0 or 7.4). For inulin-doxorubicin conjugate release in neutral pH, 1× PBS (pH 
7.4) was used and over the duration of 6 hr, samples were taken and replaced to maintain 
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sink conditions. Inulin-doxorubicin conjugate release in low pH was conducted in the 
same manner as neutral pH except 1× PBS was adjusted to a pH of 2.0 using 1N HCl. 
To mimic the physiological conditions and residence time in the stomach and 
small intestine, inulin-doxorubicin conjugate was released using a two – step pH change 
from low pH (2.0) to high pH (7.0).18 Inulin-doxorubicin conjugate loaded microparticles 
were first placed in 1× PBS at pH 2.0. After 90 min, 5N NaOH was added to increase the 
pH to 7.0 where release continued for 6 hr. Samples were obtained as above. The mass of 
inulin-doxorubicin conjugate released was determined by the fluorescent plate reader and 
reported as follows: 
 
!"##  !"#"$%"& = !!/!∞ ∗ 100                                                                              (8.4) 
 
where Mt is mass released at a given time and M∞ is total mass released.  
8.3  Results and Discussion 
An inulin-doxorubicin conjugate was formed by first placing carboxylic acids on 
the inulin backbone followed by linkage of the doxorubicin through its primary amine 
using sulfo-NHS and EDC chemistry. This procedure was a straight forward, easy 
conjugation reaction and reproducible. The inulin-doxorubicin conjugate was red due to 
the presence of doxorubicin and powder like after freeze drying. 
Synthesis of an Inulin-Doxorubicin Conjugate. Carboxymethylation of Inulin. 
The first step to the inulin-doxorubicin conjugate was to carboxymethylate the inulin.  
Inulin number average molecular weight was determined to be 1925 g/mol with a degree 
of polymerization (DP) of 11. With a DP of 11, inulin still possessed enough monomeric 
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repeat units to conjugate to doxorubicin and still remain small enough to be loaded into 
P(MAA-g-EG)-5.0NP polymer carriers. Inulin, NaOH, and monochloroacetic acid were 
dissolved in water and reacted at 60 °C for 120 min. After the reaction of inulin with 
monochloroacetic acid and sodium hydroxide, a white precipitate of carboxymethylate 
inulin (CMI) was formed when crashed out in methanol. The CMI was titrated against 0.1 
N HCl and the degree of substitution, defined as the average number of sodium 
carboxymethyl groups per anhydrofructose unit, was determined to be 0.9. 
Carboxymethylated inulin conjugated to doxorubicin using sulfo-NHS and EDC 
chemistry.  CMI, sulfo-NHS, and EDC were dissolved in water and allowed to react 1 hr 
to form  semi-stable amine-reactive NHS-esters. Doxorubicin dissolved in water was 
added to the amine reactive esters and mixed for an additional 2 hr to form an inulin-
doxorubicin conjugate. The resulting conjugate was dialyzed for two days to remove 
unreacted components and freeze dried.  
Characterization of an Inulin-Doxorubicin Conjugate. Doxorubicin present in 
the inulin-doxorubicin conjugate. The amount of doxorubicin present in the inulin-
doxorubicin conjugate was determined by dissolving the inulin-doxorubicin conjugate in 
water at a concentration of 250 µg/mL, 170 µg/mL, and 40 µg/mL. The fluorescent 
values of these samples were compared against a calibration curve of free doxorubicin 
standards. The amount of doxorubicin present was determined to be 0.462 ± 3.3 µg per 
mg of inulin-doxorubicin conjugate.  
Colorimetric assay. The amount of inulin present in the inulin-doxorubicin 
conjugate was determined by a colorimetric assay for reducing sugars. Inulin-doxorubicin 
conjugates dissolved in water at concentrations of 0.5 mg/mL, 0.25 mg/mL, and 0.1 
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mg/mL, had the sugars reduced using sulfuric acid and a 5% (v/v) phenol in water. The 
amount of sugar was determined relative to standard curves of CMI (unconjugated) 
which also underwent the sugar reducing protocol. Doxorubicin’s structure contains an 
amine sugar; thus, a doxorubicin sample at the same concentration that doxorubicin 
would be present in each inulin-doxorubicin conjugate sample was carried through. The 
amount of inulin present was determined to be 0.926 mg per mg of inulin-doxorubicin 
conjugate. These values indicated that inulin makes up the majority of the molecular 
weight of the inulin-doxorubicin conjugate and is supported by the evidence indicating a 
small amount of doxorubicin present in the inulin-doxorubicin conjugate. 
Loading studies. Inulin-doxorubicin conjugate loading of P(MAA-g-EG)-5.0NP. 
The inulin-doxorubicin conjugate was loaded into P(MAA-g-EG)-5.0NP microparticles 
by equilibrium partitioning. A stock solution of inulin-conjugate dissolved in 1× PBS and 
P(MAA-g-EG)-5.0NP was added to the solution and stirred for 2 hr. The resulting inulin-
doxorubicin P(MAA-g-EG)-5.0NP loaded microparticles were filtered, rinsed, and dried 
for release studies. The loading efficiency of the inulin-doxorubicin conjugate into 
P(MAA-g-EG)-5.0NP microparticles was 54 ± 2.0% and the weight percent,  defined as 
the mg of inulin-doxorubicin conjugate per mg of P(MAA-g-EG)-5.0NP polymer, was 
2.6%. These values are reduced as compared to the loading efficiency of free doxorubicin 
in P(MAA-g-EG)-5.0NP which was 64 ± 1% and the weight percentage of 3.1%. The 
reduced loading efficiency is due to the physical increase in size due to the presence of 
inulin. The increased size prevents the inulin-doxorubicin conjugate to migrate and 
penetrate the smaller porous network of the swollen P(MAA-g-EG)-5.0NP polymer that 
free doxorubicin can get to.  
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Release Studies. Inulin-doxorubicin conjugate release studies were completed on 
a rotary mixer placed inside a 37 °C incubation oven for small sample analysis. Inulin-
doxorubicin conjugate loaded P(MAA-g-EG)-5.0NP particles slowly swelled and 
released their contents as indicated by the red tint of the solution. Release studies were 
completed at constant, low, and two – step pH change conditions. 
Inulin-doxorubicin conjugate release from P(MAA-g-EG)-5.0NP. In neutral pH, 
maximum release occurred after 2 hr with over 90% of inulin-doxorubicin conjugate 
released from P(MAA-g-EG)-5.0NP (Figure 8.4). This fast release is due to the pH 
release media being greater than the pKa value of MAA, which allows the polymer 
carrier to swell and form pores to elute out the encapsulated inulin-doxorubicin 
conjugate.  
The two – step pH experiment modeled the gastrointestinal pH conditions. First, 
inulin-doxorubicin conjugate loaded P(MAA-g-EG)-5.0NP microparticles were released 
in pH 2.0 (1× PBS) for 90 min and then increased to pH 7.0 (1× PBS) for an additional 6 
hr. P(MAA-g-EG)-5.0NP released approximately 23% of the inulin-doxorubicin 
conjugate in the low pH conditions (Figure 8.5). After the pH was increased from 2.0 to 
7.0, the remaining amount of the inulin-doxorubicin conjugate loaded in the P(MAA-g-
EG)-5.0NP polymer carrier was slowly released over 6 hr (Figure 8.5) with 98% released 
after 2 hr.  
Release studies were extended to 2 hr in low pH conditions to model longer 
residency times in the stomach. P(MAA-g-EG)-5.0NP released 27% of the inulin-
doxorubicin conjugate after 2 hr in the low pH conditions (Figure 8.6). This is a small 
increase as compared to the 23% released at 1.5 hr in the low pH conditions of the two – 
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step pH study. These values are still low and indicate that a majority of the encapsulated 
conjugate will be delivered to the upper small intestine.  
8.4  Conclusions 
 An inulin-doxorubicin conjugate was formed using a two – step synthesis: 1) 
carboxymethylation of inulin and 2) carboxymethylated inulin conjugated to doxorubicin 
using sulfo-NHS and EDC chemistry. Inulin conjugates are not a new concept to the 
research community, but an inulin-doxorobucin conjugate appears to be a first of its kind.  
 The inulin-doxorubicin conjugate is predominantly composed of the sugars from 
the inulin and a small amount of doxorubicin (0.462 µg) is present per mg of inulin-
doxorubicin conjugate. Since inulin with a DP of 11 was utilized for the conjugate, its 
small nature allowed it to be loaded into the P(MAA-g-EG)-5.0NP polymer carrier. A 
loading efficiency of 54% and a weight percent, defined as the mg of inulin-doxorubicin 
conjugate per mg of P(MAA-g-EG)-5.0NP polymer, was 2.6%. Release studies 
demonstrated that at low pH conditions, P(MAA-g-EG)-5.0NP minimized inulin-
doxorubicin conjugate release and then released its remaining payload upon change of pH 
from acidic to neutral conditions. Concentration levels of the inulin-doxorubicin 
conjugate were 10 – 13 µg/mL.    
  Overall, it appears that the size of the inulin-doxorubicin conjugate plays a 
leading role in its loading and release profiles as compared to free doxorubicin. For 
loading, the smaller doxorubicin molecule can more easily penetrate smaller pores of the 
swollen P(MAA-g-EG)-5.0NP polymer carrier resulting in high loading levels (64%). 
However, due to its small nature, free doxorubicin release in low pH conditions in both 
the two – step pH experiment (27%) and 2 hr low pH experiment (33%) was higher than 
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the inulin-doxorubicin conjugate (23% and 27%, respectively). The loading and release 
profiles of the inulin-doxorubicin conjugate from the P(MAA-g-EG)-5.0NP prove that 
this polymer drug carrier can be utilized to deliver colon targeted cancer drugs via the 
oral route.  
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Figures 
 
 
      
Figure 8.1. The structure of inulin. Inulin contains 2 to 60 repeat units of β, 2-1 linked 
D-fructose molecules with normally, but not necessarily, one glucopyranose unit at the 
reducing end.19 
H
H
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Figure 8.2. Carboxymethylation of inulin. Inulin, NaOH, and monochloroacetic acid 
were dissolved in water and reacted for 120 min in a 60 °C water bath. The 
carboxymethyl inulin was precipitated out in methanol and dried in a vacuum oven.  
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Figure 8.3. Carboxymethyl inulin conjugated to doxorubicin using sulfo-NHS and 
EDC chemistry. Carboxymethyl inulin (CMI), sulfo-NHS, and EDC were dissolved in 
water and mixed for 1 hr. Then doxorubicin was added and its primary amine reacted 
with the semi-stable amine-reactive NHS-esters of CMI to form the inulin-doxorubicin 
conjugate.  
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Figure 8.4. Inulin-doxorubicin conjugate release of P(MAA-g-EG)-5.0NP in neutral 
pH conditions. Inulin-doxorubicin conjugate loaded P(MAA-g-EG)-5.0NP crushed 
particles (75 – 150 µm) were released in 1× PBS (pH 7.4) for 6 hr. Doxorubicin release is 
expressed as Mt/M∞. Curves generated are n = 3 and error bars represent error 
propagation due to ratio of Mt/M∞.  
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Figure 8.5. Inulin-doxorubicin conjugate release of P(MAA-g-EG)-5.0NP in two – 
step pH conditions. Inulin-doxorubicin conjugate loaded P(MAA-g-EG)-5.0NP crushed 
particles (75 – 150 µm) were released in 1× PBS (pH 2.0) for 90 min. Then the pH was 
increased to 7.0 by adding 5 N NaOH and release continued for 6 hr. Inulin-doxorubicin 
conjugate release is expressed as Mt/M∞. Curves generated are n = 3 and error bars 
represent error propagation due to ratio of Mt/M∞. 
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Figure 8.6. Inulin-doxorubicin conjugate release of P(MAA-g-EG)-5.0NP in low pH 
conditions. Inulin-doxorubicin conjugate loaded P(MAA-g-EG)-5.0NP crushed particles 
(75 – 150 µm)  were released in 1× PBS (pH 2.0) for 2 hr to evaluate longer gastric 
transit times.  Inulin-doxorubicin conjugate release is expressed as Mt/M∞. Curves 
generated are n = 3 and error bars represent error propagation due to ratio of Mt/M∞. 
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Chapter 9 
Cytotoxicity, DNA Binding, and Imaging of an Inulin-Doxorubicin Conjugate 
 
9.1  Introduction 
The inulin-doxorubicin conjugate was loaded into the P(MAA-g-EG)-5.0NP 
polymer. The ensuing formulation exhibited release in model conditions of the upper 
small intestine. Since this polymer carrier may release the loaded contents in the upper 
small intestine, the inulin-doxorubicin has been developed for two primary purposes: i) 
so that the toxicity of doxorubicin is reduced or inactive until it reaches the colonic 
environment; and ii) the overall size of the molecule is increased so it resides in the GI 
tract for local, direct delivery to the colon and prevents early transport across the small 
intestine into the bloodstream. Once it reaches the colon, the presence of Bifidobacteria 
can reduce the inulin carbohydrate chains and release doxorubicin to begin its toxic 
effects on colon cancer. 
As tumors form, they require a necessary supply of nutrients and oxygen to 
survive and avoid a necrotic core. Thus, tumors have become proficient at angiogenesis, 
but at the sacrifice of developing a leaky vasculature.1,2 This leaky vasculature has 
allowed tumors to exhibit the enhanced permeation and retention (EPR) effect which 
allows small molecules such as doxorubicin and other therapeutic compounds to 
penetrate the tumor and reside there for a period of time.3-5 The inulin-doxorubicin once 
exposed to reducing enzymes can release the doxorubicin and allow the EPR effect to 
increase localization and concentration of doxorubicin in the colon tumor.   
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Doxorubicin is an FDA approved chemotherapeutic, but modification with inulin 
would require new extensive testing for FDA approval as a colon targeting 
chemotherapeutic. Thus, initial and thorough in vitro investigations of the conjugate need 
to be completed to determine if the concept of utilizing colonic enzymes to reduce the 
conjugate is possible and if the resulting released doxorubicin is still capable of inducing 
toxicity to colon cancer. 
 Free doxorubicin and the inulin-doxorubicin conjugate with or without inulinase 
(model enzyme for colonic environment) were utilized for calf thymus DNA (ctDNA) 
binding experiments and cytotoxicity experiments. ctDNA experiments investigate a 
compounds ability to bind with DNA, which is necessary for doxorubicin to be an 
effective cytotoxic agent. Cytotoxicity studies were completed on SW620, a colon tumor 
model, and then extended to the Caco-2 and HT29-MTX cell lines. 
9.2  Materials and Methods  
Materials. Dulbecco’s Modified Eagle’s Medium (DMEM), Roswell Park 
Memorial Institute Medium (RPMI), fibronectin, inulinase from Aspergillus niger, and 
calf thymus DNA (ctDNA) were purchased from Sigma – Aldrich (St. Louis, MO). Fetal 
bovine serum (FBS) and trypsin with EDTA were obtained from Hyclone (South 
Plainfield, NJ). 1× Phosphate Buffered Saline (PBS) without calcium or magnesium 
along with penicillin and streptomycin were from MediaTech (Manassas, VA). The cell 
proliferation MTS assay was purchased from Promega (Madison, WI). Paraformaldehyde 
and ProLong® Gold Antifade Reagent with DAPI was purchased from Fisher Scientific 
(Fair Lawn, NJ). Doxorubicin was purchased from Selleck Chemicals (Houston, TX). 
Caco-2, SW620 cells, and Leibovitz’s media (L-15) were obtained from American Type 
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Culture Collection (ATCC, Rockwell, MD) and HT29-MTX cells were a gift from Dr. 
Thecla Lesuffleur, INSERM, Paris, France. 
Cytotoxicity. The inulin-doxorubicin conjugate was intended to provide targeted 
drug delivery to the colon, undergo enzymatic degradation of inulin, and release free 
doxorubicin to destroy colon cancer. To assess this hypothesis, free doxorubicin and an 
inulin-doxorubicin conjugate with or without inulinase were tested for toxicity against 
SW620 cells. The cytotoxicity of the inulin-doxorubicin conjugate versus free 
doxorubicin was extended to the Caco-2 and HT29-MTX cell lines, which model the 
gastrointestinal tract. General cell culture, cell seeding, and 96 – well plating of Caco-2, 
HT29-MTX, and SW620 cells lines were followed as discussed in Chapter 7. 
After 96 – well plates of SW620 cells were seeded and grown for 48 hr, the cell 
media was removed, rinsed once with 1× PBS, and then exposed to concentrations of 
inulin-doxorubicin conjugate dissolved in RPMI ranging from 54.3 to 0.01 µg/mL for 4 
hr. The inulin-doxorubicin conjugate was removed from the cells, rinsed 3 times with 1× 
PBS, and finally incubated in fresh media. After 96 hr, the media was removed and the 
MTS assay completed as discussed in Chapter 7. This procedure was repeated for the 
inulin-doxorubicin conjugate, which was incubated 24 hr with 6.25% (v/v) inulinase in 
RPMI before being placed with SW620 cells. An inulinase control was carried through to 
subtract any potential toxicity that may have risen from its exposure to the SW620 cell 
line. 
The cytotoxicity of the inulin-doxorubicin conjugate versus free doxorubicin was 
completed against Caco-2, HT29-MTX, and SW620 cell lines. In these studies, the 
concentration of doxorubicin present in the inulin-doxorubicin conjugate was compared 
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to the same concentrations of free doxorubicin. The concentrations of doxorubicin in the 
inulin-doxorubicin conjugate and free doxorubicin were 5.43 µg/mL, 2.715 µg/mL, 0.543 
µg/mL, and 0.135 µg/mL. No inulinase was used for these studies.  
ctDNA Binding. The chromophore site of the doxorobucin backbone is 
responsible for the majority of binding and the intercalation of DNA. As doxorubicin 
begins to bond and intercalate with DNA, florescent intensity is decreased. Thus, an 
experiment utilizing free doxorubicin and the inulin-doxorubicin conjugate with or 
without inulinase paired with their fluorescent intensity can be designed to determine 
how well each binds to ctDNA.6,7 Inulinase is used to simulate the enzymatic 
environment found in the colon and liberates doxorubicin from the inulin backbone.  
A 10 µg/mL stock solutions of doxorubicin and inulin-doxorubicin conjugate 
were made using 1× PBS while the inulin-doxorubicin with inulinase was made at the 
same concentration using 6.25 % (v/v) inulinase in 1× PBS. ctDNA standards were 
dissolved in 1× PBS in the following concentrations: 50 µg/mL, 40 µg/mL, 30 µg/mL, 20 
µg/mL, 15 µg/mL, 10 µg/mL, and 5 µg/mL. Stock solutions and standards were allowed 
to mix for 24 hr before testing. The binding of ctDNA to doxorubicin was completed by 
adding 100 µL of free doxorubicin or inulin-doxorubicin with or without inulinase with 
100 µL of one of the ctDNA concentrations to black 0.5 mL centrifuge tubes. After 24 hr 
of reacting, the fluorescent intensity of the samples was determined using the UV/VIS 
spectrometer (Biotek Synergy-HT, Winooski, VT) operating at 485 nm excitation and 
580 nm emission. Fluorescent quenching was computed using equation 9.1: 
 !"#$%&'(&)*  !"#$%ℎ!"# = !/!!                                                                                 (9.1) 
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where F0 is the fluorescent intensity of 100 µL of the doxorubicin, inulin-doxorubicin 
conjugate, or  inulin-conjugate with inulinase diluted with 100 µL of 1× PBS, 1× PBS, 
and 6.25% (v/v) inulinase in 1× PBS, respectively.  
Confocal Imaging. Confocal imaging was completed to illustrate the localization 
of free doxorubicin and the inulin-doxorubicin conjugate into the nucleus of the HT29-
MTX and SW620 cell lines. LabTEK 8 – well chamber slides (Nunc, Rochester, NY) 
were coated with fibronectin at a concentration of 1 µg/cm2 and then seeded with HT29-
MTX or SW620 cells at a seeding density of 3.0 × 104 cell/cm2 and 1.5 × 104 cell/cm2, 
respectively. Cells were incubated for 48 hr at 37 °C and 5% CO2.  
In these studies, the concentration of doxorubicin present in the inulin-
doxorubicin conjugate was compared to the same concentrations of free doxorubicin. 
Free doxorubicin and the inulin-doxorubicin conjugate were dissolved in 1× PBS to 
doxorubicin concentration levels of 1.36 µg/mL, 0.54 µg/mL, and 0.27 µg/mL. The cell 
lines were exposed to these concentration levels for 4 hr, then rinsed with 1× PBS 3 
times, and then fixed with 3.7% (w/v) paraformaldehyde in water for 30 min. The cells 
were rinsed 3 times with 1× PBS to remove the paraformaldehyde solution, air dried, and 
then stained with the Prolong® Gold Antifade Reagent with DAPI overnight. The slides 
were covered with a #1 cover slip and imaged using a confocal microscope (Leica SP2 
AOBS, Wetzlar, Germany).  
9.3 Results and Discussion 
 The inulin-doxorubicin conjugate was tested for its toxicity along with free 
doxorubicin and inulin-doxorubicin conjugates which were incubated with inulinase for 
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24 hr before testing. All cytotoxicity experiments were completed as follows: Caco-2, 
HT29-MTX, or SW620 cell lines were exposed to free doxorubicin and the conjugate 
with or without inulinase for 4 hr, washed with 1× PBS, allowed to growth for 96 hr in 
fresh cell media, and then assayed using the MTS reagent.  
 Cytotoxicity. First, SW620 cells were exposed to the conjugate with and without 
incubation with inulinase for concentrations between 54.3 µg/mL and 0.01 µg/mL 
(Figure 9.1). Surprisingly, the inulin-doxorubicin conjugate not incubated with inulinase 
was more toxic than the inulin-doxorubicin conjugate incubated with inulinase. It was 
expected that the presence of inulin would reduce the cytotoxicity of doxorubicin against 
the GI tract, enter the colon where local enzymes could degrade the inulin chain, liberate 
doxorubicin, and allow doxorubicin to return to its original activity However, the 
combination of inulin conjugated to doxorubicin has resulted in a more toxic substance as 
compared to free doxorubicin (Figure 9.1). Cell proliferation began to decrease at 0.05 
µg/mL and 0.5 µg/mL of conjugate with and without inulinase, respectively. For both 
scenarios, cell proliferation decreased with increasing concentration and at the highest 
concentration (54.3 µg/mL) cell proliferation was reduced to 12% and 17% for the 
conjugate with and without inulinase, respectively.  
Inulin itself was investigated for any toxic effects against the SW620 cells. Inulin 
which had been carboxymethylated, but not conjugated to doxorubicin was tested with 
and without inulinase incubation (Figure 9.2 and 9.3). Inulinase at its highest 
concentration was also tested (not shown). In all cases, these substances were non-toxic 
with cell proliferation ranging between 98 – 100%. Thus, it is hypothesized that the 
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combination of inulin with doxorubicin is providing unique structural and size properties 
to elicit stronger cytotoxic effects.   
Cytotoxicity studies of the inulin-conjugate versus free doxorubicin were 
completed on SW620 cells and extended to Caco-2 and HT29-MTX cell lines since they 
are more resistant to free doxorubicin (Figure 7.13). In these studies the concentration of 
doxorubicin present in the inulin-doxorubicin conjugate was compared to the same 
concentrations of free doxorubicin and ranged from 5.4 µg/mL to 0.135 µg/mL. In all cell 
lines, the inulin-doxorubicin conjugate was more toxic than free doxorubicin (Figure 9.4 
– 9.6). For SW620 cells, as concentration increased the degree of cytotoxicity increased 
for both doxorubicin and the inulin-doxorubicin conjugate. The inulin conjugate induced 
approximately 70% more toxicity than free doxorubicin for concentrations up 2.7 µg/mL 
(Figure 9.4). For Caco-2 cells, toxicity was minimized until a concentration of 0.135 
µg/mL was reached at which point the inulin-doxorubicin conjugate induced 
approximately 60% more toxicity for the remaining higher concentrations (Figure 8.5). 
The HT29-MTX cells experienced minor toxicity for free doxorubicin, but for the inulin-
doxorubicin conjugate experienced 76% increase in toxicity for concentrations higher 
than 0.54 µg/mL (Figure 9.6).  
  ctDNA Binding. Stock solutions of free doxorubicin, inulin-doxorubicin 
conjugate, and inulin-doxorubicin conjugate with inulinase were combined with 
increasing concentrations of ctDNA, mixed overnight, and imaged with the UV/VIS 
spectrometer to measure fluorescent intensity to determine cell – free binding to DNA. 
Fluorescence quenching indicated that free doxorubicin, inulin-doxorubicin conjugate, 
and inulin-doxorubicin incubated with inulinase were bound to DNA. As shown in Figure 
252	  
	  
9.7, various degrees of fluorescent quenching were exhibited with the inulin-doxorubicin 
being the highest and free doxorubicin being the lowest. Appropriately, the inulin-
doxorubicin conjugate incubated with inulinase exhibited a fluorescent quenching 
between the other two because free doxorubicin and inulin-doxorubicin conjugates both 
contributed to the binding of ctDNA.  
Similar studies utilizing dextran-doxorubicin conjugates with varying molecular 
weights was completed and demonstrated that the degree of ctDNA binding increased 
with polymer molecular weight.6 Contrary to our results, free doxorubicin demonstrated 
the highest degree of binding to ctDNA. It has been reported that the major binding of 
doxorubicin to DNA occurs with the chromophore site with the amino sugar extending 
into the minor groove of the DNA to form a hydrogen bond.8 Since this inulin-
doxorubicin conjugate is bonded through the primary amine on the amino sugar of 
doxorubicin, its ability to hydrogen bond with DNA would be limited by steric hindrance 
and should reduce overall binding to DNA. However, our results indicate the highest 
degree of ctDNA binding was the inulin-doxorubicin conjugate. Thus, the unique 
properties of inulin have aided in the binding process to DNA and could be contributive 
to the observed increase cytotoxicity as compared to free doxorubicin.  
Confocal Imaging. SW620 and HT29-MTX cells were exposed to free 
doxorubicin and inulin-doxorubicin conjugate for 4 hr, then rinsed with 1× PBS, and 
fixed with paraformaldehyde. The cells were then stained with DAPI and imaged using a 
confocal microscope. The concentration of doxorubicin present in the inulin-conjugate 
and the concentration of free doxorubicin were equal. Cells with the inulin-conjugate 
were imaged first and the settings used to capture these images were maintained for 
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imaging the cells with doxorubicin and control cells for comparison purposes. SW620 
and HT29-MTX cell lines were chosen as the represented the least resistant and most 
resistant to free doxorubicin, respecitively.  
 All cell nuclei were stained blue using the DAPI reagent. Since doxorubicin 
excites at 485 nm and emits at 580 nm, a series of images can be captured sequentially 
and overlayed to determine the localization of doxorubicin or inulin-doxorubicin 
conjugate in the nucleus. The inulin-doxorubicin conjugate was present in greater 
quantities in the cellular nucleus as compared to free doxorubicin in both SW620 and 
HT29-MTX cells (Figure 9.8 and 9.9). In fact, there is little detection of doxorubicin at 
equal setting when comparing the conjugate to free doxorubicin (Figure 9.8 and 9.9); 
however, when the signal was amplified in the cells exposed to free doxorubicin, 
doxorubicin was present in the cellular nuclei (not pictured). As higher concentrations 
were tested, the amount of inulin-doxorubicin conjugate present in the cellular nuclei was 
always greater than free doxorubicin. Control cells indicated no contribution of natural 
fluorescence when excited at 485 nm. 
9.4 Conclusions 
 Cytotoxicity, ctDNA binding experiments, and confocal imaging have been 
completed on free doxorubicin and the inulin-doxorubicin conjugate with or without 
inulinase. The inulin-doxorubicin conjugate was intended to reduce the activity of 
doxorubicin until it reached the colon where microflora could digest the inulin and 
liberate doxorubicin to begin its toxic effects on colon cancer cells. However, 
cytotoxicity results indicate that the inulin-doxorubicin conjugate is more potent than free 
doxorubicin. Despite these opposite effects, a more potent conjugate could be beneficial 
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to the medical community because less drug could be given while still achieving the same 
therapeutic effect. Free doxorubicin is an effective drug; however, once a certain amount 
of this drug is administered it can longer be used by the patient due to deadly 
cardiotoxicity. Perhaps utilizing the inulin-doxorubicin conjugate would allow patients to 
continue the use of the drug for longer periods of time with reduced cardiotoxicity. 
Literature research has publicized the importance of inulin in human diets and its 
potential for role in colon cancer prevention.9 Inulin type fructans consumed in human 
and rat diets reduced colon cancer risks by reducing exposure to genotoxic carcinogens in 
the gut or by reducing their genotoxic impacts.10 In this same paper, inulin based products 
have shown reduction in metastasis activities of colon tumor cells and inhibition of 
growth. Inhibition of growth could be a driving mechanism for the observed increased 
toxicity of the inulin-doxorubicin conjugate. Lastly, nontoxic potentiation of cancer 
chemotherapy by dietary inulin has also been cited.11 Seven days before administration of 
six different cytotoxic drugs, inulin was incorporated into male rat diets. For all 
experiments, inulin considerably potentiated the therapeutic effects induced by six 
different cytotoxic drugs commonly utilized in human cancer treatment. In this paper and 
others, these non-digestible carbohydrates appeared to decrease serum glucose level in 
rats and humans as well as insulin levels,12 each of which are important regulators of cell 
and/or tumor proliferation.13  
In each of these cited cases inulin was used as a dietary supplement and not 
physically bonded to the chemotherapeutic drugs. It is hypothesized that due to the 
intimate contact between cancer cells and doxorubicin that these effects above could be 
enhanced. The following information about inulin-doxorubicin can be contributive to its 
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increased cytotoxicity: 1) the inulin-doxorubicin conjugate is uptaken into these cells (see 
confocal results) in quantities higher than free doxorubicin, 2) an increase in molecular 
size could prevent “efflux pumps” from removing the inulin-conjugate as effectively as 
free doxorubicin, 3) the presence of inulin inside of the cell in greater concentrations than 
outside of the cell could play larger effects with the insulin and glucose levels needed for 
tumor proliferation and 4) ctDNA binding studies indicate that the inulin-doxorubicin 
conjugate more readily binds to DNA as compared to free doxorubicin. Again, these 
results were not expected, but perhaps this serendipitous discovery could make a major 
contribution to new treatments for battling cancer.    
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Figures 
 
 
 
  Figure 9.1. Effect of 4 hr exposure of inulin-doxorubicin conjugate with and 
without inulinase on SW620 cell proliferation. SW620 cells were seeded at 1.5 × 104 
cells/cm2 and cultured in a 96-well plate for 48 hr. Inulin-doxorubicin conjugate with and 
without inulinase was dissolved in RPMI and placed on SW620 cells for 4 hr. The 
conjugate with inulinase was incubated with inulinase 24 hr before testing. 
Concentrations tested ranged from 0.00543 µg/mL to 54.3 µg/mL. Error bars represent 
error propagated over control cells. n = 6 – 8. 
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Figure 9.2. Effect of 4 hr exposure of carboxymethylated inulin on SW620 cell 
proliferation. SW620 cells were seeded at 1.5 × 104 cells/cm2 and cultured in a 96-well 
plate for 48 hr. Carboxymethylated inulin was dissolved in RPMI and placed on SW620 
cells for 4 hr. Concentrations tested ranged from 0.00543 µg/mL to 54.3 µg/mL. Error 
bars represent error propagated over control cells. n = 6 – 8. 
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Figure 9.3. Effect of 4 hr exposure of carboxymethylated inulin with inulinase on 
SW620 cell proliferation. SW620 cells were seeded at 1.5 × 104 cells/cm2 and cultured 
in a 96-well plate for 48 hr. Carboxymethylated inulin with inulinase was dissolved in 
RPMI and placed on SW620 cells for 4 hr. The carboxymethylated inulin was incubated 
with inulinase 24 hr before testing. Concentrations tested ranged from 0.00543 µg/mL to 
54.3 µg/mL. Error bars represent error propagated over control cells. n = 6 – 8. 
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Figure 9.4. Effect of 4 hr exposure of inulin-doxorubicin conjugate versus 
doxorubicin on SW620 cell proliferation. SW620 cells were seeded at 1.5 × 104 
cells/cm2 and cultured in a 96-well plate for 48 hr. The amount of doxorubicin present in 
the inulin-doxorubicin conjugate and free doxorubicin was equal. The conjugate and free 
doxorubicin were dissolved in RPMI and placed on SW620 cells for 4 hr. Concentrations 
tested ranged from 0.00543 µg/mL to 5.43 µg/mL. Error bars represent error propagated 
over control cells. n = 6 – 8. 
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Figure 9.5. Effect of 4 hr exposure of inulin-doxorubicin conjugate versus 
doxorubicin on Caco-2 cell proliferation. Caco-2 cells were seeded at 2.0 × 104 
cells/cm2 and cultured in a 96-well plate for 48 hr. The amount of doxorubicin present in 
the inulin-doxorubicin conjugate and free doxorubicin was equal. The conjugate and free 
doxorubicin were dissolved in DMEM and placed on Caco-2 cells for 4 hr. 
Concentrations tested ranged from 0.00543 µg/mL to 5.43 µg/mL. Error bars represent 
error propagated over control cells. n = 6 – 8. 
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Figure 9.6. Effect of 4 hr exposure of inulin-doxorubicin conjugate versus 
doxorubicin on HT29-MTX cell proliferation. HT29-MTX cells were seeded at 3.0 × 
104 cells/cm2 and cultured in a 96-well plate for 48 hr. The amount of doxorubicin 
present in the inulin-doxorubicin conjugate and free doxorubicin was equal. The 
conjugate and free doxorubicin were dissolved in DMEM and placed on HT29-MTX 
cells for 4 hr. Concentrations tested ranged from 0.00543 µg/mL to 5.43 µg/mL. Error 
bars represent error propagated over control cells. n = 6 – 8.  
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 Figure 9.7. ctDNA binding with free doxorubicin and the inulin-doxorubicin 
conjugate with and without inulinase. Stock solutions of free doxorubicin and inulin-
doxorubicin conjugate were made to a concentration of 10 µg/mL in 1× PBS and the 
conjugate with inulinase to the same concentration in 6.25% (v/v) inulinase in 1× PBS. 
ctDNA standards ranged from 5 µg/mL to 50 µg/mL in 1× PBS. Stock solutions and 
standards were mixed overnight and then combined and allowed to mix overnight again. 
Sample fluorescent values were measured on a UV/VIS plate reader and the ratio of F / 
F0 was indicative of fluorescent quenching where F is the fluorescent value of the sample 
and F0 the fluorescent value with no ctDNA present.  n = 3 ± SD 
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Figure 9.8. Confocal imaging of HT29-MTX cells incubated with free doxorubicin 
or inulin-doxorubicin conjugate for 4 hr.  HT29-MTX cells were seeded at 3.0 × 104 
cells/cm2 and cultured in a 96-well plate for 48 hr. The amount of doxorubicin present in 
the inulin-doxorubicin conjugate and free doxorubicin was equal. The conjugate and free 
doxorubicin was dissolved in DMEM and placed on HT29-MTX cells for 4 hr, then 
rinsed with 1× PBS, fixed with paraformaldehyde, and cell nuclei stained with DAPI. A) 
DAPI stain (blue) of cell nuclei, B) fluorescence (red) of conjugate or free doxorubicin, 
C) transmission image of cells, D) overlay of A,B, and C).  
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Figure 9.9. Confocal imaging of SW620 cells incubated with free doxorubicin or 
inulin-doxorubicin conjugate for 4 hr.  SW620 cells were seeded at 1.5 × 104 cells/cm2 
and cultured in a 96-well plate for 48 hr. The amount of doxorubicin present in the inulin-
doxorubicin conjugate and free doxorubicin was equal. The conjugate and free 
doxorubicin was dissolved in RPMI and placed on SW620 cells for 4 hr, then rinsed with 
1× PBS, fixed with paraformaldehyde, and cell nuclei stained with DAPI. A) DAPI stain 
(blue) of cell nuclei, B) fluorescence (red) of conjugate or free doxorubicin, C) 
transmission image of cells, D) overlay of A,B, and C). 
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Chapter 10 
Transepithelial Electrical Resistance and Transport Studies of Doxorubicin and an 
Inulin-Doxorubicin Conjugate in the Presence of Polymer Carriers 
 
10.1  Introduction 
 Oral delivery of chemotherapeutics requires overcoming a variety of barriers 
including the low pH and degrading environment of the stomach, increasing solubility of 
traditional hydrophobic chemotherapeutics, targeted delivery for reduced side effects, and 
delivery of quantities sufficient enough to elicit therapeutic effects. The synthesized 
P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles have demonstrated that these 
polymer carriers can protect encapsulated chemotherapeutics from the low pH 
environment, reduce the amount of drug release prematurely in the stomach, and release 
the remaining loaded contents in the small intestine. The inulin-doxorubicin conjugate 
was synthesized to provide local and targeted delivery to the colon because inulin only 
degrades by enzymes present in greater numbers in colon as compared to the small 
intestine. However, the use of P(MAA-g-EG) based polymer carriers have been used 
extensively in the past to not only deliver therapeutic agents to the upper small intestine, 
but also as a way to improve permeation across the GI tract for increased 
bioavailability.1-4  
  The transport from the GI tract lumen to the bloodstream can occur through a 
number of different mechanisms and for this thesis needs to be avoided so that free 
doxorubicin or the inulin-conjugate can remain in the GI tract and travel to the colon. The 
four pathways for transport include paracellular, passive diffusion, carrier-mediated, and 
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transcytosis (Figure 10.1). The primary mechanism to enhance permeation is to loosen 
tight junctions between the epithelial cells and increase paracellular transport. Tight 
junctions are protein complexes (primarily composed of occluding and claudins)5,6 
formed between cells which are regulated by a host of intracellular and extracellular 
signaling. Due to rising costs in pharmaceutical research and final drug approval, the 
development of model systems which can mimic the characteristics of these tight 
junctions and assess paracellular transport has been established. 
 The most well established and widely used in vitro model to study oral drug 
delivery systems and predicting drug absorption or transport uses Caco-2 cells, a human 
colon adenocarcinoma cell.7,8 As discussed in more detail in Chapter 7, Caco-2 cell 
monolayers differentiate into columnar absorptive cells, exhibit brush border, and form 
tight junctions similar to the small intestine epithelial layer.9 However, the human GI 
tract is lined with a mucosal layer, a critical component to any paracellular and transport 
model. Thus, HT29-MTX goblet cells have been co-cultured with Caco-2 cells to develop 
monolayers with cellular properties more similar to native tissue including absorption and 
electrical resistance.10 Co-cultures of Caco-2 and HT29-MTX cells were used in all 
transport and permeation studies. 
 Through tight junctions, epithelial cells form a sealed layer of cells which 
separate the apical and basolateral side of the GI tract lumen. This separation develops a 
polarity above and below the epithelial cell layer and can be correlated to transepithelial 
electrical resistance (TEER) measurements which monitor the electrical resistance 
between cell layers. TEER measurements are routinely used to determine when cell 
cultures have reached confluency as well as if the cell layers are compromised when 
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exposed to biological or non-biological substances. A chopstick electrode is often used in 
combination with specialized cell culture dishes which allow cells to grow on a porous 
surface with cell media above and below the cell layer. Using a chopstick electrode, the 
TEER values can be determine by placing one tip of the electrode in the basolateral side 
and the other electrode in the apical side. Figure 10.2 illustrates the TEER measurement.  
 For this thesis, Caco-2 and HT29-MTX co-cultures and TEER measurements 
were utilized to determine the potential of transport across the GI tract with and without 
the presence of P(MAA-g-EG) and P(MAA-g-EG)-5.0NP polymer carriers. Transport 
studies of free doxorubicin or inulin-doxorubicin conjugates were also completed with 
and without the presence of P(MAA-g-EG) and P(MAA-g-EG)-5.0NP polymer carriers 
to determine the diffusional coefficients. 
10.2 Materials and Methods   
Materials.  P(MAA-g-EG) and P(MAA-g-EG)-5.0NP (75 – 150 µm) were 
synthesized using the procedures described in Chapter 4 and 5. Inulin-doxorubicin 
conjugate was used as synthesized in Chapter 8. Dulbecco’s Modified Eagle’s Medium 
(DMEM), Roswell Park Memorial Institute Medium (RPMI), and fibronectin were 
purchased from Sigma – Aldrich (St. Louis, MO). Fetal bovine serum (FBS) and trypsin 
with EDTA were obtained from Hyclone (South Plainfield, NJ). Penicillin and 
streptomycin were from MediaTech (Manassas, VA). Hanks’ Balanced Salt Solution was 
from SAFC Biosciences (Lenexa, Kansas). Doxorubicin was purchased from Selleck 
Chemicals (Houston, TX). Caco-2 were obtained from American Type Culture Collection 
(ATCC, Rockwell, MD) and HT29-MTX cells were a gift from Dr. Thecla Lesuffleur, 
INSERM, Paris, France. 
270 
 
Caco-2 and HT29-MTX Transwell® Co-Culture. All experiments used co-
cultures of Caco-2 and HT29-MTX cells plated on 12 – well Costar Transwell® plates 
(Corning, Corning, NY) with a 0.4 µm porous membrane. Caco-2 and HT29-MTX cells 
were cultured as discussed in Chapter 7 in separate T-75 flasks until enough cells were 
available for plating the Transwell® plates. After subculturing, cells were counted and 
mixed together in a 1:1 ratio before seeding onto the Transwell® plate at a density of 1.0 
× 105 cells/cm2 and cultured for 21 – 24 days with media replaced every other day. 
Transepithelial Electrical Resistance (TEER) Studies. TEER measurements 
monitored the development of tight junction in the Transwell® cultures. Measurements 
were taken every other day just before changing the media to avoid artificially high or 
low measurements as a result of disturbance to the cell layer when changing the media. 
Transwell® plates were placed on a heating mat with a variable voltage control (Glas-
COL®, Terre Haute, IN) set to keep cells at 37 °C. TEER measurements were taken 
using a chopstick electrode and an EVOM epithelial volt-ohm meter (World Precision 
Instruments, Sarasota, FL). Resistance of the cell monolayer, Rcell, was computed using 
equation 10.1: 
 
 =	 −		                                                                                              (10.1) 
 
where Rt is the resistance at each time point and R0 is the resistance due to the membrane 
and media without cells. Rcell values were multiplied by the growth area (1 cm2) of the 
Transwell® to report TEER values as a unit area resistance and allowing comparison to 
other experiments which utilized different size Transwell® plates.  
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 TEER experiments using P(MAA-g-EG) and P(MAA-g-EG)-5.0NP 
microparticles (75 – 150 µm) of different concentrations were conducted in order to 
determine the effect of the microparticles on the TEER values. 12 – well Transwell® 
plates were used with co-cultures of Caco-2 and HT29-MTX cells grown for 21 – 24 
days or until TEER values reached constant values. Then, the cell media was removed 
from the apical and basolateral side and washed three times with pre-warmed Hank’s 
Balanced Salt Solutions (HBSS) and finally replaced with HBSS on both sides of the 
chamber. The cells were allowed to equilibrate for 1 hr and their TEER measurement 
taken. The apical HBSS was then removed and replaced with 5 mg/mL or 20 mg/mL of 
P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles in HBSS which were pre--
swollen for 24 hr and pre-warmed to 37 °C. Control cells contained HBSS without 
microparticles. TEER values were monitored every 15 min for 3 hr. After this time, the 
microparticles were removed by washing with HBSS 3 times, media was placed back 
onto the cells, and the TEER measurements monitored over the next 8 hr. All 
measurements were completed on Transwell® plates placed on a heating mat to maintain 
a temperature of 37 °C. 
 Free Doxorubicin and Inulin-Conjugate Transport Studies. The amount of 
free doxorubicin and inulin-conjugate transported across a cell monolayer in both the 
presence and absence of P(MAA-g-EG) and P(MAA-g-EG)-5.0NP microparticles (75 – 
150 µm) was determined using porous Transwell® plates (Figure 10.3). 12 – well 
Transwell® plates with co-cultures of Caco-2 and HT29-MTX cells were grown for 21 – 
24 days or until TEER values plateaued. Then, cell media was removed from the apical 
and basolateral side and washed 3 times with pre-warmed HBSS and finally replaced 
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with HBSS on both sides of the chamber. The cells were allowed to equilibrate for 1 hr 
and their TEER measurement taken. The apical HBSS was then removed and replaced 
with 5 mg/mL of P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles in HBSS plus 
25 µg/mL of doxorubicin or inulin-doxorubicin conjugates in HBSS. Microparticles were 
pre-swollen for 24 hr. Microparticles, doxorubicin, and inulin-doxorubicin conjugates 
were pre-warmed to 37 °C before being added to the Transwell® plate. Two sets of 
controls were used: 1) cells with only HBSS and 2) cell with only doxorubicin or inulin-
doxorubicin conjugate. 
After adding the therapeutic agents and microparticles, 100 µL samples were 
taken from each basolateral well at 0, 0.5, 1, 2, and 3 hr time points. Samples were 
replaced with 100 µL of HBSS warmed to 37°C to maintain sink conditions. TEER 
values were recorded at each sample time point. At the conclusion of the transport study, 
both apical and basolateral sides were washed 3 times with HBSS and replaced with cell 
media. For 24 hr, the TEER values were monitored. Doxorubicin or conjugate transport 
across the cell monolayer was determined by UV/VIS spectrometry (Biotek Synergy-HT, 
Winooski, VT) operating at 485 nm excitation and 580 nm emission.  
 The apparent drug permeability coefficient, Papp, was calculated using equation 
10.2: 
 

 =	 ∙ 	

	∙
                                                                                                       (10.2) 
 
Here dQ/dt is the steady-state flux of doxorubicin or inulin-doxorubicin conjugate 
across the cell monolayer. This value was calculated from the slope of doxorubicin or 
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inulin-doxorubicin conjugate transported to the basolateral chamber versus time. Here, 
the term A is the surface area of the membrane and C0 is the initial concentration of 
doxorubicin or inulin-doxorubicin added to the apical chamber. 
10.3  Results and Discussion    
 Transepithelial Electrical Resistance (TEER) Studies. Caco-2 and HT29-MTX 
cells were combined to form confluent monolayers with tight junctions to serve as a 
model for permeation and transport studies. Caco-2 and HT29-MTX cells were combined 
in a 1:1 ratio and grown on Transwell® plates for 21 – 24 days or until TEER 
measurements plateaued. TEER measurements, after 21 days, measured between 400 and 
500 Ω * cm2 (Figure 10.4) and were much higher than resistance values measured in 
human small intestinal epithelia (50 – 100 Ω * cm2)7,11,12 and those previously published 
from our laboratory.13-16 Variation in the TEER measurements can be contributed to 
culture conditions such as seeding density, passage number, and which medium was 
used.   A small variation (10 – 30 Ω) in TEER measurements can also be contributed to 
the chopstick and EVOM volt-ohm meter. Since these in vitro TEER values are much 
higher than in vivo TEER values, results and conclusions developed from these models 
and experiments may under estimate permeation and transport values.  
A co-culture of Caco-2 and HT29-MTX was exposed to P(MAA-g-EG) and 
P(MAA-g-EG)-5.0NP microparticles (75 – 150 µm) at a concentration of 5 mg/mL and 
20 mg/mL in HBSS for 3 hr. The 5 mg/mL concentration of microparticles experiment 
illustrated no significant drop in resistance across the monolayer as compared to the 
control wells (Figure 10.5). However, with the 20 mg/mL concentration level, a decrease 
in TEER values was observed as compared to the controls (Figure 10.6). Decrease in 
274 
 
TEER values in the presence of P(MAA-g-EG) particles has been discussed by Madsen 
and Peppas17 as well as Ichikawa and Peppas.18 In each paper, P(MAA-g-EG) chelated 
Ca2+ in the apical side and caused an increase of Ca2+ flux from the basolateral to apical 
direction to maintain homeostasis. At low concentration levels (5 mg/mL), P(MAA-g-
EG) and P(MAA-g-EG)-5.0NP may not chelate Ca2+ in amounts necessary to drive Ca2+ 
in the basolateral side to the apical side through the tight junctions. With the increased 
concentration (20 mg/mL) of P(MAA-g-EG) and P(MAA-g-EG)-5.0NP enough Ca2+ was 
chelated to drive Ca2+ flux through the opening of tight junctions. Since HT29-MTX 
were present in the cell culture, the development of a mucosal layer could have also 
influenced TEER values by increasing the distance between microparticles and the cell 
monolayer. With the 5 mg/mL, the mucus layer retarded microparticle penetration, but 
with 20 mg/mL the mucus layer could have been saturated with microparticle presence 
and failed to keep the polymer carriers away from the cell monolayer. The presence of 
PMMA nanoparticles in P(MAA-g-EG)-5.0NP appeared to play no role in TEER values. 
After removal of the microparticles, TEER values were monitored for 24 hr to 
determine if cells recovered to their original TEER values. At the lower concentration (5 
mg/mL), TEER values returned to 98% of their original value, but at the higher 
concentration (20 mg/mL), TEER values returned to only 85 – 90 % of their original 
value. Microparticles which were not removed during the washing steps could be the 
driving force for these lower values. Also high concentration of microparticles have been 
cited to damage epithelial layers.19  
Free Doxorubicin and Inulin-Conjugate Transport Studies. Free doxorubicin 
and conjugate transport studies were completed to determine the transport properties with 
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and without the presence of microparticles. Based on loading levels, release profiles of 
P(MAA-g-EG) and P(MAA-g-EG)-5.0NP, and cytotoxicity profiles of free doxorubicin 
and inulin-doxorubicin conjugate, concentrations of microparticles were kept at 5 mg/mL 
and free doxorubicin and the conjugate kept at 25 µg/mL. Microparticles were pre-
swollen in HBSS 24 hr before testing and were added in the unloaded state so that the 
presence of either P(MAA-g-EG) or P(MAA-g-EG)-5.0NP would only influence 
permeability and not affect a variable rate of doxorubicin or conjugate concentration on 
the apical side.  
Caco-2 and HT29-MTX co-cultures were seeded on Transwell® plates and 
subjected to transport studies by placing the microparticles mixed with free doxorubicin 
or conjugate directly onto the cells. Samples from the basolateral side and TEER 
measurements were collected over a 3 hr time period. The UV/VIS plate reader 
determined the concentration of transported free doxorubicin or inulin-doxorubicin 
conjugate. 
 The analysis of transport of free doxorubicin or the inulin-doxorubicin conjugate 
was based on calculations using equation 10.2 to determine the apparent permeability, 
Papp. The apparent permeability of free doxorubicin with and without P(MAA-g-EG) or 
P(MAA-g-EG)-5.0NP microparticles is shown in Table 10.1. Free doxorubicin 
permeability (4.5 × 10-6 cm/s) was calculated as slightly higher than P(MAA-g-EG) (3.8 
× 10-6 cm/s) and P(MAA-g-EG)-5.0NP (3.26 × 10-6 cm/s), but was not significant.  
TEER values monitored during the experiment demonstrated no decrease in value 
as compared to the control cells. Since TEER values were unchanged, the tight junctions 
were not significantly compromised and permeability of free doxorubicin primarily 
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occurred through passive diffusion. It is not surprising that the tight junctions were not 
opened due to the presence of microparticles because we previously demonstrated that 
concentrations of 5 mg/mL of microparticles did not decrease TEER values. Passive 
diffusion is a concentration driven process, thus the slightly lower permeability values 
when the microparticles were present could be due to the microparticles absorbing a 
small amount of doxorubicin into its polymer structure and thus reducing the doxorubicin 
concentration present in the HBSS solution. 
 The apparent permeability of the conjugate and the conjugate in the presence of 
P(MAA-g-EG) or P(MAA-g-EG)-5.0NP is shown in Table 10.2 and demonstrated similar 
trends seen with free doxorubicin. The conjugate’s permeability (2.6 × 10-6 cm/s) was 
calculated as slightly higher than with P(MAA-g-EG) (1.9 × 10-6 cm/s) and P(MAA-g-
EG)-5.0NP (1.8 × 10-6 cm/s), but was not significant. Again TEER values were 
monitored and demonstrated no decrease in values as compared to control cells. Thus, 
tight junctions were not compromised and transport of the conjugate from the apical to 
basolateral side was dominantly passive diffusion. Reduced permeability values of the 
conjugate with microparticles was due to the  microparticles absorbing the conjugate into 
or on its polymer structure and thus reducing the conjugate concentration necessary to 
drive passive diffusion to higher levels.  
The apparent permeability values of doxorubicin have been determined in other 
model systems, but not for co-cultures of Caco-2 and HT29-MTX cell lines. The closest 
comparison was determining Papp for doxorubicin across a Caco-2 monolayer using either 
HBSS or with fasted state simulated intestinal fluids (FaSSIF). The HBSS Papp was 2.8 × 
10-5 cm/s and FaSSIF was 2.9 × 10-5 cm/s.20 These slightly higher values can be 
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contributed to the single Caco-2 layer which does not possess the mucus layer secreted by 
the HT29-MTX cells. Additional Papp value have been computed for doxorubicin across  
human red blood cells (2.4 × 10-7 cm/s), Ehrlich ascites tumor cells (2.4 × 10-5 cm/s), 
leukemia cells (7.4 × 10-5 cm/s), and has been estimated on the order of 10-6 cm/s for 
hepatocyte membranes from male Wistar rats.21-24 Though these latter experiments are 
not focused on GI transit, they do indicate that the magnitude and reported values of 
transport studies with doxorubicin and inulin-doxorubicin conjugates completed in this 
thesis are within the realm of other published results.  
10.4  Conclusions 
 P(MAA-g-EG) and P(MAA-g-EG)-5.0NP microparticles can serve as polymer 
carriers for colon drug delivery if their concentration are kept at or below 5 mg/mL. At 5 
mg/mL, the microparticles do not cause TEER values to decrease and indicated that tight 
junctions remained closed which is favorable for local, direct delivery of therapeutic 
agents to the colon. If tight junctions were compromised or open, free doxorubicin or 
inulin-doxorubicin conjugate could significantly be transported across the GI tract into 
the bloodstream and reduce the amount necessary to achieve therapeutic effects against 
colon cancer. 
 As discussed above, 5 mg/mL concentrations of P(MAA-g-EG) or P(MAA-g-
EG)-5.0NP did not decrease TEER values, but if the concentration was increased to 20 
mg/mL then TEER values were decreased. TEER values returned to normal within 8 hr 
of removing the 5 mg/mL concentration while TEER values only returned to 85 – 90% of 
their initial TEER value once the 20 mg/mL concentration was removed. The inability to 
return to the original TEER values indicates that tight junctions have been compromised 
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for an extended period of time or permanently damaged all together. Damaged tight 
junctions or tight junction open for a lengthy period of time can compromise the human 
body since foreign or toxic materials which should remain in the GI tract can transport 
into the bloodstream. 
  Free doxorubicin and inulin-doxorubicin conjugate permeability values were 
slightly higher than the same studies completed in the presence of microparticles because 
microparticles absorbed small amounts of doxorubicin or the conjugate into or on the 
polymer structure. Since the molecular weight of free doxorubicin (543 g/mol) is smaller 
than the inulin-doxorubicin conjugate (~2000 – 2500 g/mol) the higher permeability 
values of free doxorubicin is expected since it can more readily penetrate the mucosal 
layer.      
 Lastly, the measured Papp values for free doxorubicin and the inulin-doxorubicin 
conjugate were on the order of 10-6 cm/s and were in the range of Papp values previously 
published using different human cells or cell models. Thus, the data presented here could 
prove to be a strong contribution to the scientific community, especially since this is the 
first time free doxorubicin transport properties have been analyzed using the co-culture 
model of Caco-2 and HT29-MTX cell lines.   
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Figures 
 
  
 
Figure 10.1. Animation of the four major mechanisms of transport across the 
intestinal epithelium.  Therapeutic agents can transport from the apical to the basolateral 
side by paracellular (A) transport or transcellular transport (B, C, D). Transcellular 
transport can occur by transcytosis (B), passive diffusion (C), and carrier-mediated 
transport (D).  
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Figure 10.2. Schematic of TEER measurement using Transwell® membrane with 
Caco-2 and HT29-MTX cultures. The chopstick electrode attached to the EVOM volt-
ohm meter is placed with one tip submerged below the liquid level in the basolateral side 
and the second tip submerged below the liquid line in the apical side. The resistance 
between the apical and basolateral side is correlated to the formation of tight junctions 
and cell confluency across the porous Transwell® membrane.  
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Figure 10.3. Schematic of Transwell® membrane with Caco-2 and HT29-MTX 
cultures in the presence of doxorubicin or inulin-doxorubicin conjugate and 
P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles.  P(MAA-g-EG) or P(MAA-g-
EG)-5.0NP microparticles plus doxorubicin or inulin-doxorubicin conjugate were added 
to the apical side of the Transwell® plate. Samples are taken over time from the 
basolateral side where doxorubicin or inulin-doxorubicin conjugate has diffused to.  
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Figure 10.4. Comparison of TEER values of Caco-2 and HT29-MTX cell culture 
grown over 24 days. Caco-2 and HT29-MTX were combined in a 1:1 ratio and seeded at 
a concentration of 1.0 × 105 cells/cm2 on a permeable (0.4 µm) 12-well Transwell® plate 
and cultured for 21 – 24 days or until the TEER values plateaued. TEER values were 
taken before media change every other day. n = 12 ± SD 
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Figure 10.5. Evaluation of TEER values on Caco-2 and HT29-MTX cell culture with 
5 mg/mL of P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles present. Caco-2 
and HT29-MTX were combined in a 1:1 ratio and seeded on a permeable Transwell® 
plate and cultured for 21 – 24 days or until the TEER values plateaued. Cells were 
incubated with 5 mg/mL P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles (75 – 
150 µm) for 3 hr and TEER values recorded every 15 min. n = 3 ± SD 
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Figure 10.6. Evaluation of TEER values on Caco-2 and HT29-MTX cell culture with 
20 mg/mL of P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles present. Caco-2 
and HT29-MTX were combined in a 1:1 ratio and seeded on a permeable Transwell® 
plate and cultured for 21 – 24 days or until the TEER values plateaued. Cells were 
incubated with 20 mg/mL P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles (75 – 
150 µm) for 3 hr and TEER values recorded every 15 min. n = 3 ± SD
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Figure 10.7. Doxorubicin transport across Caco-2 and HT29-MTX cell culture with 
and without 5 mg/mL of P(MAA-g-EG) or P(MAA-g-EG)-5.0NP. Caco-2 and HT29-
MTX were combined in a 1:1 ratio and seeded on a permeable Transwell® plate and 
cultured for 21 – 24 days or until the TEER values plateaued. Cells were incubated with 5 
mg/mL P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles (75 – 150 µm) + 25 
µg/mL of free doxorubicin. Doxorubicin concentration was determined using a UV/VIS 
spectrometer. n = 4 – 6 ± SD 
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Figure 10.8. Inulin-doxorubicin conjugate transport across Caco-2 and HT29-MTX 
cell culture with and without 5 mg/mL of P(MAA-g-EG) or P(MAA-g-EG)-5.0NP.  
Caco-2 and HT29-MTX were combined in a 1:1 ratio and seeded on a permeable 
Transwell® plate and cultured for 21 – 24 days or until the TEER values plateaued. Cells 
were incubated with 5 mg/mL P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles 
(75 – 150 µm) + 25 µg/mL inulin-doxorubicin conjugate. Inulin-doxorubicin conjugate 
concentration was determined using a UV/VIS spectrometer. n = 4 – 6 ± SD 
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Tables 
 
Formulation 
Apparent Permeability, Papp  
( × 10-6 cm/s) 
Doxorubicin 4.53 
P(MAA-g-EG) 3.80 
P(MAA-g-EG)-5.0NP 3.26 
  
Table 10.1. Apparent permeability of free doxorubicin mixed with  P(MAA-g-EG) or 
P(MAA-g-EG)-5.0NP microparticles (75 - 150µm) across Caco-2 and HT29-MTX cell 
monolayers. 
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Formulation 
Apparent Permeability, Papp  
( × 10-6 cm/s) 
Inulin-Doxorubicin Conjugate 2.67 
P(MAA-g-EG) 1.93 
P(MAA-g-EG)-5.0NP 1.87 
 
 
Table 10.2.   Apparent permeability of free doxorubicin mixed with  P(MAA-g-EG) or 
P(MAA-g-EG)-5.0NP microparticles (75 - 150µm) across Caco-2 and HT29-MTX cell 
monolayers. 
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Chapter 11 
Conclusions and Recommendations 
 
11.1  Conclusions 
The two primary objectives of this research were to (i) develop environmentally 
sensitive hydrogels which possess hydrophobic and hydrophilic properties for the oral 
administration of chemotherapeutics; and (ii) to develop a chemotherapeutic conjugate 
for the local, direct, and targeted delivery to the colon. The environmentally – sensitive 
hydrogels were composed of methacrylic acid (MAA) grafted with poly(ethylene glycol) 
(PEG) tethers (P(MAA-g-EG)). The introduction of hydrophobic properties was 
completed by forming an interpenetrating polymer networks (IPN) with poly(n-butyl 
acrylate) (PBA) or photoencapsulating poly(methyl methacrylate) (PMMA) nanoparticles 
within the hydrogel network during polymerization. The conjugate was synthesized using 
inulin and doxorubicin. Both the polymer carriers and the synthesized conjugate were 
thoroughly characterized for their potential use in the medical field.  
Interpenetrating Polymer Networks. The research first focused on the synthesis 
and characterization of the IPN polymer carriers. The synthesis was achieved by using 
sequential UV-initiated free radical polymerizations to form hydrophilic (P(MAA-g-EG)) 
and hydrophobic (PBA) networks. Equilibrium swelling studies were performed to 
determine the molecular properties of the IPNs. Of particular interest was to determine 
the effect of introducing the hydrophobic properties to swelling properties. For all IPN 
compositions there was minimal swelling in gastric pH conditions indicating collapsed 
networks which could minimize the release of an encapsulated therapeutic agent. 
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Swelling in intestinal conditions showed that as the amount of hydrophobic PBA was 
incorporated into the P(MAA-g-EG) hydrogel, the equilibrium swelling was decreased. 
Calculated mesh size from equilibrium swelling studies was found to be large enough to 
facilitate chemotherapeutic or a chemotherapeutic conjugate loading and release.  
Surface contact angle measurements and sequential equilibrium swelling in water 
and isopropanol experiments were used to qualify if the degree of hydrophobicity was 
different between IPN compositions. Contact angle measurements increased with 
increasing PBA content in the P(MAA-g-EG) hydrogel indicating an increase of 
hydrophobicity on the surface of the IPNs. The equilibrium swelling ratio of water 
divided by the equilibrium swelling ratio in isopropanol decreased with increasing PBA 
content in the P(MAA-g-EG) hydrogel indicating an increase of hydrophobicity in the 
bulk of the IPNs.  
The loading and release of doxorubicin, a chemotherapeutic drug, was completed 
using IPN microparticles (75 – 500 µm). Each IPN demonstrated a certain degree of 
swelling as determined above and possessed a certain degree of hydrophobicity based on 
how it was synthetically formed. It was the balance of the swelling properties and 
hydrophobicity which ultimately determined the loading efficiency of doxorubicin. 
P(MAA-g-EG) exhibited loading levels higher than two of three IPN compositions; 
however, the 75/25 IPN, which demonstrated a proper balance of hydrophobicity and 
swelling, loaded the greatest amount of doxorubicin. The release of doxorubicin from the 
IPNs was not ideal because in gastric conditions a large portion of doxorubicin was 
released (30 – 70 %) as compared to intestinal conditions. The high release amount in 
gastric conditions would mean the stomach could be potentially harmed by the cytotoxic 
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drug and the amount released in the small intestine may not be enough to provide 
therapeutic effects to colon cancer.  
All IPN compositions and P(MAA-g-EG) were tested for biocompatibility with 
varying concentration levels and exposure length using Caco-2, HT29-MTX, and SW620 
cell lines. For all concentrations and exposure lengths, the polymer carriers were 
determined to be biocompatible. The mucoadhesive behavior of the 75/25 IPN and 
P(MAA-g-EG) hydrogel was also tested using tensile measurements of the force 
generated between polymer disks and freshly harvested small intestine porcine tissue. 
The 75/25 IPN was more mucoadhesive than P(MAA-g-EG).   
Overall, the IPNs were polymer carriers which exhibited the proper amount of 
swelling and hydrophobicity to load doxorubicin; however, there are several drawbacks 
to this system for their use in oral drug delivery applications. First, during the 
polymerization of PBA network, it is hard to determine if PBA is uniformly distributed 
throughout the P(MAA-g-EG) hydrogel. If during the polymerization process a non-
uniform distribution of PBA is formed, variations could arise in both the loading and 
release experiments. Second, the time it takes to form the IPNs is greater than 2 – 3 
weeks. A one step polymerization process would be more ideal for scale up purposes than 
the current two – step process. Third, release profiles demonstrate a majority of 
doxorubicin would be released in the stomach and could be at quantities high enough to 
be harmful to the stomach lining. Fourth, the mucoadhesion of the 75/25 IPN was higher 
than P(MAA-g-EG) and would result in longer residency times and increased release of 
doxorubicin in the small intestine instead of the colon. Fifth, the use of PBA as a material 
could delay this polymer carrier from being utilized faster because it is not heavily used 
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in today’s medical market and may require extensive analysis as compared to other 
materials such as poly(methyl methacrylate).  
Despite these drawbacks, the IPNs were capable of loading doxorubicin and at 
levels higher than P(MAA-g-EG) illustrating that the presence of the hydrophobic PBA 
network is important in loading hydrophobic compounds. Since the 75/25 IPN 
demonstrated 50% doxorubicin release in model stomach conditions and 50% 
doxorubicin released in model upper small intestine conditions it is not appropriate for 
this thesis, but perhaps would be ideal for a hydrophobic therapeutic agent requiring 
immediate and long term release. Lastly, at room temperature and in the dry state, these 
materials exhibit both crystalline (P(MAA-g-EG)) and rubbery properties (PBA) and 
maybe utilized in other industrial applications than just the medical field. However, to 
achieve the objectives set forth in this thesis, the drawbacks to this system outweigh the 
good and thus the remainder of the thesis focused on utilizing the P(MAA-g-EG) 
hydrogel containing PMMA nanoparticles.   
 P(MAA-g-EG) hydrogels containing PMMA nanoparticles. P(MAA-g-EG) 
hydrogels containing PMMA nanoparticles were formed by first polymerizing PMMA 
nanoparticles in a surfactant free emulsion polymerization and then photoencapsulated 
during the free radical UV polymerization of the P(MAA-g-EG) hydrogel. Equilibrium 
swelling studies were completed to determine pKa values and molecular properties in 
gastric and intestinal conditions. In gastric conditions, all compositions of P(MAA-g-EG) 
containing nanoparticles exhibited minimal swelling. In intestinal conditions, the 
P(MAA-g-EG) hydrogel demonstrated the highest equilibrium swelling ratio and then the 
equilibrium swelling ratio decreased with increasing weight percent of nanoparticles 
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present in the P(MAA-g-EG) hydrogel. All compositions illustrated the highest pH 
response between pH values of 4 and 5. 
 To determine how the nanoparticles were incorporated into the P(MAA-g-EG) 
hydrogel, rheological testing and cyclic swelling experiments in low and neutral pH 
conditions were completed. Rheological measurements were performed on P(MAA-g-
EG) and P(MAA-g-EG)-5.0NP samples to determine the storage modulus. The storage 
modulus for P(MAA-g-EG)-5.0NP samples was lower than P(MAA-g-EG) and thus the 
nanoparticles were determined to be physically entangled within the P(MAA-g-EG) 
hydrogel and not crosslinked. Cyclic swelling experiments were used to determine if the 
entangled nanoparticles were being released from the P(MAA-g-EG) hydrogel. SEM 
images demonstrated that the presence of nanoparticles before and after swelling 
experiments was still uniform throughout the P(MAA-g-EG) hydrogel structure and 
minimal to no nanoparticle release was observed.    
The loading and release of doxorubicin and the inulin-doxorubicin conjugate was 
completed using microparticles (75 – 150 µm) of P(MAA-g-EG) containing 
nanoparticles. All compositions of P(MAA-g-EG) containing nanoparticles loaded more 
doxorubicin than P(MAA-g-EG) without nanoparticles. The loading efficiency of 
doxorubicin increased with increasing nanoparticle content and the P(MAA-g-EG)-2.5NP 
and P(MAA-g-EG)-5.0NP loaded more doxorubicin than the 75/25 IPN. Release studies 
were a marked improvement as compared to the IPNs with only 23 – 27 % of 
doxorubicin released in the low pH before being switched to more neutral pH conditions.  
Just the P(MAA-g-EG)-5.0NP sample was loaded with inulin-doxorubicin conjugate and 
released in model GI tract conditions. The loading levels of inulin-doxorubicin conjugate 
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were slightly lower than free doxorubicin and release profiles of the inulin-doxorubicin 
conjugate were appropriate for oral drug delivery.  
All compositions of P(MAA-g-EG) containing nanoparticles and P(MAA-g-EG) 
were tested for biocompatibility with varying concentration levels and exposure length 
using Caco-2, HT29-MTX, and SW620 cell lines. For all concentrations and exposure 
lengths, the polymer carriers were determined to be biocompatible. The mucoadhesive 
behavior of the P(MAA-g-EG)-5.0NP and P(MAA-g-EG) hydrogel was also tested using 
tensile measurements of the force generated between polymer disks and freshly harvested 
small intestine porcine tissue. The P(MAA-g-EG) polymer carrier was more adhesive 
than the P(MAA-g-EG)-5.0NP polymer carrier. 
 Overall the P(MAA-g-EG) containing nanoparticles are polymer carriers which 
are better suited for oral drug delivery than the IPNs. First, the complete process to 
develop these carriers is fast and done with ease. The PMMA nanoparticles are 
reproducible, uniform, relatively monodisperse, and require no special combination of 
surfactants which are difficult to remove during purification. For the formation of 
P(MAA-g-EG) with nanoparticles, repeated polymerization and SEM images illustrated 
the nanoparticles are uniformly distributed on the surface and in the bulk of the films 
which correlate well with repeatable loading efficiencies and release profiles. Second and 
unlike the IPNs, the entire process can be completed in 1 week and even shortened if the 
film purification is optimized. Third, the loading levels of doxorubicin were high and the 
release profiles demonstrated a low amount released in modeled stomach conditions and 
quick release in modeled small intestine conditions. The presence of the nanoparticles 
and the hydrophobicity they incorporated into the polymer carrier is critical to loading of 
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the doxorubicin and is apparent as P(MAA-g-EG) loaded less than any of the 
nanoparticle containing carriers. Fourth, the decrease in mucoadhesion of the P(MAA-g-
EG)-5.0NP polymer carrier can allow release of an encapsulated therapeutic agent to 
occur closer to the colon. Fifth, by using PMMA which is already FDA approved for 
certain biomedical applications plus P(MAA-g-EG) which has been extensively studied 
in this laboratory, the length of time from benchtop to market could be reduced.  
 Despite these positive attributes, the P(MAA-g-EG) containing nanoparticles does 
have some drawbacks. After drying the doxorubicin or inulin-conjugate loaded 
microparticles, the microparticles aggregated together and required a secondary crushing. 
This second crushing could prove difficult in scaled up conditions. Next, if more 
nanoparticles were needed to be incorporated into the P(MAA-g-EG) hydrogel for 
increased loading or eliciting new properties, it will be difficult for them to be dissolved 
and uniformly mixed in the pre-polymerization solutions because strong hydrogen 
bonding between nanoparticles would be expected. In the end, this polymer carrier 
exceeds in properties and performance necessary for oral drug delivery and the 
drawbacks could be solved with further experiments or small alterations to the current 
synthetic procedure and the drug loading procedure. 
Inulin-Doxorubicin Conjugate. The inulin-doxorubicin conjugate was formed by 
first carboxymethylating the inulin and then attaching it to doxorubicin using EDC and 
sulfo-NHS chemistry. Cytotoxicity experiments were completed to compare the toxicity 
levels of free doxorubicin and the inulin-doxorubicin conjugate incubated with or without 
inulinase (model colonic enzyme which degrades inulin) on Caco-2, HT29-MTX, and 
SW620 cell lines. Initial cytotoxicity studies compared the inulin-doxorubicin conjugate 
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with and without inulinase (model colonic enzyme used to digest inulin). The inulin-
doxorubicin conjugate demonstrated greater toxicity than the conjugate with inulinase. 
These results were not expected since it was assumed free doxorubicin would be less 
sterically hindered than the conjugate and more readily penetrate cell nuclei to intercalate 
with the DNA. Thus, a set of cytotoxicity studies were completed comparing the same 
concentrations of free doxorubicin to the concentration of doxorubicin present in the 
inulin-doxorubicin conjugate. In all studies completed, the inulin-doxorubicin conjugate 
was more toxic than free doxorubicin. The combination of inulin with doxorubicin 
possessed unique properties which made the conjugate more toxic than free doxorubicin. 
ctDNA binding and confocal imaging studies were used to characterize the inulin-
doxorubicin conjugate’s potential behavior with cells and cell DNA. ctDNA binding 
studies demonstrated that the conjugate bound to ctDNA more readily than free 
doxorubicin and confocal imaging illustrated that the conjugate was present in cell nuclei 
at greater quantities than free doxorubicin when tested at the same concentration and 
exposure time.  
 Overall, the synthesis of the inulin-doxorubicin conjugate was easy and could be 
completed in a short period of time (<  1 week). It has been previously demonstrated that 
inulin present in the diets of cancer patients enhanced the therapeutic effects of several 
different cancer drugs, but no reference to an inulin-doxorubicin conjugate has been seen 
in literature. It is hypothesized the structure the inulin-doxorubicin conjugate has allowed 
interactions with the cell and cell nuclei to enhance cytotoxicity. First, the inulin-
doxorubicin conjugate is uptaken in these cells in quantities higher than free doxorubicin. 
Greater present of the inulin-doxorubicin conjugate in the cell allows a greater 
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opportunity for intercalation of DNA leading to ultimate increase in cytotoxicity. Second, 
an increase in molecular size could prevent “efflux pumps” from removing the inulin-
conjugate as effectively as free doxorubicin. Efflux pumps are effective in removing 
doxorubicin, but the larger inulin-doxorubicin conjugate maybe to large or not flexible 
enough to enter the efflux pump. Third, inulin can decrease glucose and insulin levels 
necessary for cell growth and proliferation. With increased presence of the inulin-
doxorubicin conjugate in the cell as compared to outside the cell, the inulin can play 
larger effects with the insulin and glucose levels needed for tumor proliferation. Fourth, 
ctDNA binding studies indicate that the inulin-doxorubicin conjugate more readily binds 
to DNA as compared to free doxorubicin. Increased binding gives doxorubicin more 
opportunities to intercalate the DNA and increase cytotoxicity to cancer cells.  
The inulin-doxorubicin conjugate does demonstrate improved cytotoxicity, but a 
few limitations still exist. It was hoped that the introduction of the inulin to doxorubicin 
would improve solubility. Though not directly tested, visual observations demonstrated a 
small increase in solubility, but was still limited to concentrations just sufficient enough 
to induce cytotoxicity to the more resistance Caco-2 and HT29-MTX cell lines. Next, 
after the freeze drying process, the conjugate was difficult to measure and took extended 
periods of mixing or vortexing to re-dissolve it in physiological solutions. Alternative 
ways to freeze drying could eliminate this issue and make the inulin-doxorubicin 
conjugate a more viable option for future cancer therapy. Despite the unexpected increase 
in toxicity, the inulin-doxorubicin conjugate could prove vital to the medical community 
where a limited amount of free doxorubicin can only be given before cardiotoxic side 
effects arise. With the inulin-doxorubicin conjugate, perhaps longer therapeutic regimes 
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can be tolerated before the cardiotoxicity arises because the amount of doxorubicin 
needed for toxic effects is reduced. 
Transepithelial electrical resistance and transport studies. Transepithelial 
electrical resistance (TEER) values were measured with and without P(MAA-g-EG) or 
P(MAA-g-EG)-5.0NP microparticles to determine if tight junctions formed by Caco-2 
and HT29-MTX co-cultures were opened. Open tight junctions would allow increased 
transport of therapeutic agents from the GI lumen to the bloodstream, but for the purpose 
of this thesis the therapeutic agent must remain in the GI tract for local, targeted delivery 
to the colon. Concentrations of 5 mg/mL and 20 mg/mL of microparticles in 1× PBS 
were tested for 3 hr and TEER values measured. The 5 mg/mL concentration induced no 
change to TEER values while the 20 mg/mL concentration did. Therefore, the delivery of 
P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles loaded with doxorubicin or 
inulin-doxorubicin conjugate would be recommended to stay at or below the 5 mg/mL 
concentration level.  
 Transport studies of doxorubicin or inulin-doxorubicin were completed with or 
without the presence of P(MAA-g-EG) or P(MAA-g-EG)-5.0NP microparticles. In all 
studies, the presence of the microparticles did not increase the permeability of 
doxorubicin or the inulin-doxorubicin across the cell monolayer. The permeability values 
with doxorubicin were higher than the permeability values of the inulin-doxorubicin 
conjugate. 
 Overall, the transport studies demonstrated positive results for the focus of this 
thesis. At concentrations of 5 mg/mL the tight junctions were not opened and the 
transport of doxorubicin or the inulin-doxorubicin conjugate was driven by passive 
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diffusion. The lower permeability values of inulin-doxorubicin conjugate as compared to 
doxorubicin was expected and likely due to the larger conjugate molecules inability to 
more readily penetrate the mucosal layer secreted by the HT29-MTX cells. Based on 
these results, the inulin-doxorubicin conjugate would be more advantageous than free 
doxorubicin for local, direct, and targeted delivery to the colon.  
The complete system. This thesis focused on developing both polymer carriers 
appropriate for the oral delivery of hydrophobic chemotherapeutics and an inulin-
doxorubicin conjugate which provides local, direct targeting to the colon. Both IPNs and 
P(MAA-g-EG) containing nanoparticles were synthesized and evaluated as potential 
polymer carriers for oral drug delivery using either free doxorubicin or the inulin-
doxorubicin conjugate as therapeutic agents. The results of loading and release studies, 
biocompatibility, and transport studies indicate that the P(MAA-g-EG)-5.0NP loaded 
with the inulin-doxorubicin conjugate would be the most appropriate system for the 
treatment of colon cancer. The P(MAA-g-EG)-5.0NP polymer carrier was capable of 
loading and releasing enough inulin-doxorubicin conjugate to elicit therapeutic effects 
using the SW620 cells as the colon cancer model. The release of the inulin-doxorubicin 
conjugate was reduced in the low pH environment and readily released in more neutral 
pH conditions. The inulin-doxorubicin conjugate better performs than free doxorubicin 
and will not be as readily digested in the small intestine as compared to the colon. Plus 
the inulin-doxorubicin conjugate is less permeable to Caco-2 and HT29-MTX cell 
monolayers which will result in higher amounts of the therapeutic agent in the colon. 
Therefore, it is the recommendation to use the P(MAA-g-EG)-5.0NP and the inulin-
doxorubicin conjugate for any future studies. 
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11.2 Future Recommendations 
 The information presented in this thesis is thorough and encompasses a variety of 
experiments and studies appropriate for understanding the polymer carrier’s and inulin-
doxorubicin conjugate’s performance for in vitro conditions. However, additional 
experiments using the current polymer carrier and conjugate can be completed. 
Developing new polymer carriers and new conjugates can also be explored. 
 Additional experiments for P(MAA-g-EG)-5.0NP and inulin-doxorubicin 
conjugate. To fully evaluate this polymer carrier and inulin-doxorubicin conjugate 
system, future work would include an in vivo assessment of the release of the conjugate 
and the conjugate distribution and amount delivered as it travels from the upper small 
intestine to the colon. It would be important to determine dosing amount which includes 
the amount of polymer carrier loaded with conjugate to achieve concentrations levels that 
are effective at reducing or eliminating colon tumors.  Additional optimization of the 
P(MAA-g-EG)-5.0NP carrier can include the purification process after polymerization of 
the film and the loading process of the conjugate. The inulin-doxorubicin conjugate could 
also be optimized by developing improved freeze drying methods or any method to 
recover the conjugate dissolved in water. It is hypothesized that the freeze drying method 
may be influencing the conjugates ability to re-dissolve in physiological conditions.  
 Further exploration of P(MAA-g-EG) containing nanoparticles. The P(MAA-g-
EG) hydrogel was polymerized in the presence of 1 %, 2.5%, and 5% (w/v) of PMMA 
nanoparticles (Ø 200 nm). Future studies could investigate using these same weight 
percentage values, but using nanoparticles with smaller or larger nanoparticle diameters. 
Smaller nanoparticle diameters could maintain the same degree of hydrophobicity, but 
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still maintain swelling properties similar to the P(MAA-g-EG) hydrogel without 
nanoparticles. Currently, the 5% (w/v) nanoparticles with 200 nm diameters takes a 
period of vortexing and sonication to get the nanoparticles to separate and become 
uniformly dispersed in the pre-polymerization solution. Higher weight percent of 
nanoparticles with 200 nm diameters would prove difficult; however, using nanoparticles 
with smaller diameters may allow higher weight percentage of nanoparticles incorporated 
into the P(MAA-g-EG) hydrogels. Higher weight percentage of nanoparticles in the 
P(MAA-g-EG) hydrogel may improve loading efficiency.  
Further exploration of the inulin-doxorubicin conjugate. Since the inulin-
doxorubicin conjugate is more toxic than doxorubicin, assessing whether the conjugate 
elicits the same cardiotoxic effects as free doxorubicin should be determined. If the 
conjugate can be used and achieve the same cytotoxicity effects as free doxorubicin while 
exposing the human to less amounts of doxorubicin in the conjugate, it would be a better 
therapeutic agent for cancer therapy.  Lastly, during carboxymethylation of inulin the 
amount of NaOH or monchloracetic acid can be varied to achieve different degrees of 
substitutions. Different degrees of substitutions will allow varying amounts of 
doxorubicin to be incorporated into the final conjugate and may result in different 
cytotoxic effects. Ultimately, the design of a conjugate with the least amount of 
doxorubicin conjugated to inulin while still achieving the same cytotoxic effects would 
be ideal.  
Currently, the polymer carrier and conjugate system discussed in this thesis are 
promising candidates for oral delivery.  In vivo assessments should reconfirm this system 
as a great candidate for oral delivery and developing new polymer carriers and conjugates 
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as discussed above, may result in improved results that can be eventually be used as a 
new regime for cancer treatment.  
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Appendix A 
Mesh Analysis for Hydrogel Dispersed with Hydrophobic Nanoparticles 
 
A.1  Introduction 
 Mesh analysis for P(MAA-g-EG) has been extensively studied and published.1-3 
These methods were developed for P(MAA-g-EG) hydrogels which did not contain 
nanoparticles embedded within the network during polymerization.  
In this work, nanoparticles are now present in the P(MAA-g-EG) hydrogel and an 
attempt was made to develop new methods for mesh analysis. These nanoparticles are not 
crosslinked into the P(MAA-g-EG) hydrogel, but could influence the way the P(MAA-g-
EG) swells and consequently have an effect on mesh sizes. This appendix reports the 
mesh analysis studies utilizing the traditional methods as discussed in chapter 4 and using 
new methods developed for this thesis. 
A.2  Materials and Methods 
Materials. P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles were 
synthesized as discussed in chapter 5. 3,3-dimethylglutaric acid (DMGA) was purchased 
from Sigma–Aldrich (St. Louis, MO). Sodium hydroxide and sodium chloride were 
purchased from Fisher Scientific (Fair Lawn, NJ). Double distilled water was used in all 
studies.  
   Swelling Studies. Equilibrium swelling studies were used to determine the mesh 
size of P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles. Swelling studies 
utilized 0.1 M 3,3-dimethyl glutaric acid (DMGA) buffers ranging from pH 3.2 to 7.6. 
Sodium chloride was added to control ionic strength. 10 mm P(MAA-g-EG) or P(MAA-
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g-EG) containing nanoparticles discs were punched from hydrated samples and dried. 
The dried discs were placed in approximately 100 mL of the 0.1 M DMGA buffer 
solutions housed in the same swelling chamber as discussed before (Figure 4.5). For 
equilibrium swelling conditions, polymer discs were placed in each pH level for 24 hr, 
removed, blotted, weighted in air. All samples were thermostated to physiological 
conditions (37 °C). The swelling ratio, q, was calculated as the swollen weight divided by 
the dry weight of the polymer disk.  
The mass of the polymer discs was additionally measured in n-heptane, a non-
solvent, using a hanging basket scale apparatus (Figure 4.6). Through this extra 
measurement, polymer volume fractions in the relaxed, dry, and swollen state were 
determined and used in calculating mesh sizes. Measurements of sample values in the 
“relaxed state” (i.e., in the state immediately after polymerization but before swelling) 
were taken just after polymerization, dry measurements after 10 days in vacuum or once 
no mass loss could be detected, and swollen measurements were made after a 24 hours 
equilibrium swelling study utilizing the same buffer series as above. 
A.3 Results and Discussion 
 Mesh analysis was performed on P(MAA-g-EG) and P(MAA-g-EG) samples 
containing nanoparticles. The traditional method for obtaining mesh sizes was utilized 
first for P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles samples. The 
traditional method utilizes equations which only account for the swelling of the P(MAA-
g-EG) hydrogel without nanoparticles. A new method for analysis was introduced to try 
to account for the presence of the nanoparticles and compared to the traditional method. 
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Mesh Analysis Method #1. The mesh analysis used for swollen P(MAA-g-EG) 
hydrogels without nanoparticles was performed on P(MAA-g-EG) hydrogels with and 
without nanoparticles and was termed Mesh Analysis Method #1. Measurements of the 
volume fraction of P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles in the 
relaxed and swollen state were determined to gain insight into whether these polymer 
carriers could be useful for loading and releasing hydrophobic, therapeutic agents. The 
volume fraction of the polymer in the relaxed state, υ2,r, was calculated using Equation 
A.1.  
 
, = ,	
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			                                                                                                                                                                  (A.1) 
 
where the subscripts ‘r’ and ‘d’ represent the relaxed and dry states, respectively. The 
volume fraction of the polymer in the swollen state, υ2,s, was calculated using Equation 
A.2.  
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where Wa and Wh are the weights in air and n-heptane and the subscripts ‘s’ and ‘d’ 
represent the swollen and dry states, respectively.  
The equilibrium polymer volume fractions in the swollen state were compared for 
the P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles (Figure A.1). Like the 
IPNs in Chapter 4, all nanoparticle containing carriers exhibited an inverse relationship 
between volume fraction and swelling ratio due to increased water as compared to 
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polymer content at higher pH levels. In low pH levels, polymer mass was significantly 
larger than water mass which indicated little solvent penetration. Reduced solvent 
penetration will keep encapsulated therapeutic agents from prematurely releasing while 
maximizing drug release to the targeted site.  
Using the values of υ2,s and υ2,r, the molecular weight between crosslinks, Mc, 
could be determined using the Peppas-Merrill equation (Equation A.3). The Peppas-
Merrill equation does not account for ionic units present in the polymer system, but since 
the equation uses the ratio of ionic to neutral components, this analysis technique is 
acceptable. 
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The volume fraction of the polymer in the relaxed state, υ2,r , and the volume 
fraction of the polymer in the swollen state, υ2,s , were used as determined above. V1 is 
the molar volume of the swelling solution which is primarily composed of water and thus 
determined to be 18.1 cm3/mol. 
 The term ὐ was determined using equation A.4 and is the specific volume of the 
polymer calculated using Wa,d, Wa,h, and the density of n-heptane (ρh). 
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 The Flory interaction parameter, χ, is a parameter indicating how well the 
polymer and solvent interact. Values above 0.5 indicate favorable interactions and values 
below 0.5 indicate unfavorable interactions between the polymer and the solvent. For 
these studies, χ1 was calculated as weighted average of the Flory interaction parameter of 
methacrylic acid4,5 given by Equation A.5 and poly(ethylene glycol) (0.44).   
 
+ = 0.44 + 0.6,                        (A.5) 
 
In these experiments, χ1 was greater than 0.5 at pH < 5.4 and lower than 0.5 at pH 
> 5.4. Since the Flory interaction parameters indicate favorable thermodynamic 
interaction for values lower than 0.5, investigation of mesh analysis focused on pH 
conditions greater than 5.4. The term Mn is the number average molecular weight of the 
same hydrogel system without crosslinker and was determined to be 20,000 kDa by gel 
permeation chromatography (Agilent 1200 Series operating with Viscotek I-Series 
column) of samples prepared under exactly the same conditions of preparation. This 
value is in good reasonable agreement to those previously published in our lab.6-8 
 With all values independently determined for Equation A.3, Mc could be 
calculated and then used to compute the mesh size, ξ, or the linear distance between 
adjacent crosslinks using Equation A.6. 
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Here, Mr is the molecular weight of the repeating unit (86 g/mol) of 
poly(methacrylic acid), Cn is the Flory characteristic ratio (14.6 for PMAA6,9) and ‘l’ is 
the length of the bond along the polymer backbone (1.54 Å for vinyl polymers). 
Calculated mesh sizes are plotted in Figure A.2 for hydrogels swollen at pH 
values ranging from 3.6 to 7.2. Mesh sizes varied from 312 Å to 349 Å and P(MAA-g-
EG) exhibited the largest mesh size at 349 Å. The relatively large P(MAA-g-EG) mesh 
sizes are due to the absence of the hydrophobic nanoparticles which can reduce ionic 
repulsion and displace water molecules which could have deprotonate carboxyl groups on 
the PMAA backbone. Mesh sizes decreased with increasing nanoparticle content and 
were 334 Å, 317 Å, and 312 Å for P(MAA-g-EG)-1.0NP, P(MAA-g-EG)-2.5NP, and 
P(MAA-g-EG)-5NP respectively. Unlike the IPNs, nanoparticles minimally reduced 
mesh size while still providing hydrophobic characteristics to the overall polymer carrier. 
Mesh sizes for samples swollen at low pH conditions were between 7 – 15 Å, values that 
cannot be given any serious consideration. Since the polymer carriers were minimally 
hydrated under these conditions, it was inappropriate to use the Peppas Merrill equation 
(which is based on a balance of thermodynamic and elastic forces in a swollen network). 
It can only be inferred that the polymer structure is collapsed which is appropriate for 
protecting encapsulated therapeutic agents from the stomach. As indicated in Figures A.3, 
the Mc values calculated were as high as 9,500 g/mol for P(MAA-g-EG) containing 
nanoparticles which corresponds to just 2 crosslinks per chain. 
Mesh Analysis Method #2. To try and account for the presence of the 
nanoparticles in the P(MAA-g-EG) when determining mesh sizes, Mesh Analysis 
Method #2 was used. The swollen values for P(MAA-g-EG) containing nanoparticles in 
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the relaxed and swollen state were determined to gain insight into whether these polymer 
carriers could be useful for loading and releasing hydrophobic, therapeutic agents. The 
volume fraction of the polymer in the relaxed state, υ2,r,polymer system, was calculated using 
Equation A.7.  
 
,,456789	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where the subscripts ‘r’ and ‘d’ represent the relaxed and dry states, respectively. For 
P(MAA-g-EG) containing nanoparticles the volume fraction of the polymer in the 
swollen state, υ2,s,polymer system, was calculated using Equation A.8.  
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where Wa and Wh are the weights in air and n-heptane and the subscripts ‘s’ and ‘d’ 
represent the swollen and dry states, respectively. However, for P(MAA-g-EG) 
containing nanoparticles, the physical presence of the nanoparticles, though not 
crosslinked into the P(MAA-g-EG) hydrogel, could influence how the P(MAA-g-EG) 
hydrogel swells and ultimately, how mesh sizes were calculated. Thus, to account for the 
presence of the nanoparticles the υ2,s,polymer system was redefined as equation A.9. 
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where υ2,s,polymer system is now defined as the swollen volume fraction of polymer as 
observed for the combination of PMMA nanoparticles and the P(MAA-g-EG) hydrogel. 
VPMMA, Vdry,P(MAA-g-EG), and Vswollen,P(MAA-g-EG) are the volume fraction of PMMA 
nanoparticles, the dry volume fraction of P(MAA-g-EG) hydrogel, and the swollen 
volume fraction of P(MAA-g-EG) hydrogel, respectively.  Vswollen,P(MAA-g-EG) can be re-
written as shown in equation A.10. 
 
NO5669P,Q(RR	S	TU) =	NV7,Q(RR	S	TU) +	NOW:9                                                 (A.10) 
 
where Vwater is the volume fraction of water. VPMMA includes no water component 
because it was previously determined not to swell in all pH ranging from 2.0 – 7.5. To 
determine the true swollen volume fraction of the P(MAA-g-EG) hydrogel, υ2,s,P(MAA-g-
EG), equation A.11 was defined. 
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Using equation A.10 and A.11 to solve for Vwater, plugging into equation A.9, and 
rearranging to solve for υ2,s,P(MAA-g-EG), equation A.12 was determined. 
 
,,Q(RR	S	TU) =	 
%,,A?∗X
EFFG<,E(FGGIJIKL) Y	X
EFFG<,E(FGGIJIKL) Y	
                    (A.12) 
 
315 
 
Using equation 5.6, υ2,s,P(MAA-g-EG) can now be measured and used to compute 
mesh sizes following similar equations as the Mesh Analysis Method #1. VPMMA was 
defined as the amount (grams) of PMMA nanoparticles added (known from synthesis; ) 
divided by the density of PMMA, ρPMMA, which is 1.18 g/cm3.10  
The equilibrium polymer volume fractions in the swollen state were compared for 
the P(MAA-g-EG) and P(MAA-g-EG) containing nanoparticles (Figure A.1). Like the 
IPNs in Chapter 4, all nanoparticle containing carriers exhibited an inverse relationship 
between volume fraction and swelling ratio due to increased water as compared to 
polymer content at higher pH levels. In low pH levels, polymer mass was significantly 
larger than water mass which indicating little solvent penetration. Reduced solvent 
penetration will keep encapsulated therapeutic agents from prematurely releasing while 
maximizing drug release to the targeted site.  
Using the values of υ2,s,P(MAA-g-EG) and υ2,r,polymer system, the molecular weight 
between crosslinks, Mc, could be determined using the Peppas-Merrill equation (Equation 
A.13). The Peppas-Merrill equation does not account for ionic units present in the 
polymer system, but since the equation uses the ratio of ionic to neutral components, this 
analysis technique is acceptable. 
 

 =  −
 ὐ	,,E(FGGIJIKL) 	,,E(FGGIJIKL) !,,E(FGGIJIKL)"
,[X %,,E(FGGIJIKL)%,,=>?<@A	<BA@Y
'	X %,,E(FGGIJIKL)%,,=>?<@A	<BA@Y]
                    (A.13)                                                    
 
V1 is the molar volume of the swelling solution which is primarily composed of 
water and thus determined to be 18.1 cm3/mol. The term ὐ was determined using equation 
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A.9 and is the specific volume of the polymer system calculated using Wa,d, Wa,h, and the 
density of n-heptane (ρh). 
 
ὐ = 	 )
 ∗ ,	,
,                           (A.14) 
  
The Flory interaction parameter, χ, is a parameter indicating how well the 
polymer and solvent interact. Values above 0.5 indicate favorable interactions and values 
below 0.5 indicate unfavorable interactions between the polymer and the solvent. For 
these studies, χ1 was calculated as weighted average of the Flory interaction parameter of 
methacrylic acid4,5 given by Equation A.15 and poly(ethylene glycol) (0.44).  
 
+ = 0.44 + 0.6,,Q(RR	S	TU)                                                                (A.15) 
       
In these experiments, χ1 was greater than 0.5 at pH < 5.4 and lower than 0.5 at pH 
> 5.4. Since the Flory interaction parameters indicate favorable thermodynamic 
interaction for values lower than 0.5, investigation of mesh analysis focused on pH 
conditions greater than 5.4. The term Mn is the number average molecular weight of the 
same hydrogel system without crosslinker and was determined to be 20,000 kDa by gel 
permeation chromatography (Agilent 1200 Series operating with Viscotek I-Series 
column) of samples prepared under exactly the same conditions of preparation. This 
value is in good reasonable agreement to those previously published in our lab.6-8 
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 With all values independently determined for Equation A.13, Mc could be 
calculated and then used to compute the mesh size, ξ, or the linear distance between 
adjacent crosslinks using Equation A.16. 
 
 1 = ,,Q(RR	S	TU)	

' 2 

 3                                                                          (A.16) 
 
Here, Mr is the molecular weight of the repeating unit (86 g/mol) of 
poly(methacrylic acid), Cn is the Flory characteristic ratio (14.6 for PMAA6,9) and ‘l’ is 
the length of the bond along the polymer backbone (1.54 Å for vinyl polymers). 
Calculated mesh sizes are plotted in Figure A.4 for hydrogels swollen at pH 
values ranging from 3.6 to 7.2. Mesh sizes varied from 349 Å to 647 Å and P(MAA-g-
EG)-5.0NP exhibited the largest mesh size at 647 Å. Mesh sizes increased with 
increasing nanoparticle content and were 446 Å, 545 Å, and 647 Å for P(MAA-g-EG)-
1.0NP, P(MAA-g-EG)-2.5NP, and P(MAA-g-EG)-5NP respectively. P(MAA-g-EG) 
mesh size was 349 Å. This trend is not expected, since all equilibrium swelling ratios of 
P(MAA-g-EG) containing nanoparticles were lower than P(MAA-g-EG) without 
particles (Figure 5.14). P(MAA-g-EG) mesh sizes should be the largest because the they 
possess no nanoparticles which can reduce ionic repulsion and displace water molecules. 
Thus, it should follow suit to see a decrease in mesh size as opposed to an increase.   
Mesh sizes for samples swollen at low pH conditions were between 11 – 108 Å and are 
values that cannot be given any serious consideration. Since the polymer carriers were 
minimally hydrated under these conditions, it was inappropriate to use the Peppas Merrill 
equation (which is based on a balance of thermodynamic and elastic forces in a swollen 
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network). It can only be inferred that the polymer structure is collapsed which is 
appropriate for protecting encapsulated therapeutic agents from the stomach. As indicated 
in Figures A.5, the Mc values calculated were as high as 9,900 g/mol for P(MAA-g-EG) 
containing nanoparticles which corresponds to just over 2 crosslinks per chain. 
A.4  Conclusions    
Mesh sizes of the networks of the nanoparticles-containing hydrogels were 
between 312 – 349 Å for the Mesh Analysis Method #1. The mesh size was only reduced 
by 10% when adding the nanoparticles while the introduction of a secondary 
interpenetrating network in Chapter 4 reduced mesh size by 36%. The mesh values 
trended as expected, with decreasing mesh size corresponding with decrease in 
equilibrium swelling ratios; however, this analysis does not account for the presence of 
nanoparticles in the polymer carrier. 
Mesh Analysis Method #2 measured mesh sizes to be between 349 – 647 Å. Mesh 
Analysis Method #2 also demonstrated a reverse correlation of mesh size and equilibrium 
swelling ratios indicating that the current analysis setup needs adjustment. Further 
exploration of Mesh Analysis Method #2 using the current data set could result in values 
that are more appropriate and trend as the Mesh Analysis Method #1, but take into 
account the presence of the hydrophobic nanoparticles.  
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Figure A.3. Molecular weight between crosslinks, Mc, as a function of increasing 
weight percent of nanoparticles in P(MAA-g-EG) hydrogel and compositions of 
P(MAA-g-EG) containing nanoparticles using traditional method. Mc decreased with 
increasing PMMA nanoparticle content. 
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Figure A.5. Molecular weight between crosslinks, Mc, as a function of increasing 
weight percent of nanoparticles in P(MAA-g-EG) hydrogel and compositions of 
P(MAA-g-EG) containing nanoparticles using new method. Mc decreased with 
increasing PMMA nanoparticle content. 
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